










The handle http://hdl.handle.net/1887/35437 holds various files of this Leiden University 
dissertation 
 
Author: Bellanti, Francesco 
Title: From data to models : reducing uncertainty in benefit-risk assessment : application 
to chronic iron overload in children 




























FROM DATA TO MODELS: REDUCING UNCERTAINTY IN BENEFIT-RISK ASSESSMENT  
APPLICATION TO CHRONIC IRON OVERLOAD IN CHILDREN 
 
Francesco Bellanti 
Ph.D. Thesis, Leiden University, September 2015 
 
FROM DATA TO MODELS: REDUCING 
UNCERTAINTY IN BENEFIT-RISK ASSESSMENT 
 





ter verkrijging van 
de graad van Doctor aan de Universiteit Leiden, 
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker, 
volgens besluit van het College van Promoties 
te verdedigen op donderdag 24 september 2015 






geboren te Messina, Italië 
in 1986 
  
Promotor  Prof. Dr. M. Danhof 
Co-promotor  Prof. Dr. O.E. Della Pasqua 
 
Promotiecommissie Prof. Dr. P.H. van der Graaf 
Prof. Dr. C.A.J. Knibbe 
Prof. Dr. G. Pons, Université Paris Descartes, Parijs 
Prof. Dr. J. van den Anker, Universitäts Kinderspital, Basel 







“If you want to go fast, go alone 










The research leading to this thesis is part of the DEferiprone Evaluation in Paediatrics (DEEP) 
project, supported by the FP7 Framework Research Program “HEALTH-2010.4.2-1: Off-patent 
medicines for children”. The research has been performed at the Division of Pharmacology of 










The printing of this thesis was financially supported by: 
 
Quantitative Solutions B.V.  
GlaxoSmithKline 
Thalassaemia International Federation 
 
 
Cover and layout by Daniele Bertuccelli 




©2015 Francesco Bellanti (francesco_bellanti@libero.it) 
No part of this thesis may be reproduced or transmitted in any form or by any means 
without written permission of the author.  
TABLE OF CONTENTS 
Section I General introduction 9 
Chapter 1 Integration of PKPD relationships into Benefit-Risk Analysis 11 
Chapter 2 Model-informed benefit-risk assessment of iron chelation in 
transfusion-dependent haemoglobinopathies - Scope and intent of the 
investigation 
49 
Section II Optimising evidence generation in paediatric trials 65 
Chapter 3 Population pharmacokinetics of deferiprone in healthy subjects 67 
Chapter 4 Sampling optimisation in pharmacokinetic bridging studies: use of 
deferiprone in children with β-thalassaemia 
87 
Chapter 5 Model-based dosing recommendations for the use of deferiprone in 
children affected by transfusional iron overload younger 6 years of age 
109 
Section III Integrated evaluation of efficacy and safety by modelling and 
simulation 
129 
Chapter 6 A disease model for iron overload in patients affected by transfusion-
dependent diseases 
131 
Chapter 7 Model-based optimisation of deferoxamine chelation therapy 153 
Chapter 8 Model-based characterisation of the acute and long-term unfavourable 
effects of iron chelation therapy 
177 
Section IV Clinical Trial Simulations: accounting for exposure, disease 
progression and uncertainty in benefit-risk analysis 
201 
Chapter 9 Model-based evaluation of benefit-risk balance in children 203 
Section V Conclusion and perspectives 227 
Chapter 10 Model-informed assessment of the benefit-risk profile of medicines for 
children: summary, conclusions and perspectives 
229 




























F Bellanti, RC van Wijk, M Danhof, and O Della Pasqua 
 
 








Aim: Despite the continuous endeavour to achieve high standards in medical care through 
effectiveness measures, a quantitative framework for the assessment of the benefit-risk balance 
(BRB) is lacking prior to drug approval. The aim of this short review is to summarise the approaches 
currently available for benefit-risk assessment. In addition, we propose the use of pharmacokinetic-
pharmacodynamic (PKPD) modelling as the pharmacological basis for evidence synthesis and 
evaluation of novel therapeutic agents. 
Methods: A comprehensive literature search has been performed using MESH terms in Pubmed, in 
which articles describing benefit-risk assessment and modelling and simulation (M&S) were 
identified. In parallel, a critical review of multi-criteria decision analysis (MCDA) is presented as a tool 
for characterising a drug’s safety and efficacy profile.  
Results: A definition of benefits and risks has been proposed by the European Medicines Agency 
(EMA), in which qualitative and quantitative elements are included. However, in spite of the value of 
MCDA as a quantitative method, decisions about BRB continue to rely on subjective expert opinion. By 
contrast, a model-informed approach offers the opportunity for a more comprehensive evaluation of 
BRB before extensive evidence is generated in clinical practice. 
Conclusions: BRB should be an integral part of risk management and as such considered prior to drug 
approval. M&S can be incorporated into MCDA to support the evidence synthesis as well evidence 
generation taking into account the underlying correlations between favourable and unfavourable 






1.1 Benefit-Risk Analysis: the current situation 
Despite the recognised implications of unmet medical needs and challenges in dealing with 
new diseases, the current regulatory framework in the European Union has made drug 
approval a demanding task. This situation is compounded by emerging safety findings, which 
have led to post-approval withdrawals of more than a dozen products with high therapeutic 
potential in the past decade (1,2). Such a landscape places regulators, clinical scientists and 
drug developers with yet another dilemma: how to balance rapid access to new drugs versus 
gathering comprehensive data on efficacy and safety? (3). Currently, regulators make these 
decisions in an isolated, fragmented, and to a large extent subjective manner.  
The decision to approve a new medicinal product is based on the assumption that a 
systematic review of all available data provides an accurate, unbiased picture of a drug’s 
efficacy and safety. This assumption may, however, not be true for the large majority of 
drugs; the evidence generated to support regulatory submission does not always account for 
the overall heterogeneity of the target population, the impact of treatment on disease 
progression or external confounding factors on treatment response. Moreover, one needs to 
acknowledge that the information gathered in the context of pivotal clinical trials may not 
provide evidence that dose selection, dosing regimen, and treatment duration are truly 
optimal. 
 
Undoubtedly, efficient gathering and use of data are required to answer the clinical 
questions that arise with new drugs or therapeutic interventions. Among other things one 
needs to distinguish effectiveness from clinical response. In addition, it is crucial to 
understand whether there is added value, as compared with other treatments. These are 
multidimensional questions which require clear understanding of how data will be 
generated and how benefit and risk will be quantified. Whereas different theoretical 
considerations and techniques have been used by health technology assessment agencies, a 
clear framework for benefit risk (BR) assessment is still lacking during drug development and 
subsequently for regulatory approval. Consequently, decision making at important 
milestones in R&D and at submission remain empirical, inconsistent and more often than 
not, non-transparent(1,4–8).  
 
In the past years awareness about the aforementioned issues has increased significantly. 
Several projects (9–13) have been funded to evaluate some of the available methodologies 
and better understand the requirements for a more systematic approach to BR analysis. In 
this context, the work of the Committee for Medicinal Products for Human Use (CHMP) of 
the European Medicines Agency (EMA) is particularly relevant. Starting in 2006, a working 
group was installed to examine the issue and provide recommendations about ways to 
improve BR assessment, including aspects such as transparency, consistency and 
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communication between stakeholders (9). Among the techniques evaluated by the working 
group, quality-adjusted life years (QALYs) and number needed to treat (NNT) were found to 
be the most used concepts in clinical practice, very likely due to their simplicity (9,14). 
However, these methods are qualitative in nature and as such lack some important features 
that allow one to make appropriate inferences about quantitative differences, especially 
when comparing treatment options. There is a clear need for more comprehensive 
methodologies, which enable better integration of data and facilitate the evaluation of 
complex clinical scenarios that arise in real life. 
Most of these complexities seem to have been addressed by the development of multi-
criteria decision analysis (MCDA), an integrative approach that has gained interest from the 
scientific and clinical community over the last few years. From 2009 to 2011, data can be 
found for nine products which have been evaluated by MCDA alone, or in combination with 
simulation, decision trees or Markov modelling (15).  
 
In this review, a brief overview of different techniques for the evaluation of benefit and risk 
is presented, with especial focus on the contribution of quantitative methodologies to the 
development and approval of novel medicines. Two main topics are discussed initially. First, 
the definition of benefit-risk balance and the impact of qualitative and quantitative 
methodologies on the measurement of benefit and risk during the drug development 
process (7). In addition, we consider further refinement of the approaches used for assessing 
BRB by integrating it with pharmacokinetic-pharmacodynamic (PKPD) modelling. It is 
envisaged that modelling and simulation may account for correlations between therapeutic 
response and adverse events, providing a biologically plausible basis for BRB. The availability 
of such an integrated approach may enable better choices regarding treatment selection and 
dose rationale in special groups or conditions involving small numbers of patients such as 
rare diseases.  
 
1.2 Methods 
Initially, an exploratory literature search was performed to retrieve relevant publications to 
identify current quantitative approaches for benefit risk assessment (BRA) to improve 
decision making in drug development. Seven documents (1,4,14,22,23,61,84) were available 
before the exploratory phase and were used to identify 58 articles, books and reports. Based 
on this pool of 65 documents 21 quantitative methodologies were identified (see Table S1). 
This result was used to integrate the available information with a systematic literature 
search within PubMed, in which the name of the methodology was combined with the term 
benefit risk assessment/analysis, which was replaced by benefit risk or risk assessment when 
the query lead to an outcome of 0 publications. This resulted in 253 publications, of which 





together with the 65 publications from the exploratory search were reviewed. Additionally, 
23 publications were added on external advice, for a total number of papers reviewed in the 
context of current approaches for benefit risk assessment equal to 110. The steps described 




Figure 1. Flow diagram of the literature search. 
 
1.3 Definition of benefit and risk 
An important aspect of any BR analysis is the definition of both terms, and more 
importantly, how to measure or quantify them. Benefit is usually described as a potential 
effect that moves the condition of the patient from disease towards health, within a given 
(pre-defined) context (Table 1) (16–19). Risk is the opposite, a potential effect that moves 
the condition of the patient from health towards disease, also within a pre-defined context. 
To measure both possibilities, at least two concepts play an important role: the magnitude 
or severity of the effect, and its incidence or frequency. Benefit or risk is then estimated by 
the product of these concepts, possibly multiplied by the duration (17) or the reliability of 
the data (19). The BR assessment, in which the no-treatment option should not be overseen, 
is simply a ratio of the two components, for which pre-defined acceptance thresholds are 
stated. 
87 publications fully 
reviewed




excluded based on title 
and abstract
23 publications 
suggested by external 
advise
110 publications 











Table 1. Glossary of terms. 
Term Definition 
ADE Adverse Drug Effects 
Bayesian statistics Probability-based statistics, concerning parameter values derived 
from distributions 
Benefit Favourable effect, accounting for uncertainty of that effect [as 
defined by the EMA] 
BILAG-index British Isles Lupus Assessment Group, a measure for severity of 
SLE 
BR Benefit Risk 
BRAT Benefit Risk Action Team, operating under PhRMA 
CHMP Committee for Medicinal Products in Human Use, operating under 
the EMA 
Decision tree Method to aid decision making by visualizing different scenarios as 
a series of events, and by calculating outcome based on assigned 
probabilities of the events 
DSD Death or serious disabled, measure of estimated outcome in the 
swine flu case study 
EMA European Medicines Agency 
FDA Food and Drug Administration [USA] 
H1N1 Influenza virus categorized by surface proteins hemagglutinin and 
neuraminidase (in this case swine flu) 
In silico Experiment in a computer, virtually 
In vitro Experiments in cell cultures 
In vivo Experiment in animals (preclinical) 
IPRED Individual prediction, possible outcome of PKPD modelling 
prediction variables and parameter values of an individual patient 
M&S Modelling and Simulation, in pharmacology a way of describing 
data by constructing a validate model and simulate new data, as a 
virtual experiment 
Markov model Quantitative method of modelling states and transitions between 
states 
MCDA Multi criteria decision analysis, quantitative method analysing 
single weighted components of a problem before reassembling it 
to aid a final decision 
NDA New drug application, to be submitted to the FDA for approval 





NNH Number needed to harm, measure of the number of patients that 
has to be treated to present a single adverse effect 
NNT Number needed to treat, measure of the number of patients that 
has to be treated to prevent a single occurrence  
PhRMA Pharmaceutical Research and Manufacturers of America 
PKPD Pharmacokinetics and pharmacodynamics, two disciplines within 
pharmacology concerning what the body does to the drug and 
what the drug does to the body, respectively  
PrOACT-URL Qualitative framework by Hammond, Keeney and Raiffa, 
consisting of Problem, Objective, Alternatives, Consequences, 
Trade-offs, Uncertainty, Risk tolerance and Linked decisions 
QALY Quality-adjusted life year, measuring the outcome of therapy by 
the adjustment of a quality life year, in which the patient can fully 
function (economically) 
Risk Unfavourable effect, accounting for uncertainty of that effect [as 
defined by the EMA] 
RV-NNT Relative Value adjusted number needed to treat, a type of NNT 
accounting for patient preference as value function 
SLE Systemic Lupus Erythematosus, an autoimmune disease 
SLEDAI DLE Disease Activity Index, a measure of severity of SLE 
TURBO Transparent Uniform Risk-Benefit Overview 
 
Currently a slightly different definition of benefit and risk has been adopted by the EMA. 
They are defined respectively, as favourable and unfavourable effects and are at the same 
time coupled to the uncertainty of both effects (Figure 2) (14). Whereas the reasoning seems 
intuitive, this situation represents a mathematical challenge, i.e., integrating terms or factors 
that are measured in incommensurable units and in different time scales. Any reliable 
product of these factors imposes data manipulation or transformation to ensure that all 
terms are expressed in the same unit and time scale. However, the illusion of this 
mathematical precision tends to hide another important conceptual challenge: what is 
acceptable? (18). This depends on the perception and values of the stakeholders, i.e., the 
regulator, the clinical experts, and the patients. Procedures have been devised to ensure 
that perceived benefits and risks are quantified in a systematic manner. This process is 
known as prior elicitation and involves expert judgment. It is aimed at making subjective 
opinions more consistent, comprehensive and transparent (16,19,20). 
 










Figure 2. EMA's definition of benefit and risk, where favourable effects are beneficial to the 
population and unfavourable effects are undesirable for the population. Uncertainty is caused by 
variation, biased data, limitations of data or methodology etc. Based on [14]. 
 
1.4 Current approaches 
The assessment of benefit and risk has evolved in a rather empirical manner and still relies 
on subjective criteria, in that perceived benefits and risks depend on the context in which 
the treatment is used, i.e., which standard of care is set as reference and whether short and 
long term consequences of the intervention are considered against the progression of 
disease and any correlated co-morbidities or complications. Irrespective of the lack of 
consensus on how to assess and weight any measures associated with benefit and risk, one 
needs to consider two different dimensions of the problem. First, a qualitative approach is 
required to allow for explicit contextualisation of the problem. It is crucial to fully 
understand the main issues before any quantitative analysis starts, i.e., to identify the 
factors that contribute and/or determine benefit and risk as well as capture the views and 
differences of opinion from different stakeholders, especially with regard to the perception 
of risk, in terms of its incidence, severity, chronicity and reversibility. Second, a quantitative 
approach is needed in which results from the initial (qualitative) evaluation are normalised 
by means of mathematical and statistical procedures. Such a normalisation implies the 
availability of sufficient data for those endpoints and measures which have higher weights. It 
also imposes clear understanding of the trade-offs between benefit and risk, especially of 
the correlations between outcomes. Whereas these requirements seem obvious, little 
attention has been paid to the biological or pharmacological basis that determines 
treatment outcome, i.e. how exposure-response (PKPD) relationships underpin favourable 
and unfavourable events. 
The next paragraphs will provide an overview of the available techniques, including recent 





approval and treatment optimisation. Additional details of the methodologies can be found 
in the supplementary material (Supplementary Figure 1 and 2 and supplementary Table 1 
and 2, see Appendix).  
 
Qualitative approaches 
A qualitative framework is essential for characterising benefit and risk, as it structures the 
problem and its context, before any actual assessments are made. It provides clarity about 
the possible outcomes of the assessment, as well as the input and the process in between, 
for example by defining which decision criteria are to be used. This framework ensures that 
no alternative measures or trade-offs are overlooked during the subsequent steps, i.e., 
during which quantitative methods are applied. 
 
PhRMA BRAT 
The Pharmaceutical Research and Manufacturers of America (PhRMA) assigned a Benefit 
Risk Action Team (BRAT) to create a decision framework. Their framework consists of six 
steps which are developed and implemented prior to drug approval. Before phase III, focus is 
given to the definition of a decision frame, identification of relevant outcomes, identification 
of the data sources, and customisation of the framework for BR analysis. At the time of filing 
and NDA review, attention is paid to the outcome itself as well as to the quantification and 
interpretation of key BR metrics (13,14). It should be noted that this framework seems to 
end with the decision and defence after which a drug is approved or rejected. It does not 
involve post marketing data, which are known to potentially change BR balance. 
 
EMA PrOACT 
The qualitative framework suggested by the EMA is based on Hammond’s, Keeney’s and 
Raiffa’s PrOACT approach (21), combined with the less known addition of the so-called URL: 
Problem, Objective, Alternatives, Consequences, Trade-offs, Uncertainty, Risk tolerance and 
Linked decisions. In this way, the problem is clearly structured and information can be 
gathered in a consistent way to assist the decision-making process (14). Despite its general 
nature, the use of PrOACT-URL has proven its success since 1999. In contrast to PhRMA 




The use of a qualitative framework for assessing benefit and risk may be sufficient when 
complexity is minimal. This is however not the case in drug development where very 
complex scenarios arise. To include all data and present a sound overview of all alternatives, 
consequences and trade-offs, as well as differentiate between objectives otherwise 
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considered comparable, one or more quantitative techniques are required 
(1,4,11,14,17,19,22,23). A qualitative framework will still be essential to define the problem 
and the objectives of the analysis and as such will precede the implementation of a 
quantitative BR analysis. 
In the past decades several methodologies have been developed and used to evaluate the 
BR balance of a number of drugs. These methodologies present completely different 
features and their use has been tailored for very specific cases, contributing to an increase in 
the number of options available when starting an analysis. These specificities have however 
made them unsuitable for subsequent application in a general BR framework. An overview 
of these methods (1,4,17,19,22–102, 120-124), including advantages and limitations is 
provided in Supplementary table 1. By contrast, multi criteria decision analysis (MCDA) in 
combination with decision trees has been suggested as a plausible quantitative approach 
that embeds the needed features for a generalised and structured framework for BR 
evaluation. 
 
MCDA presents several advantages compared to other methodologies: the main one is the 
simplification of a complex problem by breaking it into smaller pieces and making them 
comparable by weighting their scores on a single scale; normalizing the different criteria 
allows comparison on the same ground. In addition, the uncertainty carried by the subjective 
component, is further reduced by the possibility of performing sensitivity analysis, in which 
the model provides different outcomes depending on weights variation. There are, however, 
still limitations. Given the complexity of the scenarios analyzed, it is often expected to 
observe correlations between the endpoints considered. This is not yet taken into account 
within the methodology, where each endpoint is analyzed in an independent manner. In the 
SLE-case, which is discussed in the supplementary material, the immunosuppressive effect of 
Benlysta and the incidence of infection might very well be correlated in a nonlinear way. This 
might influence the outcome, leading to biased results. Furthermore, it is a matter of 
concern how the input data for the decision model is provided. This is not a direct limitation 
of the methodology, but of how the analysis is implemented. Many quantitative methods 
are limited by statistics and inclusion of uncertainty, confounding factors, or limited data. 
The latter concerns both the experimental data, as well as preference values of different 
stakeholders required for weighting criteria (1). MCDA offers a statistical sound method, 
where probability and uncertainty are combined with preference. Its limitation lies in the 
complexity of data required, which is often unavailable, as well as in the subjective 
judgement that is required and the dependence on risk perception differences. Besides, 
sequential decisions require data gathering over a longer time period, especially in 





Despite the aforementioned advantages, MCDA, like any other quantitative method, still 
relies on subjectivity. This is partly overcome by structuring the analysis in a  transparent, 
consistent manner and by incorporating communication with different stakeholders as a 
critical step (14,15). In fact, communication with different stakeholders is also accounted for 
in NNT/NNH. Although applicability of the former to BR assessment in general is very limited 
because of the lack of preference data, as well as the limited statistical power (57,58), it 
shows an important issue in communication. Individual patients seem unable to objectively 
estimate their own chances. In a distribution of 1 out of 20, all 20 patients expect to be the 
exception, when it comes to a beneficial effect, but not in case of an adverse effect. As a 
result, the magnitude of risk is misperceived, as the chances of common consequences are 
underestimated and those of rare consequences are overestimated (8). This problem of risk 
perception is essential when considering including different stakeholders. Although MCDA 
does present data in a transparent and consistent way, it is not a technical process, but an 
effective design of the social processes required for subjective weighting (41).  
 
1.5 Integration of PKPD modelling into BR analysis 
Modelling and Simulation (M&S) techniques represent an invaluable resource for drug 
development. Of relevance for BR analysis is the opportunity that PKPD modelling offers in 
terms of describing variability in a parametric manner. This allows the characterization and 
prediction of the time course of treatment response at individual level under physiological 
and pathological conditions (104,105). The current emphasis on mechanism-based modelling 
has also the advantages of increased understanding about drug-specific and system-specific 
properties such as, target site distribution, binding, pharmacokinetic interactions, 
transduction of signals, pharmacodynamic interactions, homeostatic feedback, tolerance 
and disease progression (106–108). In addition, model-based simulations can provide insight 
into conditions that may not have been tested experimentally, unravelling patterns or 
responses that may represent clinically relevant changes in the BR balance. 
From a technical, scientific point of view, M&S ensures for integration of data and 
knowledge in a continuous, objective and reproducible manner, thereby enhancing the 
quality of decision making (105). Over the last decade, regulatory perception and role of 
M&S in drug development has changed. Its relevance in clinical development has been 
acknowledged and processes are in place to support a more structured use of M&S 
(106,109).  
 
In the next paragraphs we evaluate how the integration of M&S can be advantageous to 
further improve the existing framework for the evaluation of benefit-risk balance, as 
suggested by the EMA. To this purpose, we consider three main aspects, namely, the 
optimisation of evidence that is generated by clinical trials, evaluation of virtual scenarios 
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and mechanism-based multivariate analysis. The optimisation of the input data available for 
decision making entails not only the integration of data from different trials, but also the use 
of optimality concepts for the design of prospective clinical studies. The availability of an 
integrated model allows for the creation of virtual experiments, which provide a more 
coherent, biologically plausible basis for performing interpolations and extrapolations. In 
contrast to current practice, multivariate modelling allows one to establish correlations 
between therapeutic and adverse events of interest, which are often linked by the very 
pharmacological nature of the treatment. This overview is complemented by a brief 
discussion of the issues associated with prior elicitation, which could be better guided by the 
use of models, rather than empirical distributions.  As such, a model-based approach could 
provide somewhat less subjective weighting and preferences.   
 
Optimizing input data: M&S techniques can be used to optimize the input data available for 
the BR analysis. PKPD modelling allows the creation of a framework that can be refined and 
improved throughout the development process, by integrating data from different sources 
as well as by pooling the information gathered across different phases of development. This 
iterative process allows one to understand and distinguish drug from system-specific 
properties. Most importantly, it allows one to identify sources of variation and assess the 
clinical implications thereof. Among other things, BR analysis could be performed with and 
without the residual variability or in by inclusion of variability in a stepwise manner. In other 
words, these procedures increase the value of data whilst decreasing uncertainty (106). On 
the other hand, M&S can also be used to optimise the design of prospective clinical trials. 
The quality of the information collected can be considerably improved through optimal 
design (110–112), enabling the generation of more informative data input for the decision 
analysis. This is particularly important in special populations where limited evidence is 
generated, such as in paediatric diseases (106,113,114). The assumptions about the 
informative value of data obtained from randomised clinical trials are often overlooked. It is 
assumed that the output or results from a trial are consequence of the drug treatment, 
rather than the consequence of the interaction between drug properties, disease processes, 
patient characteristics and experimental protocol. 
 
Evidence from virtual scenarios: A second aspect that could be beneficial for the BR 
assessment is the use of PKPD modelling for simulation purposes. The availability of a 
qualified or validated model may provide the opportunity to perform virtual experiments. 
This allows one to explore scenarios that have not been evaluated during clinical 
development. Not only efficacy and safety data can be considered, but also the influence of 
covariates such as disease severity, co-medications, co-morbidities and drug compliance can 





population or different dosing regimens. As such these simulated results can be 
subsequently used as input for BR analysis. As mentioned previously, PKPD modelling may 
have an even larger impact when considering special populations (114–117).  
 
Correlating multiple endpoints: Thus far we have highlighted the fact that PKPD modelling 
may reduce the uncertainty in a BR analysis by optimising the information used as input. 
M&S techniques may overcome another important limitation of BR methodologies, namely 
the assumption that favourable and unfavourable events are clinically, pharmacologically 
and statistically independent from each other. This assumption violates our current 
understanding of the nature and cause of adverse events. Hence, any analysis involving 
multiple endpoints in a multidimensional system will have to account for the correlations 
between them. Moreover, we believe that these correlations are often non-linear, requiring 
some advanced statistical techniques to ensure that interactions between variables and 
covariate factors are captured accordingly. Multidimensional models can be used to assess 
quantitatively how endpoints are linked together and how response changes with changes in 
drug exposure (24). 
 
Advantages from the integration of M&S techniques to BR analysis are not only conceptual. 
From a technical perspective, PKPD models may contribute to bias reduction during prior 
elicitation. In addition, it may provide a stronger basis for sensitivity analysis. Although 
weighting is a subjective procedure, expert opinions can be modelled using prior elicitation. 
Moreover, if the uncertainty associated with the weights is assessed, it is possible to factor 
in the impact of each expert’s opinion on the overall analysis. Other possibilities exist to 
weight the experts input, by scaling their precision based on training and experience, or by 
assigning them to groups of thought that are more or less representative of the common 
opinion (26,63). PKPD models describing the underlying disease processes as well as the 
impact of treatment over time through virtual scenarios may facilitate prior elicitation, 
providing systematic, consistent input for the evaluation of weights and uncertainties. 
An example of the impact of M&S concepts on BR analysis is given in Table 2.  
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Table 2. Impact of M&S on the MCDA approach is visualised and further elucidated by the example 
of Benlysta. It shows clearly the emphasis on the first part of the methodology; the input data and 
earlier data evaluation for correlations between parameters and outcomes. 
 
MCDA Modelling & Simulation Example: Benlysta 
Step 0: Input 
data gathering 
Step 0.1: Explore and refine the 
informative contents of data, accounting 
for variability and uncertainty. 
Step 0.2: Incorporation of virtual 
measurements (samples), by evidence 
generation through simulations. 
Step 0.1: Distinguish between-
subject variability in relevant 
parameters from residual error. 
Step 0.2: Evaluate parameter 
uncertainty by exploring the 
implications of different 
experimental protocol 
conditions.  
Step 1: Defining 
decision context 
Step 1.1: Prioritising elements which 






Step 2.1: Inference by extrapolation, e.g., 
an additional arm that has not been 
tested clinically. 
Step 2.1: Assess treatment 
response for alternative dosing 
regimens than the actual 
treatment arms in the trial (i.e., 





Step 3.1: Assess outcomes taking into 
account the correlation between events. 
 
Step 3.1: The correlation 
between immunosuppressive 
effects and incidence of 
infection can be incorporated 
into the model, enabling 
accurate evaluation of the 
impact of different dose levels 
on outcome. 
Step 4: Scoring Step 4.1: Estimation of the correlation 
between events in a parametric manner, 
thereby avoiding biased scoring of the 
data. 
Step 4.1: Estimation of the 
parameters describing the 
nonlinear relationship between 
immunosuppressive effects and 
incidence of infection in 







Step 5.1: Prior elicitation of expert 
opinions can be translated into 
consistent weighting, including 
distributions describing differences of 
opinion (e.g., priors in parameter 
distributions). 
Step 5.1: Simulate outcomes for 
Benlysta-treated patients taking 
into account different weighting 
factors. 
Step 6: 
Combining data  
Step 6.1: Simulated scenarios increase 
the quality of the data and therefore the 
quality of the overall value, by increasing 
Step 6.1: Simulation of different 
treatment arms to explore the 








Step 6.1: Outcome evaluation is not 
limited to the data, but to evidence 
arising from virtual clinical trials, 
including  patients who belong to risk 
groups  





Step 8.1: Irrespective of the decision 
criteria, model parameters on which the 
data are based can also be analysed. 
Step 8.1: The PKPD model of 
Benlysta has been evaluated by 
sensitivity analysis. 
 
1.6 Discussion and conclusion 
In this short review, an overview was given of the methodologies currently used for the 
evaluation of BR balance. Growing consensus suggests that a combined approach involving 
qualitative and quantitative methods is required to ensure meaningful evaluation and 
interpretation of benefit and risk data. In fact, this is recommended by the EMA, which 
suggests the use of PrOACT-URL and MCDA. 
Even though a more structured approach is still lacking for BR analysis, MCDA seems to 
address the need for a multidimensional characterisation of the scenarios that arise in drug 
development and in the clinical practice. One of its limitations is the way uncertainty is 
handled; there is the need to further reduce the uncertainty or preferably to capture it 
accordingly. Attempts have been made to construct stochastic multi-attribute models, also 
known as stochastic multi-criteria acceptability analysis (SMAA), which incorporates 
uncertainty regarding the criteria measurements. SMAA provides the possibility to include 
the sampling variation and to characterize typical trade-offs supporting a drug BR profile 
without knowing or eliciting the (exact numerical) preferences beforehand (119). An analysis 
without preference information is valuable when preferences cannot be elicited or when the 
potential benefits of a drug have to be assessed across a wide range of preferences. This 
latter situation occurs, for example, when different subgroups of patients are considered. 
However, stochastic methods do not eliminate discrepancies between perceived risk or 
benefit and their biological and pharmacological plausibility.  Undoubtedly, integration of 
mechanism-based modelling to multi-criteria decision methods will enhance our ability to 
characterise benefit-risk balance. It will provide indirect evidence from virtual scenarios in a 
more effective manner than sensitivity analysis and other statistical techniques have allowed 
for. Such an integrated approach will also represent an advancement for the field of 
modelling and simulation, which is often restricted to single endpoints, facilitating the 
assessment of causality and correlation between favourable and unfavourable events (118). 
Unfortunately, in literature there are very few examples that present in a clear manner the 
concepts discussed throughout this manuscript. Among them though, two publications 
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provide an excellent illustration of these concepts: the work carried out by Bender et al (125) 
shows how exposure-response relationships quantified through model-based approach for 
multiple endpoints can be used to explore and assess BR across different dosing regimens in 
the context of oncology trials. In the same way, the work by Pink et al (126) shows the 
feasibility of integrating M&S with pharmacoeconomic analysis to inform decision making 
throughout the whole drug development process and possibly achieve personalised 
evaluations. Both examples support the fact that PKPD relationships are crucial in the 
assessment of a drug efficacy and safety and should not be omitted when performing a BR 
appraisal. 
In addition, we propose here the use of PKPD modelling as the pharmacological basis for 
evidence synthesis and evaluation of novel therapeutic agents. Various methodologies are 
available for evidence synthesis, and among them network meta-analysis (NMA) has been 
widely used in BR analyses to combine all available evidence (127-128). These approaches 
though, rely on very large amount of information and as discussed in this manuscript depend 
only on the evidence generated. As opposite to a model-based approach, they are not able 
to provide an understanding or a quantification of the underlying PKPD mechanisms and 
subsequently cannot be used to anticipate and explore virtual scenarios through Clinical Trial 
Simulations and/or Not-in-trial Simulations (129). In a post-marketing phase the contribute 
of NMA is indeed invaluable but in a pre-marketing evaluation where limited data is 
available PKPD cannot be ignored and to our understanding may be crucial for a 
comprehensive BR evaluation.  
 
In conclusion, it should be highlighted that models do not make decisions, people do. 
Ultimately, patients, clinicians, drug developers and regulators need to acknowledge that 
decisions are better made when data are presented and communicated in a clear, 
systematic manner. PKPD modelling can complement evidence generation by providing 
stakeholders the opportunity to explore conditions that have not been experimentally tested 
at the time of BR analysis. Regardless of the limitations models and simulation scenarios may 
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The theory underlying the use of decision trees is based on visualisation of the decision 
making process by a branching structure with decisions as roots, and possible outcomes as 
branches. In this way, decisions, subsequent uncertain events, consequences and multiple 
criteria are described (14). Complexity arises with addition of extra nodes. In the EMA 
framework for benefit-risk assessment, this technique has been used as a link between 
qualitative and quantitative approaches, as it encompasses objectives and possible 
outcomes, combined with numerical data on frequencies and uncertainties, with which 
benefit-risk balance can be calculated for each outcome or decision. Figure S1 shows an 
example of a decision tree. The decision (square node) consists of two alternatives: 
approving the vaccine against H1N1 swine flu by the end of September, or waiting until 
October, so more data can be gathered on efficacy and safety. The remaining uncertainties 
are modelled as events (round nodes), for which consequences the working group 
determined the probability, mostly based on earlier experience. Disease seriousness for 
example has a probability of 20% to become severe, based on the historical observation that 
one in five pandemics becomes catastrophic (Spanish flue). For the delay, this probability 
increases, as early vaccination can prevent escalation. All other probabilities are determined 
and the estimated deaths or serious disabled (DSDs) are stated for all 24 outcomes (triangle 
nodes). The decision tree itself enables back calculation to the actual decision, providing the 
consequence of each alternative would be. This is achieved by multiplying outcomes with 
the probabilities as weight. Taking the best case scenario, the working group determined 
that in the case of early approval, moderate disease seriousness probability is 0.8, 
probability of efficacy of 75% is 0.3, with probabilities of safety events rate of 1/100,000 and 
1/10,000 at 0.9 and 0.1, respectively. The latter outcomes are stated to be 42500 and 87500 
DSDs, so calculating back, the average DSD-value of the vaccine in early approval in case of a 
moderate disease with an efficacy of 75% is 47000 DSDs. Applying these steps for all 
outcomes and events results in an average DSDs for the two alternative options, in this case 
216,500 for September and 291,547 for October, showing that earlier approval is the better 
option, a decision made after completion of a sensitivity analysis of the chosen probabilities 
(86). A reconstruction of the complete decision tree can be found in (120). This concept 
alone is valuable when cases remain relatively simple. Although the tree itself might be too 
complex in advanced cases, it remains an important building block for more evolved 
techniques, such as MCDA. 
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MCDA and the EMA’s BR framework 
When evaluating very complex scenarios with multiple endpoints and objectives, it becomes 
crucial to have a clear understanding of the context structure. In very simple words, MCDA 
allows breaking up the problem and analyzing individual factors, before reassembling each 
component to provide a thorough overview of the analysis and making a final decision (102). 
In this structure, it combines the decision tree theory with value functions. In other words, it 
converts the different inputs for the decision model into preference values, allowing 
comparing the different endpoints on a common ground. The preference value scale 
requires probability, utility and the preference of the alternative associated with the highest 
expected utility. Multiple objectives are evaluated together on different identified criteria 
and a balance is made after scoring and weighting these criteria, with uncertainty taken into 
account (14). As highlighted by the EMA BR project, the use of the PrOACT-URL approach in 
combination with decision tree and MCDA represents a more transparent and consistent 
assessment of the BR balance (44). The technique consists of eight steps that will be briefly 
discussed in the following paragraphs. In the next section, these steps are illustrated using 
Benlysta (belimumab), a drug against Systemic Lupus Erythematosus (SLE), as a paradigm 
compound (121). 
Step 1 to 3: defining decision context; identifying options, eg. study arms; identifying 
objectives and criteria, eg. maximising benefit and minimising risk, more specified in a 
decision tree. This part of MCDA overlaps with the PrOACT-URL approach: creating a 
qualitative framework of objectives and context, as well as with the decision tree, as 
mentioned earlier (120). Benlysta has been proposed for the treatment of adults with high 
disease activity, with autoantibody-positive SLE. It should be added to the standard 
treatment, which consists of hydroxychloroquine and corticosteroids (step 1). The available 
studies include two randomised, placebo-controlled clinical trials and three open-label 
continuation safety trials. The dosing regimens used in these trials include either 1 or 10 mg 
(step 2). There is a medical need for newer, more effective and better tolerated therapies. 
To specify these criteria, an effect tree is composed, as visualised in Figure S2 (step 3).  
 
Step 4 and 5: scoring; weighting. Scoring and weighting are the most important steps as their 
aim is to normalise the raw input data for the decision model by translating them into 
preference values. Scoring means scaling each criterion (input data characterised by 
different units and time scales) by assigning a new range, which is usually set between 0 and 
100. Within this range, different outcomes are directly or indirectly scored, where the ratio 
of difference is the most important. Scoring for Benlysta, as visualised in Table S2, is 
performed following defined clinical scales, like SLE Disease Activity Index (SLEDAI). First, the 
two extremes are evaluated, best and worst with corresponding units, after which the three 





The weighting step normalise all measures into one preference scale, judging which criteria 
is more important and allowing comparing the different options into one common level 
(103). This procedure allows translating the scoring into preference values, which carries the 
subjective component. Weighting can be done linear, direct or inverse, or non-linear. Finally, 
swing weights are assigned, based on trade-offs among favourable or unfavourable effects, 
or between the most important favourable and unfavourable effects. In other words, if 
objective A is twice as important as objective B, the score doubles on that scale. These swing 
weights depend on the subjective choice considering the relative difference in original scale 
and the importance of the corresponding objective to the whole. Considering as an example 
buying a car, limiting costs is an objective of importance. If, however the difference between 
alternatives in this criterion is only small, the impact of that objective becomes limited (79). 
It is also important to take into account the possibility of single events that are multiple 
times considered. In this specific case, the SLE assessment scores SLEDAI and BILAG-index 
have similar criteria, like psychosis or vasculitis. If this is not corrected by the assignments of 
weights, these events have double impact on in this case the unfavourable effects (122). 
 
Step 6 and 7: combining data to overall value; examining results. The overall score is simply 
the sum of the product of the score and weight per criterion, as stated in equation 1, where 
Si is the overall score per option i on criterion j, with sij as preference score of the option and 
wi as the weight of the criterion (41). 
 
 Si = w1si1 + w2si2 + … + wnsin = nj=1 ∑ wjsij    eq.1 
 
This aggregation is performed by software; several are currently available for this 
methodology (e.g., HiView, V.I.S.A., Web-Hipre, Expert Choice, Logical Decisions) (123). 
Cumulative weights are calculated based on the normalized weight; overall weighted scores 
per options are visualized graphically (Figure S3).  
 
Step 8: perform sensitivity analysis. The sensitivity analysis is important to identify possible 
judgments of serious impact, thus reducing uncertainty. Displaying the variation of weights 
on each criterion allows identifying possible crossovers at which a change in the relationship 
between weight and criterion might be observed for the different options. 
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Table S1. Overview of quantitative methodologies to assess benefit-risk balance, as given by the CHMP [14].  
 
Method Advantages Limitations References 
Bayesian beliefs 
networks 
Network of nodes representing risks, 
benefits, observations and 
assessments, connected by 
conditional arrows, which input 
probabilities result in probability 
distribution for all nodes. Inclusion of 
both objective data and subjective 
expert opinion. Visualisation of effect 
of factors on each other. 
Requires structural similarity across 
cases, which in BR might only be 
appropriate for similar indications. 
Probability input as a subjective 
element remains unsupported. 
Uncertainty of indirect effects 
introduces bias in their impact on the 
outcome. 
(14,29,82,96,101) 
Bayesian statistics Prior and posterior probabilities 
based on available evidence. Tgether 
describe the likelihood of an effect 
and its uncertainty, combined with 
utility function in the Bayesian 
approach. Methodology improves as 
more data are gathered, as it 
involves iterative learning.  
Significance levels state something 
about data, not hypotheses, so cannot 
directly be included into a formal BR 
assessment. The model itself doesn’t 
include multiple criteria. Mathematical 
models can get complex. 
(14,27,53,64,81,89) 
Clinical Utility Index Multi-attribute utility analysis with 
weighted trade-offs. Utility function 
introduces clinical meaning to the 
assessment. CUI is flexible over 
different indications and endpoints. 
Transparent method with possibility 
of sensitivity analysis.  
In case of limited applicable data, 
complex modelling with high 
variability and uncertainty is required. 
Subjective discussion on clinically 
relevant factors remains unsupported. 
More useful for a no-go than for a go-
decision 
(45,56,62,65,68,83,84,87,95) 
Conjoint analysis Covers preferences of different 
stakeholders, utility weight is based 
Labour intensive if all stakeholders are 






on preferred trade-offs. Realistic 
method helpful in weighting.  
independent from methodological 




Benefits are translated to financial 
values by enquiring the prize patients 
are willing to pay for it.  
Not focused on BR assessment (14) 
Decision tree Overview of all possible outcomes 
with their probabilities, calculated 
using the branches and nodes 
leading to said outcome. The 
decision tree is a useful framework. 
Too simple for complex cases. 
Uncertainties are only limited covered, 





Detailed simulation based on 
differential equations and 
continuous variables. Ability to 
handle multiple assumed 
characteristics and simultaneously 
assess impact of multiple effects on 
health economics. 
Complexity, complicate adaptability, 
lack of transparency and validation. 
Risk of underestimation in case of 
prediction limited to short term 





Model visualised as a set of scales, 
including the benefit ‘box’ with 
efficacy, including responder rate 
and evidence and the risk ‘boxes’, for 
each ADE, with seriousness, 
frequency and evidence. The method 
correlate to EMA’s definition, as the 
first two criteria of either box are 
(un)favourable effects and the third 
includes uncertainty of effects. 
Simplified multi-criteria model with 
limited (three) criteria each. There is 
no application supporting the 
translation of effects into one unit. 
Preference weights are not accounted 
for. 
(14,19) 
Incremental net Incremental net health benefit is the Although this is a version of a multi- (1,14,23,32,33,72,90) 
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health benefit difference between unfavourable 
effects and favourable effects 
derived from the treatment options, 
where all effects are normalised into 
one unit. The method is transparent 
and theoretically sound, including 
uncertainty and extrapolation in 
time.  
criteria model, such as MCDA, 
translation to a single unit requires 
another methodology (e.g., value-
adjusted life years, or QALY). QALY can 
only be transferred to health benefit 
when costs are not considered, in 
other words the willingness to pay is 
infinite. Weighting of effects is also 
dependent on another methodology, 
like conjoint analysis. This 
methodology on itself is incomplete. 
Subject to bias by confounders. 
Kaplan-Meier 
estimation 
Function of survival over time, 
impact measured in ratio of 
differences, useful in Markov 
models. 
Limited representation of 
(un)favourable effects, for example in 
non-fatal indications. It does not 
account for uncertainty and 
cumulative probabilities can be 
misleading due to lack of correlation 
structure (e.g., competing events). 
(14,49,100) 
Markov model Describes time-dependent dynamic 
processes, using transitions between 
health states and their probability 
distributions. 
Probability data might be sparse 
before approval. Complex health 




The method allows incorporating 
risks and benefits into one single 
metric. In addition, relative utilities 
can be considered during the 
analysis. 
The statistical properties are not yet 
fully understood and the methodology 
does not allow characterising the 
uncertainty around the benefit-risk 
measurements. 
(1,40,57,58) 





the problem, followed by scoring and 
weighted assessment of benefits and 
risks as most representative 
presentation of data. Sensitivity 
analysis prevents unwanted impact. 
Incorporates uncertainty. 
simple analysis. Does not account for 
possible correlations between 
endpoints. Preference value 
determination is accounted for in the 
weighting step. 
24,26,34,44,47,63,79,80,102,103) 
NNT Easy understandable measure used 
in the clinic, stating the number of 
patients required to treat one 
occurrence of the disease (or to have 
one more ADE in NNH). Patient 
preferences can be included using 
Relative Value Adjusted NNT (RV-
NNT). 
Limited statistical power and because 
of lack of preference data, 
misinterpretation by different risk 
perceptions, as well as by using the 
same scale without proper weighting 
effects. Ratio of NNT/NNH assumes 
independence and similar timescale.  
(1,4,14,22,23,36,46,48,57,58,67,69) 
Principle of threes Simplified method in which only 
three criteria per risk/benefit are 
scaled with three possible outcomes 
(e.g., low, medium, high), benefit 
and risk are summed up.  
Very limited in number of criteria. No 




Complementary to point estimate 
statistics, as it states the impact of 
risk and benefit as a probability 
distributions based on simulated 
random draws from study data. 
More precise, accounts for 
uncertainty in trade-offs. Can 
account for correlation, if suitable 
data is available. 
Limited if using non-validated or non-
representative probability 
distributions for simulation. Benefits 
or risks are not weighted, shown by 
the fatal adverse event in the 
adalimumab-study, which did not 
seem to affect the simulation analysis. 
(1,14,23,70,72,73,78,91) 
QALY Multiple dimensions are scored and Limited in uncertainty and unique (14,25,92) 
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weighted for preference, outcome 
measured in life years on population 
level. 
(disease/patient) data representation, 
more focussed on health- and 
pharmacoeconomics. Threshold is 
debatable. 
Q-TWiST The method is used to convert time 
into QALYs; time lost due to an ADR 
is subtracted to time gained from 
receiving the treatment. Q-TWiST 
allows comparing benefits and risks 
into a single metrics. Furthermore, 
allowing the inclusion of patients’ 
preferences is considered a valid tool 
for individual BR assessment. 
Although valid for individual 
assessments, it gives more difficulties 
to evaluate BR on a population level. 
Does not allow measuring uncertainty 
around QALYs. The data needed for 
the analysis might be difficult to 
acquire. In addition QALYs might have 
a major influence on the BR outcome. 
(1,22,37,39,49,50,59,75,77,93,94) 
Stated preferences Collection of methods using 
preference values to determine 
utility functions of different 
stakeholders. Measures e.g., the 
extent patients are willing to 
experience unfavourable effects to 
achieve favourable effects. 
Empirical method that does not 
account for uncertainty or weighting. 
Overlaps with conjoint analysis. 
Gathering of individual patient data is 
time consuming.   
(1,14,23,38) 
System dynamics Account for non-linearity using 
feedback and time-delays, both short 
and long term. Possibility of input 
data from different sources. 
No recorded use in drug development. 
Focus on pharmacoeconomics. No 
consideration of (weighted) 
unfavourable effects, such as ADEs. 
(14,55) 
TURBO Simplified method in which only two 
criteria per risk/benefit are scaled up 
with five possible outcomes. Pairs of 
outcomes are weighted and 
assessed. Frequency, probability, 
Very limited in terms of the number of 
criteria. There is no way of knowing 
prior to assessment which criteria to 
choose. Choice might be arbitrary. No 






severity and extent are included into 
the choices of criteria. 
 
Table S2. Scoring of Benlysta according to the different criteria, as visualised in the decision tree. FE and UFE are favourable and unfavourable 
effects, respectively. SRI is SLE Response Index, SLEDAI is SLE Disease Activity Index, PGA is Physician’s Global Assessment, BILAG is British Isles 
Lupus Assessment Group, where A indicates severe disease and B less active disease. Secondary favourable endpoints are CS, corticosteroids, 
Flare rate meaning number of new BILAG A cases and QoL measured as mean change in the total score of Short Form 36. SAE are serious adverse 
events, such as tumour development, opportunistic infections or progressive multifocal leukoencephalopathy (PML). *> 25% and to less than 7.5 
mg/day, ** per patient year. Based on (15). 
 
Effects Name Description Best Worst Units Placebo 10 mg  1 mg 
Favourable SRI SLEDAI Improved ≥ 4 100 0 % 41 53 48 
PGA No worsening 100 0 % 66 75 76 
PGA Mean change 1 0 Difference 0,44 0,48 0,45 
BILAG No new A/2B 100 0 % 69 75,2 70,1 
Secondary 
endpoints 
CS sparing Dose reduction*  100 0 % 12,3 17,5 20 
Flare rate New BILAG A cases** 0 5 Frequency 3,51 2,88 2,9 
QoL Mean change SF36 0 100 Difference 3,5 3,4 3,7 
Unfavourable  SAE Potential  100 0  100 0 90 
Infections Life-threatening infections 0 10 % 5,2 5,2 6,8 
Sensitivity 
reaction 
Hypersensitivity reactions 0 2 % 0,1 0,4 0,3 
 




Figure S1. Example of decision tree concerning approval of swine flu vaccine in 2009, where decision 
of approval planning is followed by the consequences for disease seriousness. Efficacy branches 
attach to A through D, whereas safety branches to E through G resulting in 24 scenarios with 
calculable event outcomes. Based on (116). 
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Figure S2. Outcomes tree based on identified criteria used for the Benlysta example. FE and UFE are 
favourable and unfavourable effects, respectively. SRI is SLE Response Index, SLEDAI is SLE Disease 
Activity Index, PGA is Physician’s Global Assessment, BILAG is British Isles Lupus Assessment Group, 
where A indicates severe disease and B less active disease. Secondary favourable endpoints are CS, 
corticosteroids, Flare rate meaning number of new BILAG A cases and QoL measured as mean change 
in the total score of Short Form 36. SAE are serious adverse events, such as tumour development, 























Figure S3. Different data presentations to evaluate benefit risk balance, in which the cumulative 
weight is calculated and the overall weighted scores are visualised. Left, impact of favourable effects 
(FE) and unfavourable effects (UFE) are shown in green and red, respectively. On the right, all 
different criteria are shown with their impact, which results in a more informative presentation of 
the data. For example, sensitivity reaction to 1mg has decreased impact as compared to placebo or 

















































Model-informed benefit-risk assessment of 
iron chelation in transfusion-dependent 
haemoglobinopathies  
 
Scope and intent of the investigation 
 
 
2.1 General introduction 
Drug approval by regulatory agencies is granted on the basis of the evidence on the safety 
and efficacy profile of a drug, which has been generated throughout the drug development 
phases (1–4). At this stage, decisions about the benefit-risk balance rely on the assumption 
that the data collected are sufficient to allow an unbiased evaluation of the safety and 
efficacy of a given intervention. This assumption may not be valid for all drugs, with a vast 
number of conditions and diseases in which numerous clinical questions cannot be fully 
addressed at the time of approval.  In fact, the use of a question-based approach for the 
review of regulatory submissions by some regulatory agencies has highlighted the relevance 
of understanding which clinical and scientific questions need to be considered for the 
approval of a new drug.  To be effective, such a regulatory process requires sponsors, 
researchers and clinicians to reflect on which data need to be generated, what is already 
known and how both existing and new data are integrated and processed. Moreover, as 
widely recognised by different stakeholders, including regulatory authorities, industry and 
patients (5–7), a clear framework for the assessment of benefit-risk balance (BRB) in which 
quantitative methods are used to translate findings obtained during the development 
process into measures that summarise favourable and unfavourable effects of treatment, is 
still lacking. This situation has resulted in undefined, inconsistent and non-transparent 
decision making (8–10).  
 
Clarity about which clinical and scientific questions need to be addressed as well as the 
availability of quantitative methods to translate findings into summaries of favourable and 
unfavourable effects are requirements that apply to all drugs, but they become even more 
relevant when dealing with special populations, such as the paediatric population, where 





challenging (11–14). These hurdles limit the level of evidence available at the time of the 
first-marketing authorisation, as compared to other populations. In this thesis we focus on 
the current challenges in evidence generation during paediatric drug development. We 
demonstrate how modelling and simulation (M&S) can be applied for evidence synthesis and 
decision making; by the integration of existing and new data, to address essential clinical and 
scientific questions and to support a more comprehensive evaluation of the benefit-risk 
balance of a medicinal product prior to its approval. In addition, the implementation of such 
a framework will allow for better understanding of consequences of an intervention, and 
consequently improve risk management and therapeutic use of medicinal products. The 
examples provided in the following chapters were developed in the context of paediatric 
diseases, but the concepts underpinning the proposed framework can be extrapolated to a 
broader range of diseases and conditions across any patient population. 
 
In order to demonstrate the contribution of modelling and simulation as a tool for more 
effective data generation, evidence synthesis and better decision making, the work 
presented in this thesis will be divided into three main sections, namely: 
1. Optimisation of study protocol design and data generation in children ;  
2. Integration of existing knowledge and mechanism-based parameterisation of drug-
and disease-specific properties; 
3. Use of clinical trial and not-in-trial simulations to complement data generation and 
improve benefit-risk assessment. 
 
An outline of the scope of the research and details on the implementation of the different 
sections are presented in the next paragraphs.   
 
In chapter 1, an overview of the different methodologies currently available for benefit-risk 
assessment (BRA) is presented. Focus is given to differences between qualitative and 
quantitative approaches and the relevance of the latter for accurate decision making about 
the benefit-risk profile of a medicinal product. As recently suggested by EMA, amongst the 
available approaches the use of Multi Criteria Decision Analysis (MCDA) appears to have the 
right features to address the lack of transparency in the way benefit-risk balance is assessed, 
enabling integration of different dimensions or levels of clinical concern during the process 
(15).  
Our review highlights how MCDA can benefit from the use of M&S in order to better define 
the BR balance of a given drug and vice versa, i.e. how concentration-effect relationships can 
provide a stronger basis for understanding benefit and risk, and how pharmacologists can 
gain insight into the therapeutic value of an intervention by jointly evaluating multiple 




endpoints. The advantages of such an integrated approach are illustrated by the few 
available examples in the published literature. 
 
The theoretical concepts presented in chapter 1 form the basis for the experimental work 
proposed in this thesis, which will be described in the subsequent paragraphs in this chapter. 
We will make use of chronic iron overload by transfusion-dependent haemoglobinopathies 
as a case study. Iron overload provides all the necessary elements, i.e., a complex 
multidimensional disease condition with short- and long-term complications that can lead to 
different clinical presentations over time. Moreover, it has a sufficiently low incidence to 
allow lessons learned to be applied in other rare paediatric diseases.  
 
2.2 Transfusion-dependent haemoglobinopathies 
Among the transfusion-dependent diseases, -thalassaemia major is one of the most 
common disorders. It belongs to a group of hereditary blood disorders characterised by 
reduced or absent beta-globin chain synthesis. As a result, patients suffer from reduced 
haemoglobin (Hb) levels in red blood cells (RBC) and decreased RBC production followed by 
anaemia (16).  
 
Historically, the majority of thalassaemia patients are located in the Mediterranean 
countries, in the Middle East and Asia. According to the Thalassaemia International 
Federation (TIF), around the world only about 200.000 patients are alive and registered as 
receiving regular treatment (17). Children are usually diagnosed between 6 and 24 months 
after birth. Early clinical symptoms include feeding problems, diarrhoea and progressive 
enlargement of the abdomen caused by spleen and liver enlargement. In some developing 
countries, patients also suffer from growth retardation, poor musculature and skeletal 
changes (18). Individuals affected by -thalassaemia major require regular RBC transfusions 
to survive. Without transfusions or in the presence of poor management of the disease, 
patients often die before the third decade of life. According to the guidelines for the clinical 
management of thalassaemia (17) transfusion intervals should aim to maintain a pre-
transfusion Hb level between 9 and 10 g/dl and a post-transfusion level of 14 to 15 g/dl.  This 
requirement implies the need for frequent blood transfusions, with the most common 
transfusion interval being once every two to four weeks (equal to two to three blood units 
per three weeks). 
A graphical overview of iron distribution and storage is provided in figure 1. In the context of 
transfusion-dependent diseases, it worth mentioning that there is no innate mechanism that 
is able to clear any iron excess from the body. Under normal physiological conditions, iron is 









Figure 1. Iron homeostasis. In a balanced state, 1 to 2 mg of iron enters and leaves the body each 
day. Dietary iron is absorbed by duodenal enterocytes. It circulates in plasma bound to transferrin. 
Most of the iron in the body is incorporated into haemoglobin in erythroid precursors and mature 
red cells. Approximately 10 to 15 percent is present in muscle fibres (in myoglobin) and other tissues 
(in enzymes and cytochromes). Iron is stored in parenchymal cells of the liver and reticuloendothelial 
macrophages. These macrophages provide most of the usable iron by degrading haemoglobin in 
senescent erythrocytes and reloading ferric iron onto transferrin for delivery to cells. Adapted from: 
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Iron entry into the cells is regulated by the uptake of iron-transport protein transferrin from 
the plasma. Once chronic RBC transfusion therapy has started, iron exposure in 
macrophages increases, which results in the saturation of transferrin transport capacity. This 
leads to the release of non-transferrin bound iron (NTBI) in plasma.  NBTI can then enter 
important tissues (e.g., in heart and liver) and accumulate over time. As iron is stored in 
tissues mainly as ferritin complexes, once ferritin storage capacity has saturated small 
clusters of ferritin particles will be formed and degraded by lysosomes leading to the 
formation of insoluble masses of hemosiderin (20–26). Over time these masses can cause 
severe organ damage (19,27–31). 
 
Iron overload and chelation therapy 
Even though significant improvements have been achieved in the management of the 
chronic transfusion regimens in the past decades, RBC therapy will eventually lead to a series 
of complications. Iron overload is the most common and relevant one and it is associated 
with several (lethal) co-morbidities such as cardiac dysfunction, liver fibrosis, hypogonadism, 
hypothyroidism, hypoparathyroidism and diabetes mellitus (28,30). Cardiac disease caused 
by myocardial siderosis is the most relevant complication, causing death in 71% of the 
patients affected by transfusion-dependent diseases (27). In the absence of an innate 
mechanism that allows removing iron excess from the body,  treatment with iron chelators is 
essential to prevent iron accumulation and related complications (32–35). An overview of 





Table 1. Summary of the available iron chelators. Adapted with permission from: Kwiatkowski JL. 
Pediatr Clin N Am. 2008; 55:461-82 (33) 












Usual dosage 25-50 mg/kg per 
day 
75 mg/kg per day 20-30 mg/kg per 
day 
Schedule Administered 
over 8-24 hours, 
5-7 days per 
Week 
Three times a day Daily 












Advantages Long-term data 
Available 
May be superior in removal 









Not licensed for use in 
United States. 




Drug cost $ $$ $$$ 
 
Iron chelators possess a similar mechanism of action. They act by 1) preventing the uptake of 
NTBI into organs, such as liver and heart; 2) chelating intracellular iron and thus preventing 
its incorporation into ferritin; or 3) intercepting iron released from degraded ferritin (36).   
 
Clinical assessment of iron overload 
The symptoms and signs associated with iron overload can be initially diagnosed and 
assessed by different clinical biochemistry parameters. The most common marker of iron 
imbalance is serum ferritin, which indirectly reflects the correlation between circulating 
levels and total body iron stores (37). The use of serum ferritin alone, as a single clinical 
marker however is not always sufficiently robust to detect iron overload. Ferritin levels are 
also be influenced by other factors such as inflammatory disorders and liver disease (38). 




Therefore, serial measurements of serum ferritin are still the easiest and least invasive 
method to evaluate iron overload and efficacy of chelation therapy.  
Other methods for the assessment of iron overload focus more on tissue specific 
accumulation. Liver iron concentration (LIC) is considered as the gold standard for the 
evaluation of iron overload. LIC has been shown to correlate well with total body iron 
accumulation (39). The measurement  of liver iron concentration requires,   however,  an 
invasive technique, which may lead to potential clinical complications and bias, such as in 
the case of false negative results (40). Magnetic bio-susceptometry (SQUID) is another 
option for measurement of liver iron accumulation (41). However, it is only available in a 
limited number of centres worldwide. Furthermore, cardiac complications due to iron 
accumulation in the heart have been associated with 50-70% of deaths in thalassaemia 
major patients, mainly at young age (42). Methods for cardiac monitoring were developed 
under the assumption that keeping serum ferritin and LIC level below a certain threshold 
(<2500 μg/L and <7 mg/kg dwt respectively) would lead to decreased cardiac risks. However, 
cardiac dysfunctions were often identified at relative late stage of treatment, suggesting that 
this method was not sufficient for effective intervention. In recent years, magnetic 
resonance imaging (MRI) techniques for assessing iron loading in the liver and heart have 
been introduced and validated for the evaluation of tissue specific accumulation (43). 
 
Clearly, understanding and integration of knowledge about the short and long term 
mechanisms underlying iron overload are lacking. The ability to predict iron organ 
accumulation based on systemic, non-invasive markers such as ferritin will depend on 
further characterisation of dynamic, homeostatic processes.  In this context, accurate details 
of the transfusion history and assessment of the effects of chelation therapy are equally 
important.  
 
 In the next sections we present details of the investigations, which will provide the basis not 
only for the characterisation of the disease, but also for the design and optimisation of 
clinical protocols in children.  These concepts are followed by the introduction to methods 
supporting evidence synthesis as a means to better understand the safety and efficacy 
profile of a drug.  Two important aspects reflect the novelty in the approach described here. 
First the use of a multi-model analysis in which different measures of efficacy and safety are 
derived according to underlying biological or pharmacological correlations, where applicable. 
Second, the integration of clinical data from real and virtual patients, whose responses are 
simulated from the aforementioned models, to improve the assessment of benefit-risk 






2.3 Optimising evidence generation in paediatric trials 
Practical and ethical constraints to the implementation of clinical trials in the paediatric 
population (11,12,14), make evidence generation in most paediatric diseases extremely 
challenging. The value of the new data is tremendously higher than in a standard protocol 
involving adults. Yet, little attention has been paid to the opportunities to ensure that high 
quality data are obtained whilst keeping the burden for the children to a minimum.  
As indicated previously, the approval of a medicinal product relies on the ability of a sponsor 
to address clinical and scientific questions regarding the efficacy and safety profile of the 
drug under investigation.  Here factors such as how knowledge is generated in this 
population and which type of data is needed to approve a given therapeutic intervention 
ultimately underpin the validity of the experimental evidence provided in a regulatory 
submission.  In a very simplistic manner, it can be said that three scenarios have been used 
to determine the rationale for paediatric programs, while relying on adults as a reference 
population: 1) if the disease has different features in adults and children, then both 
pharmacokinetic and efficacy/safety data must be generated; 2) if the disease and its 
progression  as well as the main endpoints of interest are similar in the two populations 
bridging concepts can be applied and pharmacokinetic and eventually pharmacodynamic 
data should be sufficient to prove comparable efficacy; 3) in some cases it is also conceivable 
that pathophysiogical processes  and pharmacological mechanisms are sufficiently 
understood to allow extrapolation of efficacy findings from the adult population without the 
need of generating new evidence in children. In all three cases the quality of the data 
collected is crucial to establish not only the effect size of a treatment, but also to define the 
actual benefit-risk profile of the intervention.   
From a clinical and scientific point of view, this implies that high accuracy and precision are 
desirable, irrespective of the nature of the trial. 
 
Whilst the aforementioned scenarios are valuable steps to mitigate the burden of evidence 
generation in children, they also imply the need for generating evidence prior to approval as 
a key requirement. None of these scenarios formally considers how current understanding 
of a drug, disease or patient population in adults can contribute to the decision making 
process for children.  We foresee the integration of available knowledge with clinical data 
can significantly improve one’s ability to assess the benefit-risk profile of a treatment and 
reduce the uncertainty associated with gaps in the data available at the time of submission. 
From a clinical pharmacology perspective, this implies that the concept of bridging could be 
expanded to situations where the disease is different in children and adults. If, such 
differences are simply due to the natural course of the disease, then these differences may 
be predicted by parametric (mathematical) representation of the underlying processes in a 
drug-disease model. This is the situation that we deal with throughout this thesis, i.e., 




haemoglobinopathies, in which long-term complications, which are the primary 
consequence of iron overload, clearly mark the difference between adults and children and 
can be anticipated using prior knowledge. 
 
Amongst the opportunities for increasing the informative value of data collected in children 
is the possibility of using population pharmacokinetic or pharmacokinetic-pharmacodynamic 
modelling in conjunction with optimal design concepts to reduce sample size and frequency 
in the so-called bridging studies.  
 
Despite the wide clinical experience with iron chelators, and more specifically with 
deferiprone, there is no pharmacokinetic data in children below 6 years of age. Given the 
nature of the disease and its progression, a model-based approach can be used to optimise a 
prospective pharmacokinetic study in children and consequently define the dosing 
requirements in this subgroup. First, we demonstrate in chapter 3 how available 
pharmacokinetic data from adults and adolescents can be characterised by means of a 
population pharmacokinetic model. We then explore how uncertainty about the changes in 
pharmacokinetic properties of deferiprone can be evaluated in conjunction with optimal 
design theory. A proposal for sampling schedule and group size is presented in chapter 4, 
where ED-optimality concepts are used to identify the most suitable sampling scheme in the 
absence of data in the population under investigation. This information will be used to 
support the design of a prospective bridging study in children with less than 6 years of age. 
Subsequently, we show how modelling and simulation enables the evaluation of the 
pharmacokinetics of deferiprone based on sparse data. Dosing recommendations are 
proposed based on the predicted exposure to deferiprone taking into account the parameter 
distributions in the target patient population.  In this investigation, it is worth mentioning 
that dosing recommendations involve more than simply the data obtained in a small group 
of children: it encompasses parameter-covariate interactions, which may not be well 
represented in the trial population. 
Whereas these concepts have been implemented for a specific drug, a similar approach can 
be applied for the evaluation of biomarkers or clinical response.  
 
2.4 Integrated evaluation of efficacy and safety by modelling and 
simulation 
The concepts underpinning the optimisation of pharmacokinetic data collected in 
prospective clinical trials are also extremely important in the evaluation of the 
pharmacodynamics of a drug. In this sense, population PKPD modelling can be applied as a 
tool for evidence synthesis. In addition to the opportunities to increase the informative 





of clinical pharmacology research, i.e., the integration of information  as the basis for the 
evaluation of treatment response when complex and multiple factors  are involved. 
Moreover, the approach enables one to account for multidimensionality, i.e., to evaluate in 
an integrated manner multiple endpoints. The correlation or interdependency between 
endpoints or measures of drug response is currently overlooked when quantitative BR 
analyses are performed. Experimental evidence from clinical trials is handled in empirical 
manner, which disregards the (pathophysiological or pharmacological) mechanisms 
associated with the underlying correlations or interdependencies. PKPD models provide an 
opportunity to quantify such correlations and account for them when performing BR analysis 
and drawing conclusions about the benefit-risk profile of an intervention. It is also worth 
mentioning that understanding of the dynamics of disease and its progression is critical to 
assess the long-term implications of a therapeutic intervention. Such an integrated approach 
will be illustrated by combining clinical data with available knowledge (e.g. epidemiological 
data on background rates of expected co-morbidities; or knowledge acquired on a different 
disease, population or drug of the same class).  
 
More specifically, in the context of chronic iron overload serum ferritin levels are often used 
as markers of total body iron accumulation. Despite known limitations of instantaneous  
serum ferritin levels as a predictor of iron organ accumulation, model-based approaches can 
be developed which incorporate MRI data as well as other measurements (e.g., SQUID or 
LIC) to better describe tissue specific accumulation (see paragraph 2.2.2). However, a 
challenge remains in that such measurements may not be easily performed or feasible in 
young patients.  Therefore, situations exist in which decision-making will have to be guided 
by evidence arising from endpoints which do not reflect drug-disease interaction in the 
target population. An attempt will be made to demonstrate how evidence synthesis by 
modelling and simulation may provide a more robust basis for extrapolating findings from 
adults to children and for translating short-term results into long-term predictions. 
 
In chapter 6 we develop a disease model based on available literature data, in which 
changes in serum ferritin levels are correlated with RBC transfusion regimen. The approach 
is developed in a stepwise manner; first we evaluate basal, physiological changes in serum 
ferritin in healthy individuals by means of a turnover model. Then, the effect of RBC 
transfusions is added into the model to quantify changes in the production rate of ferritin. 
Our investigation provides for the first time in a parametric way, evidence of the relationship 
between blood transfusions and serum ferritin levels. This physiological turnover model 
forms the basis for a more structured evaluation of chelation therapy in transfusion-
dependent iron overload. The approach is subsequently validated in chapter 7, where data 




from 27 patients affected by transfusion-dependent diseases are used to predict the effects 
of deferoxamine on ferritin levels.  
 
The scope of the drug-disease model for iron overload is not only to establish the relevance 
of ferritin levels as a measure of effective chelation therapy. The ultimate goal will be to 
demonstrate its value as a tool to support decision making in benefit-risk analysis. Of note is 
the opportunity to explore different scenarios in addition to available clinical evidence. Such 
scenarios may provide further insight into the role of differences in patient population 
characteristics and dosing regimens on treatment response as well as enable one to predict 
potential long-term complications based on short-term effects. Given the multidimensional 
nature of benefit-risk profile, our approach involves not only the integration and 
parameterisation of a drug-disease model for efficacy measures, but also for safety 
endpoints. Therefore, in chapter 8, we evaluate the acute and long-term complications of 
iron chelation therapy using the data obtained from patients undergoing chelation with 
deferoxamine. Different adverse events are considered, which reflect typical features of 
adverse drug reactions, including short and long term events, as well as dose-dependent and 
dose-independent effects.  Such a comprehensive analysis is proposed by integrating 
epidemiological (literature) and pharmacological data. In doing so, we also ensure that 
interdependencies and correlations between the different endpoints under evaluation are 
taken into account in a quantitative manner.  
As in many other chronic diseases, compliance to the prescribed dose and dosing regimen is 
an important factor in chelation therapy. We illustrate how patient behaviour regarding 
compliance to treatment contributes to changes in ferritin levels and consequently affect the 
overall benefit-risk profile of an intervention. Simulation scenarios are evaluated in which 
different compliance patterns are used to assess changes in the magnitude and incidence of 
acute and long-term complications.  
 
2.5 Clinical trial and not-in-trial simulations: accounting for 
exposure, disease progression and uncertainty in benefit-risk 
analysis 
Throughout this thesis we have hypothesised that model-guided evidence generation and 
subsequent integration of new clinical data with available knowledge (i.e., evidence 
synthesis) provides a robust framework for characterising the benefit-risk profile of any 
intervention. We also highlight the limitations of current practice in that any attempt to 
establish the benefit-risk profile at the moment of drug approval relies only on the evidence 
generated (e.g. treatment arms tested throughout the drug development phases). Such an 





target population and suffice to support key decisions about the favourable benefit-risk 
profile and suitability of the recommended dose and dosing regimens. The underlying 
assumptions appear to overlook the fact that in children the natural time course of disease 
occurs in parallel to developmental (physiological) growth and maturation processes. The 
interaction between these processes may lead to significant changes in the benefit-risk 
profile over time and such changes are not evident at the time of approval, nor necessarily 
well captured by long term safety monitoring, as implemented in pharmacovigilance plans. 
Once more we show that a model-based approach can be used in which virtual scenarios are 
created taking into account clinical trial design features, as well as real life factors which are 
known to play a role in clinical practice, such as variable compliance patterns. By performing 
clinical trial simulations and not-in-trial simulations, intrinsic and extrinsic sources of 
variation as well as confounding factors can be appropriately evaluated and incorporated 
into the decision process.  
 
Clearly, most of the points-to-consider described in the previous paragraph are currently 
overlooked or excluded from quantitative BR analysis, independent of the methodology 
used. The highlight of this thesis is therefore presented in chapter 9.,  where we illustrate 
how new evidence (from typical clinical programmes) can be integrated with existing 
knowledge in a parametric manner, using drug-disease models in the context of clinical trial 
protocols or real-life use of the drug. This simulation framework provides a more robust 
basis for establishing the benefit-risk profile of treatment in children.  In fact, clinical trial 
and not-in-trial simulations offer the opportunity to explore scenarios in which the impact of 
covariate factors can be assessed without being limited only to the data available.  
Moreover, we propose the use of Multi Criteria Decision Analysis (MCDA) as the method of 
choice for evaluating real and virtual data together. As discussed in the introduction of this 
thesis, MCDA appears to have the necessary features to characterise and summarise the BR 
profile of a treatment in a systematic and transparent manner. In chapter 9, we perform 
MCDA to establish the benefit-risk profile of iron chelation therapy with deferoxamine in 
thalassaemic patients undergoing frequent transfusions. The drug-disease models developed 
in the previous chapters are used to simulate a range of scenarios; describing typical clinical 
trials and long term follow up. During the analysis the same relative weight is given to both 
types of data, i.e., the available data from clinical trials and the predicted profiles inferred 
from the models. A standard phase III trial (“real data”) is used as a reference scenario and a 
number of alternative dosing algorithms are proposed and compared (“virtual data”). For 
the sake of clarity, here we only look at the optimisation of the dosing regimen and how the 
different options proposed can influence the BR profile. The intent of these scenarios is to 
illustrate how drug-disease models in conjunction with simulations can better support 
regulatory and clinical decision making. A range of applications can be considered, in that 




the proposed simulation framework could also be used to optimise study design before the 
implementation of clinical trials. But most importantly, it could form the basis for 
personalised medicines. Clinical trial and not-in-trial simulations allow us to quantify the 
impact of relevant covariate factors on treatment outcome, thereby demonstrating the 
implications of treatment and population stratification. 
 
2.6 Conclusions and perspectives 
The results and conclusions drawn from our research are summarised and discussed in 
chapter 10. In this concluding chapter, we revisit the different examples presented in this 
thesis and we attempt to shed light on the issues currently faced by clinicians, sponsors and 
regulators involved with the evaluation of the benefit risk profile of a treatment. We make 
clear that evidence generation has been the paradigm for the development and approval of 
new drugs. This paradigm is inefficient and should be questioned for a number of reasons. 
The assumption that arising evidence from clinical trials discriminates drug-specific 
properties from the underlying progression of disease overlooks shortcomings such as 
limited accuracy and precision of the estimates for endpoints, which will be subsequently 
used for BR assessment.  
We defend the need for a development and approval paradigm which relies on a framework 
which supports evidence generation and evidence synthesis as the basis for approval.  
Clinical events or the absence thereof are not spurious, random features of an intervention. 
They are greatly determined by the patient population, the context in which the treatment is 
assessed and by the dose rationale. In addition, we emphasise in this last section, how 
clinical trial and not-in-trial simulations can be used to complement clinical evidence. We 
envisage that such a framework will provide a more structured basis for BR analysis, 
reducing uncertainties about the changes in benefit-risk profile, which are intrinsic to the 
progression of disease and take place in parallel to maturation developmental growth in 
children.  
 
We conclude this thesis with a set of answers to longstanding clinical questions regarding 
the use of iron chelators in chronic iron overload. The approach used to address those 
questions also highlights opportunities for future research in quantitative pharmacology, 
especially with regard to the development of multidimensional models and the relevance of 
Bayesian statistical inference for the implementation of such models. In our final remarks we 
include suggestions regarding the requirements for the prospective implementation of this 
framework as a tool for regulatory approval and risk management for paediatric medicines. 
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Aims: To characterise the pharmacokinetics of deferiprone in healthy subjects using a model-based 
approach and assess the effect of demographic and physiological factors on drug exposure. 
Methods: Data from 55 adult healthy subjects receiving deferiprone (solution 100 mg/ml) were used 
for model building purposes. A population pharmacokinetic analysis was performed using NONMEM 
VII. The contribution of gender, age, weight, and creatinine clearance (CLCR) on drug disposition was 
evaluated according to standard forward inclusion, backward deletion procedures. Model selection 
criteria were based on graphical and statistical summaries.  
Results: A one-compartment model with first order oral absorption was found to best describe the 
pharmacokinetics of deferiprone. Simulated AUC and Cmax (respectively mean of 45.80 mg*h/L and 
17.67 mg/L after 25 mg/kg single dose and 137.40 mg*h/L and 26.50 mg/L after 75 mg/kg b.i.d.) 
were comparable with literature references. Gender differences in the apparent volume of 
distribution (20%) have been identified, which may contribute to an increase in peak concentrations in 
females. Furthermore, simulation scenarios reveal that dose adjustment is required for patients with 
reduced CLCR. Doses of 60, 40 and 25 mg/kg for patients showing mild, moderate and severe renal 
impairment are proposed based on CLCR values of 60-89, 30-59 and 15-29 ml/min, respectively. 
Conclusions: Our analysis has enabled the assessment of the impact of gender and CLCR on the 
pharmacokinetics of deferiprone. Moreover, it provides the basis for dosing recommendations in renal 
impairment. The implication of these covariates on systemic exposure is currently not available in the 





Patients with β-thalassaemia and other transfusion-dependent diseases develop iron 
overload from chronic blood transfusions and require regular continuous iron chelation to 
prevent potentially fatal iron-related complications (1–5). Deferiprone (DFP) is the most 
extensively studied oral iron chelator to date. DFP is a hydroxypyridone derivative, which 
was authorised in Europe in 1999 for the treatment of iron overload in patients with β-
thalassaemia major when deferoxamine (DFO) is contraindicated or inadequate.  
 
Despite the wide clinical experience with DFP, its pharmacokinetics has not been fully 
characterised in patients. In addition, there are still limited experimental data available on 
DFP in children and no data in children under 6 years of age, where the drug is still used off-
label. Thus far, it has been established that when administered orally, DFP is rapidly and 
completely absorbed. Plasma levels show peak concentrations (Cmax) within 1 hour of 
administration. Food reduces its absorption rate without affecting the overall exposure to 
the drug. In patients with -thalassaemia, the administration of deferiprone at doses of 75 
mg/kg/day as a twice-daily regimen yields Cmax of 34.6 mg/L and area under the plasma 
concentration-time curve (AUC) of 137.5 mg/L • h (6,7). On the other hand,  peak serum 
concentrations were 17.53 mg/L and 11.82 mg/L in fasting and fed state, respectively after a 
dose of 25 mg/kg (8). DFP is for the most part inactivated by glucuronidation (>85%) and 
more than 90% of the drug is removed from plasma within 6 hours of ingestion, with an 
elimination half-life of 1 to 2.5 hours in patients affected by β-thalassaemia (5,6,9–14). DFP 
forms a 3:1 complex with iron, which is removed mainly through the kidneys in a similar 
manner as for the free parent drug. The area under the curve (AUC) of free deferiprone in 
patients shows high inter-individual variability, which may be related to the variation in the 
therapeutic response (5,10–12).  
 
The impact of demographic and other physiological factors on the exposure of DFP has not 
been assessed thus far. In addition, the consequences of such factors for the dosing regimen 
have not been described in the published literature or on the SmPC (Summary of Product 
Characteristics) of the drug. Moreover, no information on dose adjustment requirements is 
provided for patients with hepatic or renal impairment. Given the fast renal elimination of 
the glucuronide metabolite, renal function is expected to play a major role in affecting the 
overall exposure to the parent drug. 
 
The aim of this analysis is to characterise the DFP pharmacokinetics in healthy subjects using 
a model-based approach and assess the effect of demographic and physiological factors on 
drug exposure. Furthermore, it is our endeavour to show the clinical relevance of simulation 
scenarios to evaluate the impact of renal impairment on drug disposition and consequently, 
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for the optimisation of the dosing regimen in special populations. Moreover, we anticipate 
that the availability of population pharmacokinetic model for deferiprone will facilitate the 
evaluation of extrapolation of pharmacokinetic data from adults to children. More 
specifically, it will provide the basis for pharmacokinetic bridging of the dosing regimen for 




The pharmacokinetics of deferiprone was evaluated using data collected from two clinical 
studies: LA20-BA and LA21-BE (15,16), in which healthy subjects received a single dose of 
1500 mg of DFP as a 100 mg/ml solution. The studies have been conducted in full 
conformance with the principles of the Declaration of Helsinki and with the local laws and 
regulations concerning clinical trials. The protocol and the informed consent documents for 
each study have been formally approved by the relevant research ethics committee of each 
clinical site. The data was supplied by ApoPharma Inc, Canada and shared within the DEEP 
consortium (www.deep.cvbf.net). The DEEP consortium addresses an EU call with the 
objective of increasing the knowledge of deferiprone chelation therapy in the paediatric 
population.  
Both study protocols were approved by Ethics Committee and all experimental procedures 
performed according to good clinical practice guidelines. In brief, 55 adult healthy subjects 
(39 males and 16 females) who had received the active medication were included in the 
analysis. Blood samples for the evaluation of deferiprone concentrations were taken before 
and at the following sampling times after dosing: 0.167, 0.333, 0.5, 0.75, 1, 1.333, 1.5, 1.667, 
2, 2.5, 3, 4, 5, 6, 8, 10, and 14 hours. On average, 15 samples were collected per subject. 
Median (range) age (years) and body weight (kg) of the adult population were 39 (19-55) and 
72 (52-92) respectively.  
 
Bioanalysis 
Deferiprone plasma concentrations were analysed by a validated method previously 
developed by ApoPharma (Toronto, Canada) using high performance liquid chromatography 
with UV detection (HPLC-UV). Extraction of deferiprone from supernatant was performed 
after precipitation of plasma proteins by trichloroacetic acid (TCA - 15%) and centrifugation 
at 10,000 g for 20 minutes at 4 ºC.  The analytical column used for the analysis was a 
Hamilton PRP-1 and separation of the chromatogram of interest was achieved using an 
isocratic mobile phase (pH 7.0). The UV detector was set at 280 nm. In a recent review of the 
method, calibration, accuracy and precision estimates have been revisited by our group. The 
analytical range was between 3.13 and 800 µM (equivalent to 0.43 to 111 g/ml); and an R2 




quantification (LLOQ) was 1 µM (equivalent to 0.14 g/ml). Inter- and Intra-day accuracy and 




Nonlinear mixed effects modelling was performed in NONMEM version 7.2 (Icon 
Development Solutions, USA). Model building criteria included: (i) successful minimisation, 
(ii) standard error of estimates, (iii) number of significant digits, (iv) termination of the 
covariance step, (v) correlation between model parameters and (vi) acceptable gradients at 
the last iteration.  
Fixed and random effects were introduced into the model in a stepwise manner. Inter-
individual variability in pharmacokinetic parameters was assumed to be log-normally 
distributed. A parameter value of an individual i (post hoc value) is therefore given by the 
following equation: 
θi = θTV * eηi 
in which θTV is the typical value of the parameter in the population and ηi is assumed to be 
random variable with zero mean and variance ω2. Residual variability, which comprises 
measurement and model error, was described with a proportional error model. This means 
for the jth observed concentration of the ith individual, the relation Yij: 
Yij = Fij + εij * W 
where Fij is the predicted concentration and εij the random variable with mean zero and 
variance σ2. W is a proportional weighing factor for ε. 
Goodness of fit was assessed by graphical methods, including population and individual 
predicted vs. observed concentrations, conditional weighted residual vs. observed 
concentrations and time, correlation matrix for fixed vs. random effects, correlation matrix 
between parameters and covariates and normalised predictive distribution error (NPDE) 
(18,19).  Comparison of hierarchical models was based on the likelihood ratio test. A 
superior model was also expected to reduce inter-subject variability terms and/or residual 
error terms.  
 
Covariate analysis 
Continuous and categorical covariates were tested during the analysis. The relationship 
between individual PK parameters (post-hoc or conditional estimates) and covariates was 
explored by graphical methods (plot of each covariate vs. each individual parameter). 
Relevant demographic covariates (body weight, age, gender, creatinine clearance) were 
entered one by one into the population model (univariate analysis). After all significant 
covariates had been entered into the model (forward selection), each covariate was 
removed (backward elimination), one at a time. The model was run again and the objective 
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function recorded. The likelihood ratio test was used to assess whether the difference in the 
objective function between the base model and the full (more complex) model was 
significant. The difference in – 2Log likelihood (DOBJF) between the base and the full model 
is approximately χ2 distributed, with degrees of freedom equal to the difference in number 
of parameters between the two hierarchical models. Because of the exploratory nature of 
this investigation, for univariate analyses, additional parameters leading to a decrease in the 
objective function of 3.84 was considered significant (p<0.05). During the final steps of the 
model building, only the covariates which resulted in a difference of objective function of at 
least 7.88 (p<0.005) were kept in the final model. 
 
Model validation 
The validation of the final pharmacokinetic model was based on graphical and statistical 
methods, including visual predictive checks (15). Given the importance of the validation 
procedures for the subsequent use of a model for simulation purposes, in this study we have 
included a wide range of diagnostic methods to assess the accuracy of the parameter 
estimates and the predictive performance of the model (16). Bootstrap was used to identify 
bias, stability and accuracy of the parameter estimates (standard errors and confidence 
intervals). The bootstrap procedures were performed in PsN v3.5.3 (University of Uppsala, 
Sweden) (20), which automatically generates a series of new data sets by sampling 
individuals with replacement from the original data pool, fitting the model to each new data 
set. Subsequently, parameter estimates were used to simulate plasma concentrations in 
subjects with similar demographic characteristics, dosing regimens and sampling scheme as 
in the original clinical studies. Mirror plots were also generated to evaluate the variance-
covariance structure of the parameters in the model, which is reflected by the degree of 
similarity between the original fit and the pattern obtained from the fitting of the simulated 
data sets using the final pharmacokinetic model. 
In addition to the graphical analysis, posterior predictive check was performed using AUC 
(area under the plasma concentration vs. time curve) and Cmax (peak plasma concentration) 
as a measure of model performance. AUC and Cmax values were calculated non-
compartmentally by trapezoidal method from simulations of 1000 data sets with the same 
demographic characteristics, dosing regimens and sampling scheme as in the original clinical 
studies. 
The distribution of model-predicted AUC and Cmax values were presented for geometric 
mean, lower and upper boundaries of the 95% confidence intervals and compared to the 
findings from non-compartmental analysis in the two clinical studies. Model performance 







Simulations were performed using the final model to assess whether predicted secondary PK 
parameters, such as AUC and CMAX would be in line with literature references (7,14,21). 30 
simulated patients (15 males and 15 females) with a mean body weight of 55 kg (sd 8.4) 
received DFP under the following dosing recommendations: 25 and 75 mg/kg/day. 
Furthermore, additional simulation scenarios were evaluated to assess the implications of 
renal impairment for the pharmacokinetics of deferiprone in a group of patients with similar 
demographic characteristics, as described above. Taking into account the correlation 
between the reduction in creatinine clearance and the severity of renal impairment, three 
scenarios were considered, including 80, 50 and 25% of the normal clearance values. They 
were meant to reflect the changes in renal function in mild, moderate and severe 
impairment, respectively.  Simulated patients received 75 mg/kg/day DFP and their exposure 
was compared to healthy subjects (reference population). Dosing regimens were adjusted to 
ensure that deferiprone exposure similar to the levels observed in the reference population 
is achieved and maintained irrespective of the degree of renal impairment.   
 
3.3 Results 
Population Pharmacokinetic Modelling 
The pharmacokinetics of DFP was best described by a one-compartment model with first-
order absorption, lag-time to central compartment, and first-order elimination. Inter-
individual variability (IIV) could be estimated for apparent clearance (CL/F), apparent volume 
of distribution (V/F), and absorption rate constant (Ka). Residual variability was 
characterised by a proportional error model with a weighting factor. 
During covariate model selection, the effect of age, gender and body weight was tested on 
relevant pharmacokinetic parameters. Initially when tested separately, significant effects of 
gender on V/F and body weight on CL/F and V/F were identified and described according to 
a linear model. However, despite statistical significance and improvement in the goodness-
of-fit,  the inclusion of body weight on either CL/F or V/F also led to an important reduction 
in model stability during bootstrapping procedures, which is likely caused by the limited 
range of the covariate values in the study population. Therefore, only gender on V/F was 
retained in the final model. This resulted in a better description of the data, subsequently 
increasing the model performance. An overview of the parameter estimates is presented in 
Table 1. 
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Table 1. Population pharmacokinetic parameters of deferiprone and bootstrap results. 
 Final model Bootstrap = 500 runs 
Parameters Estimate Median CV (%) 
CL/F (L/h) 30.8 30.9 3.12 
V/F males (L) 78.4 78.53 2.39 
Ka (h-1) 8.2 8.73 29.2 
Lagtime (h-1) 0.146 0.145 3.93 
Error: weighting factor 2.4 2.41 15.26 
V/F females (L) 65.3 65.3 3.88 
Eta CL/F (%) 0.057 (23.87 %) 0.0557 (23.6 %) 17.59 
Eta V/F (%) 0.0278 (16.67 %) 0.0267 (16.34 %) 20.22 
Block CL-V 0.0345  0.0335 20 
Eta Ka (%) 0.991 (99.54 %) 1.00 (100 %) 23.8 
Sigma (%) 0.00566 (7.52 %) 0.00568 (7.53 %) 25.88 
 
 
Internal model validation diagnostics were satisfactory. Individual predicted profiles and 
goodness-of-fit plots reveal that the model provides an adequate and non-biased description 
of the data, as shown in Figure 1 and 1S (see supplemental material in appendix).  In 
addition, despite a small deviation at the tails of the distribution, NPDE summaries (Figure 
2S, see supplemental material in appendix) show that the discrepancy between predicted 






Figure 1. Visual Predictive Check and a random selection of individual plots. VPC on the left panel: 
observed data are plotted using blue circles; the black solid line represents the median of the 
simulated data; the red solid lines represent the 5th and 95th percentiles of the simulated data. 
Individual plots of 4 randomly selected patients: observed data are plotted using blue circles; the 
black solid line represents the population prediction (Pred) and the red solid line represents the 
individual predictions (IPred). 
 
The predictive performance of the model in subsequent simulations was deemed critical to 
achieve the objective of our analysis. To this purpose, mirror plots were therefore used to 
assess whether the variance and covariance structures have been well characterised. Lastly, 
the median parameter estimates from the bootstrap analysis were found to be in close 
agreement with the results observed during the original fitting. Results from the bootstrap 
analysis are presented in Table 1. Overall these diagnostic techniques confirm that the final 
model is suitable for the purposes of data simulation. 
 
Simulation scenarios 
First an attempt was made to perform external validation of the model by deriving 
secondary parameters (AUC and Cmax) and comparing model-predicted estimates literature 
references (7,14,21). As shown in Figure 2, reference values lie within the distribution of 
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simulated AUC and Cmax, for which the  mean and 90% CI were 45.80 (44.42-47.17) mg*h/L 
and 17.67 (17.13-18.20) mg/L,  respectively after administration of a single oral dose of 25 
mg/kg deferiprone and 137.40 (133.27-141.52) mg*h/L and 26.50 (25.70-27.29) mg/L, 
respectively after administration of 75 mg/kg/day dose as a twice-daily regimen. Despite the 
gender differences in the volume of distribution, no signifcant differences observed when 
comparing Cmax values. This may be explained by the limited number of females in our 
analysis as well as by the differences in deferiprone formulation used in past protocols. 
 
 
Figure 2. Comparison of secondary PK parameters (Cmax and AUC) with literature references. 
Predicted DFP exposure expressed as CMAX and AUC for adult patients receiving 25 mg/kg as a single 
dose and 75 mg/kg/day b.i.d. The dashed black lines depict the mean simulated values, whereas the 
solid coloured lines depict published results (7, 14, 17). Percent of total indicates the percentage of 
cases for each beam of 100 simulations with 55 patients in each simulated trial. 
 
As the population available for the analysis was limited to healthy volunteers, the impact of 
another important covariate could not be estimated during the fitting procedures, namely, 




a simulation-based approach was used to quantify the implications of renal impairment for 
the disposition of deferiprone. Systemic exposure expressed as AUC was simulated for three 
scenarios representing mild, moderate and severe impairment and compared to the 
estimates obtained for healthy subjects.  It is evident from Figure 3 that over-exposure 
occurs when comparing the three sub-populations receiving 75 mg/kg/day DFP with the 
reference data, particularly in the case of moderate and severe impairment. Given the 
magnitude of the increase in systemic exposure, dose adjustment should be recommended 
for patients with renal impairment.  
 
 
Figure 3. AUC distributions: 80, 50 and 25% of total clearance (DFP 75 mg/kg/day). Predicted DFP 
exposure expressed as AUC for adult patients receiving 75 mg/kg/day and presenting 80%, 50% and 
25% of the total clearance respectively. The black line represents the median of the reference 
population which presents normal renal function, whereas the red lines represent 5th and 95th 
percentiles of the same reference population. Percent of total indicates the percentage of cases for 
each beam of 100 simulations with 55 patients in each simulated trial. 
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As shown in Figure 4, dose adjustments can be considered that allow for deferiprone 
exposure to be maintained at the desired levels for all three scenarios.  In addition, Figure 5 
depicts the consequence of reduced clearance for the systemic exposure of deferiprone 
assuming first-order pharmacokinetics in this population. Doses of 60, 40 and 25 mg/kg for 
patients showing mild, moderate and severe renal impairment are proposed based on 
creatinine clearance values of 60-89, 30-59 and 15-29 ml/min, respectively. An overview of 
these recommendations is summarised in Table 2. 
 
 
Figure 4. AUC distributions: 80, 50 and 25% of total clearance (new dosing recommendations). 
Predicted DFP exposure expressed as AUC for adult patients receiving the adjusted dosing 
recommendation based on the severity of renal impairment. The three populations present 80%, 
50% and 25% of the total clearance respectively. The black line represents the median of the 
reference population which presents normal renal function, whereas the red lines represent 5th and 
95th percentiles of the same reference population. Percent of total indicates the percentage of cases 






Figure 5. AUC – Dose relationship: 80, 50 and 25% of total clearance. AUC – Dose relationship in the 
presence of renal impairment. The open circles represent the reference population with normal renal 
function. The open triangles, filled circles and filled triangles represent mild (80%), moderate (50%) 
and severe (25%) renal impairment respectively. 
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Table 2. New dosing recommendations for renal impairment. 








80% of total 
Clearance 
Mild 60-89 75 mg/kg/day 60 mg/kg/day 
50% of total 
Clearance 
Moderate 30-59 75 mg/kg/day 40 mg/kg/day 
25% of total 
Clearance 
Severe 15-29 75 mg/kg/day 25 mg/kg/day 
 
3.4 Discussion and Conclusion 
As generally known, inter-individual variability in PK can significantly affect the outcome of a 
given therapeutic intervention. Therefore, full optimisation of the therapeutic regimen 
cannot be achieved without taking variability into account. The use of model-based 
approaches for the evaluation of the dose rationale and personalisation of dosing regimens 
for subgroups of patients and special populations has become an invaluable tool as it allows 
characterisation and quantification of the contribution of different sources of variability to 
the overall pharmacokinetic properties. This has an even larger impact when considering 
special populations and rare diseases, as is the case of transfusion dependent diseases and 
other pathologies associated with renal and hepatic impairment. Despite the continuous 
emphasis on the need for evidence-based clinical and regulatory decisions, modelling and 
simulation is becoming an essential component of evidence synthesis, which ultimately 
underpins decisions and  recommendations (22–24).  
 
Deferiprone Pharmacokinetics 
With this analysis we show how population pharmacokinetics can be used to explore the 
implications of different sources of variability on the exposure of the oral iron chelator 
deferiprone. The estimates of the main parameters of interest (table 1) were in line with 
previously published results (6,7,10–13,21,25–27). As shown in figure 2, similar agreement 
was also observed for the secondary PK parameters (AUC and Cmax). By contrast, no gender 
differences have been identified in previous studies. In this respect, our analysis illustrates 
the importance of parametric methods for accurate evaluation of covariate effects. We have 
quantified gender differences in the apparent volume of distribution, where V/F was 
estimated to be 78.4 and 65.3 L in males and females, respectively (i.e., a 20% difference 
between the two groups). Assuming that overall exposure (AUC) rather than Cmax is the 






Dosing recommendations in patients with renal impairment 
Considering the lack of details in the label of DFP regarding the dose rationale for special 
populations, it was our interest to provide insights on dosing recommendations for patients 
with renal impairment, which occurs as co-morbidity in thalassaemia. Given that, 
independently of the metabolic rate, 90% of the total drug (free, metabolised and iron-
complex) is excreted in the urine within 5 to 6 hours of ingestion, we have assumed that 
renal impairment would be clinically more relevant, as compared to hepatic impairment. We 
have selected a discrete number of scenarios to describe different levels of impairment 
(mild, moderate and severe). As could be anticipated for any drug with primary renal 
elimination (28,29), use of the standard recommended dose of 75 mg/kg/day leads to 
overexposure to deferiprone; especially when clearance is reduced beyond 50% of the 
normal range. Taking into account the deferiprone levels associated with effective response, 
dosing regimens are proposed for the three sub-populations allowing exposure to remain 
comparable to values observed in patients with normal renal function. 
 
A look into the future: rare diseases and special populations 
As discussed above, model-based approaches can be critical for therapeutic decisions when 
limited evidence is available. This is certainly the case for transfusion dependent diseases, 
especially when considering young paediatric patients, for whom limited data or no data 
exist and the use of DFP is still off label.  
Our analysis represents the first attempt to synthesise current knowledge on the 
pharmacokinetics of deferiprone and subsequently optimise the dosing regimen in special 
populations. In addition to renal impairment, we envisage the use of this model for the 
optimisation of clinical trial design in children. It is worth mentioning that  optimisation of 
protocol design may enable the use of smaller cohorts as well as a considerable reduction in  
the burden associated with sampling procedures thanks to the use of sparse sampling 
techniques.  
 
Limitations and Assumptions 
Given that the model has been developed on data collected in healthy subjects, questions 
arise about the relevance of the parameter estimates for the target patient population. No 
differences have been found in previous analyses between healthy individuals and patients. 
In the work carried out by Stobie et al. (21), who compared the pharmacokinetics of DFP in 
healthy individuals with patients affected by β-thalassaemia, only a slight difference in the 
apparent volume of distribution was observed, but the results were found not to be 
statistically significant (6,21). Most importantly, the authors did not find any differences in 
the drug clearance between the two groups. Moreover, AUC and Cmax values simulated by 
our model (figure 2) were comparable with published data obtained in patients treated with 
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DFP. We have to acknowledge that a lower mean Cmax is observed when comparing 
simulated data and reference data at 75 mg/kg/day b.i.d. This could be the consequence of a 
difference in the Vd observed in patients and/or differences in the formulation. Having said 
that, we anticipate that such a change should have limited clinical implications for the 
following reasons: overall exposure is the determinant of the response and AUC values were 
comparable between the two groups; an increase in Cmax is not expected to have 
consequences from a safety perspective, as discussed also for gender differences; and 
additionally the recommended dosing regimen is given as a three times daily administration 
which further reduces the impact of Cmax changes. We believe therefore that eventual 
differences in haemodynamics in patient affected by transfusion dependent diseases will not 
be relevant for the overall disposition properties of deferiprone. 
 
Conclusion 
In conclusion, our analysis has allowed the identification of the effect of gender on the 
volume of distribution of DFP and enabled the evaluation of the dosing requirements for 
patients with renal impairment. The changes in dose regimen proposed for this special 
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Figure 1S: Goodness-of-fit Plots. Upper panels show the observed data (Obs) vs. population 
predictions (Pred) (left) and the observed data vs. individual predictions (IPred) (right). Lower panels 







Figure 2S: Model validation: normalised prediction distribution errors. Upper panels show the QQ-
plot of the distribution of the NPDEs for a theoretical N (0, 1) distribution (left) and the histogram of 
the distribution of the NPDE together with the density of the standard normal distribution (right). 





Sampling optimisation in pharmacokinetic 
bridging studies: use of deferiprone in 
children with β-thalassaemia 
 
 
Francesco Bellanti, Vincenzo Luca Di Iorio, Meindert Danhof, and Oscar Della Pasqua 
 
 









Despite a wide experience with deferiprone, the optimum dosage in children aged less than 6 years 
remains to be established. This analysis is aimed at optimizing the design of a prospective clinical 
investigation for the evaluation of deferiprone pharmacokinetics in children. A one-compartment 
model with first order oral absorption was used for the design optimization. Different sampling 
schemes were evaluated under the assumption of a constrained population size. A sampling scheme 
with 5 samples post-dose per subject was found to be sufficient to ensure accurate characterization of 
the pharmacokinetics of deferiprone. Whereas the accuracy of parameters estimates was high, 
precision was slightly reduced due to the small sample size (> 30% for Vd/F and KA). AUC values 
(mean and SD) were found to be 33.37 (19.24) and 35.61 (20.22) μg/ml.h and Cmax values 10.17 
(6.05) and 10.94 (6.68) μg/ml in sparse and frequent sampling respectively. The results illustrate how 
ED-optimality concepts can be used to support PK bridging. Predefined sampling schemes and sample 
sizes do not warrant accurate model structure and parameter identifiability. Of importance is the 
accurate estimation of the magnitude of the covariate effects, as they may determine the dose 





Patients with β-thalassaemia and other transfusion-dependent diseases develop iron 
overload from chronic blood transfusions and require regular iron chelation to prevent 
potentially fatal iron-related complications 1–5. Deferiprone (DFP) is the most extensively 
studied oral iron chelator to date. It has been authorized in Europe in 1999 for the treatment 
of iron overload in patients with β -thalassaemia major when deferoxamine (DFO) is 
contraindicated or inadequate. Despite a wide experience of DFP there are limited 
experimental data available on DFP in children and no data in children under 6 years of age.  
 
Clinical studies, mostly in patients with beta-thalassaemia, have demonstrated that 
deferiprone at 75 to 100 mg/kg/day is capable of reducing iron burden in regularly 
transfused iron-overloaded patients 5–10. The degree of iron loading is directly related to the 
level of iron intake from transfusions. Iron excretion with DFP, like with any chelator, was 
found to be dose-related. However, factors affecting response to deferiprone appear to 
include the degree of iron overload and duration, dosage and compliance with therapy. 
Although few long term comparative data are available, DFP at the recommended dosage of 
75 mg/kg/day appears to be non-inferior to deferoxamine in the adult population. However, 
compliance is superior with DFP 5,11. 
The optimum dosage of DFP in children less than 6 years of age remains to be established. 
Given that dose adjustment may be required in children, the aforementioned findings 
highlight the need for optimizing the dosing regimen and gathering supporting evidence for 
the dose rationale for subsequent assessment of efficacy in the pediatric population. 
 
The information available so far in the adult population can be used to integrate the lack of 
knowledge in the pediatric population. The E11 guideline of the International Conference on 
Harmonization (ICH) supports the use of PK bridging concepts for the development of drugs 
in the pediatric population. Nevertheless, bridging studies can be implemented only if the 
following criteria are met: in the populations of interest the medicinal product should have 
the same indication, the disease process should be similar and the outcome of therapy 
should comparable 12. This is true and applicable to patients affected by β-thalassaemia or 
other transfusion-dependent diseases.  
 
Practical and ethical constraints impose special requirements for clinical trials in children 12–
15. The application of population pharmacokinetic (PK) analysis and PK bridging to sparse 
data allows reducing the burden in such a vulnerable population; yet it is important to 
optimize the quality of the information gathered.  
The quality of the study can be dramatically improved through design optimization analysis. 
However, a PK model is needed to apply this methodology. When extrapolating information 
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from adults to children we have to make use of a hypothetical model which is derived from a 
different population than the population of interest. ED-optimality concepts can be applied 
to handle the uncertainty during the optimization procedure. Several studies have already 
shown how ED-optimization can be successfully applied to the design of clinical studies in 
children when extrapolating information from the adult population 16–21.  
 
Based on simulation scenarios that take into account the impact of developmental growth, 
the aim of this analysis is to optimize the sampling times for the evaluation of the 
pharmacokinetics of deferiprone in a prospective clinical investigation in children younger 
than 6 years of age. The results of this trial will be subsequently used to define the most 
appropriate dosing regimen for this population.  
 
4.2 Methods 
Prospective Clinical Study: Design 
A prospective study has been proposed to establish the pharmacokinetics of deferiprone in 
children. This will be investigated in a prospective multi-centre, randomized, single blind, 
and single dose study in patients affected by transfusion dependent heamoglobinopathies 
aged less than 6 years. Sample size of the study will range between a minimum of 18 up to a 
maximum of 30 evaluable pediatric patients. Patients will be randomized to three dose 
levels (8.3, 16.7 and 33.3 mg/kg) and will be exposed to a single dose of deferiprone. A 
maximum of 5 samples will be collected per patient. An optimization algorithm will be 
applied to evaluate the best sampling times in order to ensure high precision in parameter 
estimates and PK model identifiability.  
 
Sampling Times Optimization 
Several actions have been taken throughout the analysis that can be summarized in 6 major 
steps as depicted in the following flow-chart (Figure 1). Each step will be briefly discussed in 






Figure 1. Data analysis flowchart. 
 
Hypothetical PK Model  
A one-compartment PK model with first-order absorption, lag-time to central compartment, 
and first-order elimination was used for the optimization of the sampling scheme 22. 
Between-subject variability (BSV) was estimated for apparent clearance (CL/F), apparent 
volume of distribution (V/F), and absorption rate constant (Ka). Residual variability was 
characterized by a proportional error model with a weighting factor.  
 
Competing Models: extrapolation to the pediatric population  
The reference model was previously developed by our group to explore DFP exposure in 
adults 22. With the purpose of optimizing the design of a prospective pediatric trial, the 
original model has been modified with the inclusion of two different covariate models, 
namely M1 (body weight linearly correlated with CL/F and V/F), and M2 (fixed allometric 
scaling: exponent of 0.75 on CL/F and 1.00 on V/F), in order to extrapolate deferiprone 
exposure to children.  
 
Bearing in mind the objective of extrapolation across populations, focus was given to the 
model validation steps, which yield information about the variance structure and variance-
covariance matrix. Visual predictive check (VPC) and NPDE summaries have been used to 
validate the model and to assess the suitability for simulation purposes. The software 
NONMEM (non-linear mixed effect modeling; release version 7.2.0) has been used for the 
procedure.  
 
M1: the inclusion of body weight as a covariate on CL/F and V/F according to linear models 
was found to give the highest improvement in model performance in the previous 
investigation. The covariates were not included due to increase in model instability. In this 
case, given the different objective, we have considered including weight on CL/F and V/F 
into the final covariate model.  
Hypothetical model
One compartment PK 






a) M1 18 subjects
b) M1 30 subjects
c) M2 18 subjects
d) M2 30 subjects
PopED




Schemes selected based 
on PopED’s outcome 
(Table 1)
Final scheme
Selection of the best 
Scheme based on 
PopED and SSE results
(M1 and 18 subjects)




M2: Since the purpose of the analysis is to extrapolate information to the pediatric 
population, the use of allometric scaling (one of the current standard approach to 
extrapolate across populations) has been considered to evaluate possible discrepancies in 
optimizing the sampling schedule with two different approaches. Model parameters have 
been re-estimated with the new covariate relationships and the model has been tested for 
simulation purposes.  
 
Diagnostic criteria, such as visual predictive checks and NPDE summaries have been used to 
assess model performance before the optimization of the study design (ED optimality) would 
be implemented. For both M1 and M2, Visual predictive check (VPC) plots indicate that 
model is not biased and is suitable for simulation purposes. In addition, NPDE summaries 
indicate that the discrepancy between predicted and observed values can be assumed to be 
normally distributed. VPC and NPDE for both models are provided in Figures S2 to S5 (see 
Appendix). 
 
Optimization steps (and criteria) 
The two hypothetical models have been used to identify the optimal sampling schedule in 
children after single dose deferiprone. The software for population experimental design 
“PopED” (release version 2.12) has been used to optimize sampling times and to assess 
precision in parameter estimates by evaluating the coefficient of variation (CV) for each 
parameter 23–27. Subsequently, the software NONMEM (non-linear mixed effect modeling; 
release version 7.2.0), has been used after sampling times optimization in order to assess 
model stability, and accuracy (RE: relative error) and bias (SME: standard mean error) in 
parameters estimates.  
The following 4 scenarios have been evaluated in PopED to account for possible 
discrepancies between the two covariate models and differences in sample size: 
a) M1 with 18 subjects;  
b) M1 with 30 subjects;  
c) M2 with 18 subjects; and  
d) M2 with 30 subjects.  
Sampling times have been optimized in the 4 scenarios for a simulated pediatric population 
which presented the following demographic characteristics: 50% males and females, and 
mean body weight of 20.5 kg (SD: 5.4). Subjects have been randomized to 3 dose levels as in 
the study design described above. 
 
Information gathered through the optimization of the sampling times in PopED has then 




a result of a compromise between full optimization and feasibility in a real clinical trial. The 
seven scenarios have been compared and evaluated in order to define the final sampling 
schedule for the PK study. Furthermore, an extra scenario, consisting of an empirical, non-
optimized sampling scheme has been evaluated along with the previous seven.  
Given that no significant differences have been observed between the original four scenarios 
in PopED, scenario “a” (M1 with 18 subjects) has been selected and used for the final 




Sampling times optimization in PopED 
The results of the optimization of the sampling times is summarized in Figure 2, where the 
actual sampling times obtained in the 4 scenarios (“a”, “b”, “c”, “d”) are plotted. Each bar 
represents a sampling time selected during the optimization procedure, whereas each color 
indicates the contribution (in percentage) of the different scenarios.  
 
Figure 2. Sampling times obtained by ED-optimality. Sampling times selected during the optimization 
steps using ED-optimality: in red, green, dark blue and light blue are shown the time selected for 
scenarios a, b, c and d respectively. Percent of total indicates the percentage of cases for each set of 
optimized sampling times generated by PopED. 
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The data suggest that, independently of model and number of subjects, approximately 92% 
of sampling times should be collected within three intervals, namely:  
- time window A: 32% in the range 10 to 20 minutes; 
- time window B: 37% between 40 and 80 minutes; 
- time window C: 23.75% after 200 minutes; 
 
Based on the information collected in the previous step, and bearing in mind the 
compromise between full optimization and feasibility in a real clinical trial, seven sampling 
schemes (shown in Table 1 as scheme 1 to 7) have been generated and subsequently 
evaluated in PopED and NONMEM. 
 
Table 1. Scenarios evaluated for sampling scheme selection. 
Scenario Sampling schemes Scenario Sampling schemes 
0 Optimal Design 5 a: 10, 25, 50, 70, 360 
b: 15, 45, 60, 270, 420 
c: 20, 55, 75, 330, 480 
 
1 
a: 10, 25, 45, 70, 360 
b: 15, 40, 60, 180, 420 
c: 20, 55, 75, 240, 480 
 
6 
a: 10, 40, 65, 85, 360 
b: 15, 45, 60, 270, 420 
c: 20, 55, 75, 330, 480 
 
2 
a: 10, 30, 45, 180, 360 
b: 15, 40, 60, 240, 420 
c: 20, 50, 75, 300, 480 
 
7 
a: 10, 40, 65, 85, 360 
b: 15, 50, 70, 270, 420 
c: 20, 55, 75, 330, 480 
 
3 
a: 10, 40, 70, 180, 360 
b: 15, 50, 80, 240, 420 
c: 20, 60, 90, 300, 480 
8* 30, 60, 120, 240, 480 
 
4 
a: 10, 25, 50, 75, 330 
b: 15, 45, 60, 240, 360 
c: 20, 55, 75, 270, 420 
/ / 
* Empirical sampling scheme reflecting the current practice, i.e., non-optimised design. 
 
Evaluation of seven realistic sampling schemes 
As previously mentioned in the methods section, given that no major differences have been 
observed in the previous step between the two different models (M1 and M2) and different 
number of subjects (18 vs. 30), only model M1 with a total number of 18 subjects was used 
for the second part of the optimization. 
Table S1 (see Appendix) shows the coefficient of variation (CV) for the different scenarios 
compared to the optimal sampling scheme. No major differences can be observed between 
the different scenarios, except for the non-optimized scheme (number 8) in which a 




slope, and Ka. Furthermore, results clearly highlight the poor performance of the model if an 
empirical (non-optimized) pharmacokinetic sampling scheme is used. 
Table S2 (see Appendix) shows model stability results based on NONMEM stochastic 
simulation and estimation (SSE). In this overview, schemes 3 and 7 show higher stability, as 
compared to the other sampling schemes. On the other hand, scheme 8 shows the worst 
result out of the 9 scenarios. Finally, Figures 3, 4 and S1 (for Figure S1 see Appendix) show 
measures of accuracy (RE) and bias (SME) for the main parameters of interest for the 
different sampling schemes. 
Altogether, scheme 7 was the closest one to the fully optimized sampling scheme, providing 
the best combination of results in terms of bias (SME) and accuracy (RE) of parameters 
estimates. This was also true in terms of model robustness, with only 1 failed minimization 
and 435 successful covariate steps out of 500 runs (Table S2; see Appendix).  
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Figure 3. SME and RE for the slope parameters describing the effect of body weight on clearance and 
volume of distribution. Standard Mean Error (SME) and Relative Error (RE) estimates indicate, 
respectively, the bias and accuracy in parameter estimates for the different sampling schemes. Top 
panels: summary for the slope parameter describing the effect of body weight on clearance. Bottom 




Figure 4. SME and RE for the volume of distribution in males and females. Standard Mean Error 
(SME) and Relative Error (RE) estimates indicate, respectively, the bias and accuracy in parameter 
estimates for the different sampling schemes. Top panels: summary for volume of distribution in 






Secondary PK parameters: sparse sampling vs. rich sampling 
To further assess the suitability of scheme seven for the prospective PK study, focus was 
given to the ability of the model to predict secondary PK parameters. Model-predicted AUC 
and Cmax based on the sparse sampling scheme were compared with estimates obtained 
according to a rich sampling scheme (12 samples per subject). AUC has been calculated with 
the trapezoidal rule.   
 
Figure 5. AUC and CMAX estimation using sparse (5) vs. frequent (12) sampling. Model predicted 
deferiprone systemic exposure expressed as AUC and Cmax. The final scheme selected during the 
optimization procedure (scheme 7) with sparse sampling (5 samples) is compared with rich sampling 
(12 samples). Top panels: histogram and boxplot describing the distribution of Cmax. Bottom panels: 
histogram of the distribution of AUC. Percent of total represents the percentage of cases for each set 
of 500 simulations with 18 patients in each simulated trial. Red: sparse sampling; Blue: rich sampling; 
Green: overlapping area. 
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As shown by the distributions and box-plots of AUC and Cmax (Figure 5), no significant 
differences were detected for sparse and frequent sampling. AUC values (mean and 
standard deviation) were found to be 33.37 (19.24) and 35.61 (20.22) μg/ml.h and Cmax 
values 10.17 (6.05) and 10.94 (6.68) μg/ml in sparse and frequent sampling respectively. 
 
4.4 Discussion and Conclusion 
Clinical trials in children represent a very challenging phase in drug development. Given the 
ethical and practical constraints imposed to experimental protocols in this vulnerable 
population 12–15, the information gathered per subject becomes significantly more 
important, as compared to the adult population. In addition, increasing evidence suggests 
the lack of suitability of empirical protocols in pediatric research. This limitation has 
therefore prompted clinical scientists and drug developers to  consider the use of alternative 
approaches for the evaluation of pharmacokinetics, efficacy and safety in children 28–34. 
 
Our results show that highly informative data can be generated whilst reducing the burden 
of clinical trials in children. From a methodological perspective, these data also reinforce the 
benefits associated with the use of ED-optimality concepts for the design of pediatric clinical 
studies 16–21.  In fact, it should be noted that whereas optimal design is normally based on a 
model representative of the population of interest, our analysis was aimed at an 
extrapolation model derived from data available in adult patients, i.e., we have used a 
hypothetical model. Consequently, the optimization procedures carry a certain degree of 
uncertainty.  
Nevertheless, the major advantage of using ED-optimization is that this methodology 
accounts for the uncertainty parameter estimates and in the effect of covariates during the 
optimization procedure. More specifically, two scenarios with 20% and 40% uncertainty on 
the main parameters of interest (clearance and volume of distribution) were evaluated. The 
data shown throughout this report reflect the first case only. Increased uncertainty in 
parameter distributions had no significant impact on the optimization and selection of 
sampling times. Lastly, to ensure a comprehensive evaluation of the assumptions underlying 
the nature and magnitude of the covariate effects on the systemic exposure in children, we 
have resorted to two competing models (M1 and M2). These models enabled the 
identification of the best sampling scheme for the prospective pharmacokinetic study taking 
into account potential differences in the disposition of deferiprone in children younger than 
6 years of age.   
 
Based on our experience in pediatric clinical pharmacology, fully optimized designs (i.e., 
individually optimized) are not realistically applicable to pediatric trials. Our objective in this 




full optimization and feasibility in a real setting. The three time windows selected during the 
optimization procedures were found to be independent of model specification and sample 
size. Moreover, they reflect the requirements for estimating specific pharmacokinetic 
parameters, i.e., lag-time and Ka (time window A), V/F (time window B), and CL/F (time 
window C) respectively.  
 
Finally, it should be noted that our analysis clearly highlights the poor performance of an 
empirical (i.e., non-optimized) sampling scheme (scheme 8), especially when dealing with 
sparse sampling. By contrast, scenario 7 showed the best option in terms of coefficient of 
variation, relative errors and standard mean errors as well as for what concerns model 
stability. In addition, it allowed for correct predictions of AUC and Cmax. 
 
Potential limitations 
The final decision on the sampling scheme to be used in the prospective study had to take 
another unknown factor into account, namely the uncertainty around the time at which the 
peak concentration occurs (Tmax). Keeping in mind that this exercise is based on a model 
derived from pharmacokinetic data in adult patients, there might be some differences in 
children below 6 years of age. Such differences may occur despite the quick absorption after 
administration of the drug as an oral solution. They may also be caused by difficulties in the 
administration of the drug to the very young children. We have therefore included these 
considerations in scenarios 3, 6 and 7, but there are no data available at the moment to 
confirm the assumptions regarding the possible shift of Tmax.  
 
In conclusion, our analysis illustrates and confirms that despite feasibility issues, ED-
optimality concepts can be used to optimize study design, particularly with regard to the 
pediatric population. Predefined sampling schemes and sample sizes do not warrant 
accurate model structure and parameter identifiability. In addition, it shows that the 
optimization of study design does not require necessarily the use of the final model for the 
population of interest; the combination between ED-optimization and the information 
carried by a hypothetical model is sufficient to significantly increase the quality of the 
information collected in a prospective clinical trial. Nevertheless, remains of particular 
importance the accurate estimation of the magnitude of the covariate effects, as they may 
determine the final dose recommendation for the population of interest. 
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Table S1. Coefficient of variation for pharmacokinetic parameters of the model assuming a linear 
relationship between body weight and CL and Vd. Estimates calculated according to study design 
including 18 patients and 20% uncertainty in the parameter estimates for CL and V. 
 CV (%) 
 SAMPLING SCHEMES 
PARAMETERS 0 1 2 3 4 5 6 7 8 
CL intercept* / / / / / / / / / 
CL slope 7.4 7.2 6.9 6.9 7.0 7.0 7.0 7.0 29.4 
BSV CL 59.7 57.3 53.9 53.2 55.2 55.4 55.0 54.8 52.7 
V Males 22.5 23.4 24.1 24.1 23.6 23.4 23.2 23.3 23.8 
V Females 43.8 44.6 45.8 45.8 44.9 44.5 44.2 44.3 45.5 
V slope 48.9 49.7 50.8 51.1 49.9 49.6 49.4 49.6 77.4 
BSV V 57.8 59.5 61.6 62.8 60.3 59.5 59.0 59.4 59.9 
Ka 26.9 29.7 33.3 37.3 29.7 29.5 37.0 38.1 379.2 
BSV Ka 37.4 39.2 40.1 40.4 39.2 39.2 40.4 40.4 72.2 
*The parameter describing the intercept for the linear function between body weight and clearance 
has been fixed during the analysis. Therefore no CV values are reported. 
 
Table S2. Evaluation of model stability and parameter identifiability based on different sampling 
schemes. Values represent the results of 500 runs. 






0 496 391 108 
1 409 306 118 
2 476 398 82 
3 490 443 47 
4 454 362 101 
5 446 419 28 
6 471 419 33 
7 499 435 63 
8 283 217 100 
 
 




Figure S1. SME and RE for the slope parameters describing the effect of body weight on clearance 
and volume of distribution. Standard Mean Error (SME) and Relative Error (RE) estimates indicate, 
respectively, the bias and accuracy in parameter estimates for the different sampling schemes. Top 







Figure S2. Visual Predictive Check for model M1. Simulated concentration vs. time course profile of 
deferiprone according to a pharmacokinetic model in which weight is correlated with clearance and 
volume according to a linear function. Observed data are plotted using open circles; the solid line 
represents the median of the simulated data; the dashed lines represent the 5th and 95th percentiles 
of the simulated data.  




Figure S3. Normalised prediction distribution errors (NPDE) for model M1. Given that the accuracy of 
model predictions also depends on the variance structure, special attention was paid to the 
evaluation of model misspecifications for the random effects. The normalised prediction distribution 
errors (NPDE) method was applied for an in-depth diagnosis of potentially poor behaviour. Top left: 
QQ-plot of the distribution of the NPDE versus the theoretical N (0,1) distribution; Top right: 
Histogram of the distribution of the NPDE, with the density of the standard Gaussian distribution 






Figure S4. Visual Predictive Check for model M2. Simulated concentration vs. time course profile of 
deferiprone according to a pharmacokinetic model in which weight is correlated with clearance and 
volume according to an allometric function. Observed data are plotted using open circles; the solid 
line represents the median of the simulated data; the dashed lines represent the 5th and 95th 
percentiles of the simulated data.  




Figure S5. Normalised prediction distribution errors (NPDE) for model M2. Given that the accuracy of 
model predictions also depends on the variance structure, special attention was paid to the 
evaluation of model misspecifications for the random effects. The normalised prediction distribution 
errors (NPDE) method was applied for an in-depth diagnosis of potentially poor behaviour. Top left: 
QQ-plot of the distribution of the NPDE versus the theoretical N (0,1) distribution; Top right: 
Histogram of the distribution of the NPDE, with the density of the standard Gaussian distribution 
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Despite long clinical experience with deferiprone, there is still limited information on its 
pharmacokinetics in children and essentially none in children below 6 years of age. The objective of 
this analysis is to characterise the pharmacokinetics of deferiprone in the target population using a 
model-based approach and to assess the effect of demographic and physiological factors on drug 
exposure. Furthermore, it is our aim to ascertain whether equivalent doses on a mg/kg basis produce 
PK in children consistent with that in adults. Data from 18 paediatric patients receiving deferiprone 
orally (solution 80 mg/ml) were used for model building purposes. A one-compartment model with 
first order oral absorption was found to best describe the pharmacokinetics of deferiprone. Goodness-
of-fit plots, visual predictive check (VPC) and NPDE summaries indicated that the model provides an 
unbiased description of the data. Simulation scenarios revealed that similar mg/kg dose levels yield 
comparable exposure in children and adults, with median AUC values respectively of 340.6 and 318.5 
µmol/L*h at 75 mg/kg/day and 453.7 and 424.2 at 100 mg/kg/day t.i.d. doses evenly spaced. Based 
on these findings, a dosing regimen of 25 mg/kg t.i.d. is recommended in children below 6 years of 





Patients with hemoglobinopathies and certain other conditions affecting the ability to 
synthesize haemoglobin may require life-long blood transfusion therapy to survive. This 
chronic intervention results in a series of potential complications, with iron overload being 
an inevitable consequence within a few years.  Chelation therapy is therefore required to 
prevent potentially fatal iron-related complications 1–5. Deferiprone (DFP) is a 
hydroxypyridinone, which was authorised in Europe in 1999 for the treatment of iron 
overload in patients with β-thalassaemia major when deferoxamine (DFO) is contraindicated 
or inadequate. When administered orally, DFP is rapidly and well absorbed. Plasma levels 
show peak concentrations (Cmax) within 1 hour of administration. Food reduces its 
absorption rate without affecting the overall exposure to the drug. In patients with -
thalassaemia, the administration of deferiprone at doses of 75 mg/kg/day as a twice-daily 
regimen yields Cmax of 34.6 mg/L and area under the plasma concentration-time curve 
(AUC) of 137.5 mg/L • h 6,7. On the other hand,  peak serum concentrations were 17.53 mg/L 
and 11.82 mg/L in fasting and fed states, respectively after a dose of 25 mg/kg 8. DFP is for 
the most part inactivated by glucuronidation (>85%) and more than 90% of the drug is 
removed from plasma within 6 hours of ingestion, with an elimination half-life of 1 to 2.5 
hours in patients affected by β-thalassaemia 5,6,9–16. DFP forms a 3:1 complex with iron, 
which is removed mainly through the kidneys, as is the free parent drug.  
Despite the extensive clinical experience with DFP, there are few PK data in children, and 
effectively none in children under 6 years of age. To cover this gap Deferiprone was included 
in the list of priority prepared by the PDCO-EMA. The main objective of this analysis is to 
appropriately characterise the systemic exposure of DFP in paediatric patients aged less than 
6 years using a model-based approach and to assess the effect of demographic and 
physiological factors on the drug’s pharmacokinetics. Furthermore, it is our endeavour to 





This experimental and modelling study is a multi-centre, randomised, single blind, single 
dose PK study to evaluate the pharmacokinetics of DFP in children aged from one month to 
less than 6 years affected by transfusion-dependent haemoglobinopathies.  
The pharmacokinetics of deferiprone was evaluated using data collected from the clinical 
study: DEEP-1 PK Study (EudraCT, 2012-000658-67), in which paediatric patients affected by 
transfusion-dependent haemoglobinopathies received a single oral dose of DFP as an 80 
mg/ml solution. Patients undergoing a chronic transfusion program (receiving at least 150 
ml/kg/year of packed red blood cells) and, if naïve to any chelation therapy, having ferritin 
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levels above 800 ng/ml were considered eligible for the study. In addition, amongst other 
criteria, patients with Hb levels less than 8 g/dl, abnormal liver function, and severe heart 
dysfunction secondary to iron overload or serum creatinine levels above the upper normal 
level were not considered eligible for inclusion in the study. Patients were randomised to 
three dose levels: 8.3, 16.7 and 33.3 mg/kg. The study was performed within the DEEP 
Consortium (www.deep.cvbf.net) according to an approved PIP (EMEA-001126-PIP01-10). 
The study protocol was approved by concerned Ethics Committees and all experimental 
procedures performed according to good clinical practice guidelines. In brief, 18 children 
aged from 1 month to less than 6 years (9 males and 9 females) who had received the active 
medication were included in the analysis. Recruitment of up to 30 patients was provided for 
by protocol to ensure a minimum sample size of 18 evaluable subjects. In practice, the use of 
nonlinear mixed-effects modelling allowed completing the study with the data of the first 18 
evaluable subjects by providing accurate and precise estimates of the main parameters of 
interest. Blood samples for the evaluation of deferiprone concentrations were taken before 
(one pre-dose sample) and at the following sampling times after dosing: 0.167, 0.25, 0.333, 
0.67, 0.83, 0.916, 1.083, 1.167, 1.25, 1.416, 4.5, 5.5, 6, 7 and 8 hours. A maximum of 5 post-
dose samples were collected per subject according to 3 sampling schemes selected based on 
an optimal design analysis previously performed by our group (unpublished results). Blood 
samples were drawn by peripheral venous catheter following discard of 2 ml of blood; 
catheters were filled with saline (i.e., saline lock) between sampling times. Mean (sd) age 
(years), body weight (kg) and height (cm) of the patient population were 3.62 (1.33), 16.08 
(3.18) and 98.95 (9.16) respectively.  
 
Bioanalysis 
Deferiprone plasma concentrations were analysed by the laboratory of the Division of 
Pharmacology (Leiden, the Netherlands) using a validated method previously developed by 
ApoPharma (Toronto, Canada) consisting of high performance liquid chromatography with 
UV detection (HPLC-UV). Extraction of deferiprone from supernatant was performed after 
precipitation of plasma proteins by trichloroacetic acid (TCA - 15%) and centrifugation at 
10,000 g for 20 minutes at 4 ºC.  The analytical column used for the analysis was a Hamilton 
PRP-1 and separation of the chromatogram of interest was achieved using an isocratic 
mobile phase (pH 7.0). The analytical range was between 3.13 and 800 µM (equivalent to 
0.43 to 111 g/ml); and an R2 value greater than 0.98 was required to accept the standard 
curve. The lower limit of quantification (LLOQ) was 0.238 µM (equivalent to 0.033 g/ml). 
Inter- and Intra-day accuracy and precision were always below 6 %, except for the inter-day 








Nonlinear mixed effects modelling was performed in NONMEM version 7.2 (Icon 
Development Solutions, USA). Model building criteria included: (i) successful minimisation, 
(ii) standard error of estimates, (iii) number of significant digits, (iv) termination of the 
covariance step, (v) correlation between model parameters and (vi) acceptable gradients at 
the last iteration.  
Fixed and random effects were introduced into the model in a stepwise manner. Inter-
individual variability in pharmacokinetic parameters was assumed to be log-normally 
distributed. A parameter value of an individual i (post hoc value) is therefore given by the 
following equation: 
θi = θTV * eηi 
in which θTV is the typical value of the parameter in the population and ηi is assumed to be a 
random variable with zero mean and variance ω2. Residual variability, which comprises 
measurement and model error, was described with a proportional error model. This means 
for the jth observed concentration of the ith individual, the relation Yij: 
Yij = Fij + εij * W 
where Fij is the predicted concentration and εij the random variable with mean zero and 
variance σ2. W is a proportional weighing factor for ε. 
Goodness of fit was assessed by graphical methods, including population and individual 
predicted vs. observed concentrations, conditional weighted residual vs. observed 
concentrations and time, correlation matrix for fixed vs. random effects, correlation matrix 
between parameters and covariates and normalised predictive distribution error (NPDE) 
17,18.  Comparison of hierarchical models was based on the likelihood ratio test. A superior 
model was also expected to reduce inter-subject variability terms and/or residual error 
terms.  
With the objective of increasing the stability of the model and reducing the uncertainty 
around the parameters of interest, the use of the Normal-Inverse Wishart Prior (NWPRI) 
approach was used in NONMEM 19 to test the impact on the estimates of the fixed and 
random effects in the pharmacokinetic model under development. Primary PK parameters 
estimated with a previously developed model in adults 20 were used as prior information for 
the pharmacokinetic analysis of DFP in the target population. 
 
Covariate analysis 
Continuous and categorical covariates were tested during the analysis. The relationship 
between individual PK parameters (post-hoc or conditional estimates) and covariates was 
explored by graphical methods (plot of each covariate vs. each individual parameter). 
Relevant demographic covariates (body weight, height, age and gender) were entered one 
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by one into the population model (univariate analysis). After all significant covariates had 
been entered into the model (forward selection), each covariate was removed (backward 
elimination), one at a time. The model was run again and the objective function recorded. 
The likelihood ratio test was used to assess whether the difference in the objective function 
between the base model and the full (more complex) model was significant. The difference 
in – 2Log likelihood (DOBJF) between the base and the full model is approximately χ2 
distributed, with degrees of freedom equal to the difference in number of parameters 
between the two hierarchical models. Because of the exploratory nature of this 
investigation, for univariate analyses, additional parameters leading to a decrease in the 
objective function of 3.84 was considered significant (p<0.05). During the final steps of the 
model building, only the covariates which resulted in a difference of objective function of at 
least 7.88 (p<0.005) were kept in the final model. 
 
Model validation 
The validation of the final pharmacokinetic model was based on graphical and statistical 
methods, including visual predictive checks 17. Given the importance of the validation 
procedures for the subsequent use of a model for simulation purposes, in this study we have 
included a wide range of diagnostic methods to assess the accuracy of the parameter 
estimates and the predictive performance of the model 18. Bootstrap was used to identify 
bias, stability and accuracy of the parameter estimates (standard errors and confidence 
intervals). The bootstrap procedures were performed in PsN v3.5.3 (University of Uppsala, 
Sweden) 21, which automatically generates a series of new data sets by sampling individuals 
with replacement from the original data pool, fitting the model to each new data set. 
Subsequently, parameter estimates were used to simulate plasma concentrations in subjects 
with similar demographic characteristics, dosing regimens and sampling scheme as in the 
original clinical studies. Mirror plots were also generated to evaluate the variance-
covariance structure of the parameters in the model, which is reflected by the degree of 
similarity between the original fit and the pattern obtained from the fitting of the simulated 
data sets using the final pharmacokinetic model. 
 
PK bridging and dosing recommendations 
To optimise the deferiprone dosing regimen in the target population, simulations were 
performed to achieve systemic exposure values similar to the adult reference population 20. 
Simulations were carried out to explore how differences in demographic covariates might 
affect steady-state exposure to deferiprone treatment. Sampling frequency and times were 
based on a serial sampling scheme for the purposes of estimating AUC, Cmax and Css over 
the dosing interval. Integration of the concentration time data was applied according to the 




dosing regimens was assessed graphically by determining the fraction of the paediatric 
population reaching systemic exposure comparable to the target value based on PKPD 
reference in adults. 
A study duration of one week was chosen for the simulation. Each scenario consisted of 
1000 simulations. Two dosing regimens were simulated in both populations: 75 and 100 
mg/kg/day as three daily doses of 25 and 33.3 mg/kg respectively. The pharmacokinetic 
parameters of interest (AUC, Cmax and Css) were measured after administration of the first 
dose on day 7. 
A pharmacokinetic model developed in adult healthy volunteers 20 was used to simulate 
deferiprone exposure in the reference population. A population of 100 subjects (50 males 
and 50 females) with a body weight distribution of mean 55 and sd 7.5 kg was used to 
characterise a standard adult thalassaemic population. 
The final PK model developed during this analysis was used to simulate deferiprone 
exposure in the population of interest. A population of 100 subjects (50 males and 50 
females) with a body weight distribution of mean 16 and sd 2.0 kg was used to characterise a 
standard thalassaemic population of children below 6 years of age. 
 
5.3 Results 
Population Pharmacokinetic Modelling 
Data from 18 evaluable children (9 males and 9 females) were used for the pharmacokinetic 
analysis. Patients were randomised to 3 dose levels (8.3, 16.7 and 33.3 mg/kg) with 6 
patients assigned to each group. 16 patients were diagnosed with β-thalassaemia major and 
2 with thalassodrepanocytosis. Mean (and sd) body weight, height and age of the children 
were respectively 16.08 (3.18) Kg, 98.95 (9.16) cm and 3.62 (1.33) years. 
The pharmacokinetics of deferiprone after oral administration to paediatric patients was 
described by a one-compartment open model with first-order absorption and elimination 
processes. The absorption rate constant (Ka) represents a first order process. The disposition 
processes includes (apparent) clearance (CL/F) and (apparent) volume of distribution (V/F).  
Between subject variability (BSV) was tested on each parameter, and was included in the 
final model on CL/F and V/F. An omega block was implemented in the estimation of BSV for 
CL/F and V/F, accounting for the expected correlation between these two parameters. The 
inclusion of the omega block significantly decreased the OBJF. 
Different error models were tested to characterise residual variability; e.g., additive, 
proportional, exponential, combined, etc. The proportional error model provided the best 
results and was kept to describe the residual variability. 
The use of the Normal-Inverse Wishart Prior (NWPRI) approach was used in NONMEM to 
estimate the fixed effect on the PK parameter Ka and the BSV for CL/F and V/F. The use of a 
prior allowed a better description of the data, reducing significantly the uncertainty around 
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the parameters above mentioned. The prior information was derived from a population PK 
analysis performed in healthy adults receiving deferiprone as a 100 mg/ml solution 20. The 
following values were used for the different parameters: 8.2 h-1 for Ka with an uncertainty of 
4.02; 0.057 (23.87%) variation on CL/F and 0.0278 (16.67%) variation on V/F with an omega 
block of 0.0345. 54 degrees of freedom were chosen for the prior on the BSV parameters 
given that 55 individuals were used for the final population PK model in the healthy adults.  
During covariate model selection, after a visual explorative analysis of the correlations 
between covariates and model parameters, the effect of weight, height, gender, and age 
was tested on the different parameters. The inclusion of body weight on CL/F and V/F 
according to fixed allometric scaling 22 led to the highest improvement in the model fitting 
and allowed a better description of the data, increasing the model performance. The 
exponent was fixed to 0.75 and 1 for CL/F and V/F respectively. An overview of the final 
parameter estimates is provided in Table 1. 
 
Table 1. Population pharmacokinetic parameters of deferiprone in children below 6 years of age and 
bootstrap results 
Model predicted primary PK parameters 
 Estimate SE Bootstrapa 
(mean) 
CV (%) 
CL/F (L/h) 8.3 0.569 8.30 8.07 
V/F (L) 18.7 1.16 18.74 7.95 
Ka (h-1) 9.13 1.41 8.91 10.54 
WT on V/F 
Fix allom. 
1 FIX / 1 FIX / 
WT on CL/F 
Fix allom. 
0.75 FIX / 0.75 FIX / 
Error (prop) 0.0953 0.0182 0.0916 39.3 
IIV CL/Fb 0.0644 0.0115 0.0642 11.37 
IIV V/Fb 0.0392 0.0077 0.0393 13.23 
Block CL-V 0.031 0.0058 0.0313 12.14 
Model predicted secondary PK parameters stratified per dose level 
 Median (5th and 95th quantiles) 
 Dose 1c Dose 2d Dose 3e 
AUC0-8 
(μmol/L*h) 
116.7 (90.6-129.0) 210.0 (173.1-266.6) 428.8 (291.4-547.8) 
Cmax (μmol/L) 61.7 (45.1-80.7) 119.8 (106.0-154.0) 229.5 (179.7-278.1) 
Tmax (h) 0.33 (0.19-0.92) 0.33 (0.21-0.63) 0.37 (0.27-0.42) 
Css (μmol/L) 2.1 (1.6-2.3) 3.7 (3.1-4.9) 7.7 (5.1-10.0) 
Cmin (μmol/L) 1.5 (0.92-2.6) 1.9 (0.79-5.5) 6.8 (3.1-13.9) 
a 0 minimisation terminated out of 500; b Eta shrinkage was -11% and 0% for CL/F and V/F 





A bootstrap analysis was performed to assess model stability. The mean parameter 
estimates from the bootstrap analysis were found to be in close agreement with the final 
model estimates, and the CV values were found to be all below 15%, indicating that the final 
estimates are indeed reliable. Results of the bootstrap analysis can be found in Table 1. 
Internal model validation diagnostics were satisfactory. Individual predicted profiles and 
goodness-of-fit plots revealed that the model provides an adequate and non-biased 
description of the data, as shown in Figures 1 and 2.  
Figure 1. Goodness-of-fit plots. Upper panels show the observed data (Obs) vs. individual predictions 
(IPred) (left) and the observed data vs. population predictions (Pred) (right). Lower panels show the 
conditional weighted residuals (CWRES) vs. population predictions (left) and the CWRES vs time (left). 
 
 















Figure 2. Individual plots: observed data are plotted using blue circles; the black solid line represents 
the population prediction (Pred) and the red solid line represents the individual predictions (IPred). 
Panel A shows patients in dose group 1 (8.3 mg/kg); panel B shows patients in dose group 2 (16.7 
mg/kg); and panel C shows patients in dose group 3 (33.3 mg/kg). 
 
In addition, NPDE summaries (Figure 3) show that the discrepancy between predicted and 
observed values can be assumed to be normally distributed. The predictive performance of 
the model in subsequent simulations was deemed critical to achieve the objective of our 
analysis. To this purpose, visual predictive checks were therefore used to assess whether the 
variance and covariance structures have been well characterised (Figure 4). Overall these 
diagnostic techniques confirm that the final model is suitable for the purposes of data 
simulation.  




Figure 3. Normalised prediction distribution errors: upper panels show the QQ-plot of the 
distribution of the NPDEs for a theoretical N (0, 1) distribution (left) and the histogram of the 
distribution of the NPDE together with the density of the standard normal distribution (right). Lower 







Figure 4. Visual Predictive Check (VPC): observed data are plotted using open circles; the black solid 
line represents the median of the simulated data; the dashed lines represent the 5th and 95th 
quantiles of the simulated data. The left, mid and right panels show respectively dose group 1 (8.3 
mg/kg), 2 (16.7 mg/kg) and 3 (33.3 mg/kg). 
 
 
PK bridging and dosing recommendations 
The results of the simulations are shown in Figures 6 and 7 and Table 2. A similar exposure is 
achieved in adults and children in terms of AUC and Css when receiving the current 
recommended dosing regimen both at 75 and 100 mg/kg/day. The simulation generated a 
29% increase in Cmax in children when compared to the adult population.  
The performance of an individualised dosing regimen was tested on the target population, 
but the results show that it does not change significantly the exposure in children when 
compared to the non-individualised one (at 75 mg/kg/day); not shown here.  
Results suggest that the currently approved dosing regimen for the adult population is 
suitable also for children below 6 years of age in order to achieve a similar and effective 
exposure. 
 




Figure 5. Predicted deferiprone exposure expressed as AUC 0-8 (upper panel), Cmax (mid panel) and 
Css (lower panel) for children below 6 years of age receiving 75 mg/kg/day. The black line represents 
the median of the reference population (adult thalassaemic population), whereas the orange lines 
represent 1st and 3rd quartiles and the red lines represent 5th and 95th percentiles of the same 
reference population. Percent of total indicates the percentage of cases for each beam of 1000 






Figure 6. Predicted deferiprone exposure expressed as AUC 0-8 (upper panel), Cmax (mid panel) and 
Css (lower panel) for children below 6 years of age receiving 100 mg/kg/day. The black line 
represents the median of the reference population (adult thalassaemic population), whereas the 
orange lines represent 1st and 3rd quartiles and the red lines represent 5th and 95th percentiles of the 
same reference population. Percent of total indicates the percentage of cases for each beam of 1000 
simulations with 100 patients in each simulated trial. 
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Table 2. Summary statistics of the simulation scenarios for the PK bridging study.  
 75 mg/kg/day 100 mg/kg/day 
 Adults Children Adults Children 
 AUC Cmax Css AUC Cmax Css AUC Cmax Css AUC Cmax Css 
Median 318.5 132.2 5.5 340.6 170.7 5.9 424.2 176.0 7.4 453.7 227.4 7.9 
1st quartile 263.9 109.2 4.6 286.6 145.0 5.0 351.5 145.4 6.1 381.8 193.2 6.6 
3rd quartile 383.0 159.0 6.7 404.7 200.5 7.0 510.0 211.9 8.8 539.0 267.1 9.4 
5th quantile 200.4 81.6 3.5 223.2 114.9 3.9 266.9 108.7 4.6 297.3 153.1 5.2 
95th quantile 499.0 205.6 8.7 520.0 253.0 9.0 664.0 273.9 11.5 693.0 337.0 12.0 
 
AUC: µmol/L*h; Cmax: µmol/L; Css: µmol/L 
 
5.4 Discussion and Conclusion 
Model-based approaches can be critical for therapeutic decisions when limited evidence is 
available. This is certainly the case for rare diseases such as haemoglobinopathies, especially 
when considering young paediatric patients, where practical and ethical constraints wisely 
imposed by regulatory authorities, make paediatric clinical investigation a true challenge 
23,24. The lack of exhaustive experimental data available on the use of deferiprone in children 
including deferiprone pharmacokinetic data in children below 6 years of age hampered the 
ability to assess whether doses, used in adults, adjusted for weight, would produce 
comparable exposure in young children. The need for a better understanding of DFP 
behaviour in the paediatric population led to the establishment of the DEEP consortium 
(www.deep.cvbf.net). Within this project, a model-based approach has been used to 
overcome the specific challenge to better understanding DFP behaviour and allowing 
adequate dosage in the <6 years of age group, reducing at the same time the sampling 
burden on such a vulnerable population (i.e., by the use of optimal design techniques to 
increase the quality of the information gathered and by the use of population PK analysis in 
the presence of sparse sampling). Modelling and Simulations (M&S) techniques have 
become an invaluable tool for the evaluation of the dose rationale and personalisation of 
dosing regimens for subgroups of patients and special populations, allowing the 
characterisation and quantification of the contribution of different sources of variability to 
an agent’s overall pharmacokinetic properties. Furthermore, continuous emphasis has been 
placed on the need for evidence-based clinical and regulatory decisions, where modelling 
and simulation is becoming more and more an essential component 25–27.  
 
Pharmacokinetic modelling 
The pharmacokinetics of deferiprone after oral administration to paediatric patients was 
successfully characterised by a model-based approach. As shown in the results section a 




described satisfactorily the PK profile of the drug under investigation, allowing precise and 
accurate characterisation of the main PK parameters of interest (Table 1). Body weight was 
found to be a significant predictor of changes in the distribution and elimination processes of 
the drug; the relationship with CL/F and V/F was described by fixed allometric scaling. 
Furthermore, the use of prior information in the adult population allowed a more stable 
characterisation of the absorption profile, showing once more how M&S can overcome the 
limited evidence generated in the clinical study. 
 
Dosing recommendations 
Bridging concepts are applied in this context to evaluate the exposure in the paediatric 
population as compared to efficacious exposure in adults. Using the model developed for 
this population, and a previously developed model in the adult population 20, simulations 
were performed to compare PK exposure between children below 6 years of age and a 
standard thalassaemic adult population. As shown in Figures 6 and 7, AUC and Css 
distributions are comparable at 75 mg/kg/day and 100 mg/kg/day respectively, whereas an 
increase in peak concentrations (Cmax) is predi ted in children. This increase is most 
probably due to differences in the volume of distribution between the two groups, and is 
expected to have limited clinical implications. Overall exposure (AUC and Css) is the 
determinant of the response, and changes in Cmax are not expected to modify the safety 
profile of the drug. This is confirmed in literature where previous studies in children exposed 
to a 100 mg/kg/day dosing regimen have safety profiles similar to those reported in adults 
28–30. 
In conclusion, based on these findings, a dosing regimen of 25 mg/kg t.i.d. (75 mg/kg/day) is 
recommended for children aged from 1 month to < 6 years, with the possibility of titration 
up to 33.3 mg/kg t.i.d. (100 mg/kg/day), if necessary. Noticeable, this dosage will be used to 
conduct further efficacy-safety comparative phase III study and will be also adopted in any 
SmPC possible modifications. 
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The understanding of iron overload dynamics and its progression is essential to establish an adequate 
therapeutic intervention in patients affected by transfusion-dependent diseases. The main objective 
of this analysis is to develop a disease model for iron overload on the basis of available literature 
data. A thorough literature search was performed in Pubmed to retrieve all pertinent publications 
that would allow characterising the different aspects of the disease. At first, the turnover of serum 
ferritin in healthy individuals was described by an indirect response model. Subsequently, the effect of 
blood transfusions on serum ferritin levels was quantified according to an Emax model that depicts 
the non-linearity of the relationship. Finally, the relationship has been integrated as an additive 
conversion rate in the turnover model to account for disease progression. Internal model validation 
diagnostics were satisfactory and visual predictive checks reveal that the model provides an adequate 
and non biased description of the data. In conclusion, a disease model for iron overload was 
successfully developed. The relationship between blood transfusions and serum ferritin levels was 
quantified for the first time through a model-based approach. This model puts the basis for a more 





Patients affected by transfusion-dependent diseases, such as beta-thalassaemia major or 
sickle cell disease, require regular red blood cell (RBC) transfusions to survive 1–7. Without 
the chronic transfusion regimen, patients would die before the third decade of life. Based on 
the Guidelines for the Clinical Management of Thalassaemia 7, transfusions should aim at 
maintaining a pre-transfusion haemoglobin (Hb) level between 9 and 10 g/dl and a post-
transfusion level of 14 to 15 g/dl.  The most common transfusion interval in  these patients is 
once every two to four weeks (equal to two to three blood units per three weeks) 2,4,5,7,8. 
 
Iron overload in patients affected by transfusion-dependent diseases 
As generally known, iron is recycled within the body and the body itself does not have the 
capacity to remove the excess of iron that is introduced from continuous blood transfusions. 
In normal conditions (Figure 1), iron entry into the cells is regulated by the uptake of iron-
transport protein transferrin from the plasma. Chronic blood transfusions induce an 
increased iron exposure from macrophages, resulting into saturation of transferrin transport 
capacity. This leads to the release of Non-Transferrin Bound Iron (NTBI) in the plasma which 
can enter important cells (e.g., heart and liver cells) resulting over time into tissue 
accumulation. Iron is stored in tissues mainly into ferritin complexes. Once ferritin storage 
capacity is overwhelmed, small clusters of ferritin particles are formed and are degraded by 
the lysosomes leading to the formation of insoluble masses of hemosiderin 9–15. Over time 
this accumulation would cause severe organ damage 16–21. 
Even though a significant improvement has been achieved in the management of the chronic 
transfusion regimen in the past decades, the therapy will eventually lead to a series of 
complications. Iron overload is the most common and relevant one and it is associated with 
several (lethal) co-morbidities such as cardiac dysfunction, liver fibrosis, hypogonadism, 
hypothyroidism, hypoparathyroidism and diabetes mellitus 18,20. Cardiac disease caused by 
myocardial siderosis is the most relevant complication, causing death in 71% of the patients 
affected by transfusion-dependent diseases 17. 
 




Figure 1. Iron homeostasis. Adapted from Andrews et al.16.  
 
In the absence of an innate mechanism that allows removing iron excess from the body,  
treatment with iron chelators is therefore essential to prevent iron accumulation and related 
complications 22–25. Iron chelators possess overall a similar mechanism of action. They act by 
1) preventing the uptake of NTBI into organs such as liver and heart; 2) chelating intracellular 
iron and thus preventing its corporation into ferritin; or 3) intercepting iron released from 




















































Clinical assessment of iron overload 
There are several clinical measures to evaluate the disease state of iron overload. The most 
common is the biomarker serum ferritin, due to its strong correlation with total body iron 
stores 27. As a single clinical endpoint however, serum ferritin is not always reliable. It could 
also be influenced by other factors such as inflammatory disorders and liver disease 28. On 
the other hand, serial measurements of serum ferritin are still the easiest and least invasive 
method to evaluate iron overload and efficacy of chelation therapy.  
Other assessment methods for iron status focus more on tissue specific accumulation. Liver 
iron concentration is considered as the gold standard for the evaluation of iron overload due 
to a high correlation with total body iron accumulation 29. However, determination of liver 
iron concentration requires an invasive technique with complications and risks of false 
negative results 30. Magnetic Bio-Susceptometry (SQUID) is another option for measurement 
of liver iron accumulation 31. However, it is only available in a limited numbers of centres 
worldwide. Furthermore, cardiac complications due to iron accumulation in the heart have 
been associated with 50-70% of deaths in thalassaemia major patients, mainly at young age 
32. Methods that were developed for cardiac monitoring were based on keeping serum 
ferritin and LIC level below a certain threshold (<2500 μg/L and <7 mg/kg dwt respectively) 
that was associated with decreased cardiac risks. However, this method proved not to be 
sufficient for effective intervention, since any dysfunctions were often identified at relative 
late stage. In recent years, Magnetic Resonance Imaging (MRI) techniques for assessing iron 
loading in the liver and heart have been introduced and validated for the evaluation of tissue 
specific accumulation 33.  
 
Iron overload is thus a rather complex process, and the understanding of the dynamics of 
the disease and its progression is essential for an adequate improvement of the therapeutic 
intervention. Several clinical questions are still not fully understood, e.g. how much time is 
required in order to observe a true response in the patient, or in order to reach clinically 
acceptable serum ferritin levels (i.e. about 2500 ug/L). As generally recognised, ferritin 
reflects what happens at the organ level only up to a certain threshold. Above this threshold 
other mechanisms intervene (inflammatory disorders, liver status) 27,28 that influence the 
relationship between serum ferritin and body iron accumulation and the iron interchange 
between organs and the circulatory system. This project puts its main focus on the use of 
model-based approach to gain more insights in key factors that play a role in iron overload. 
The specific objective is to develop a disease model on the basis of available literature data. 









A thorough literature search was performed in Pubmed to retrieve all pertinent publications 
that would allow the development of the disease model. Stepwise mining and pooling of 
published data was subsequently performed to characterise the different aspects of iron 
overload. Data published by Dawkins et al. 34 were used to quantify the turnover of serum 
ferritin in healthy individuals; whereas clinical data published by Worwood et al., George et 
al. and Letsky et al. 35 were pooled to evaluate the impact of blood transfusions on serum 
ferritin levels in untreated patients (i.e., patients not receiving chelation therapy). 
 
Modelling 
The software R (v.2.14.0) was used for statistical summaries and literature data extraction 
(complemented with R Digitize Package 36 ), as well as data manipulation and preparation for 
modelling purposes. Nonlinear mixed effects modelling was performed in NONMEM version 
7.2 (Icon Development Solutions, USA). 
Model building criteria included: (i) successful minimisation, (ii) standard error of estimates, 
(iii) number of significant digits, (iv) termination of the covariance step, (v) correlation 
between model parameters and (vi) acceptable gradients at the last iteration. Comparison of 
hierarchical models was based on the likelihood ratio test. Goodness of fit was assessed by 
graphical methods, including population and individual predicted vs. observed 
concentrations, conditional weighted residual vs. observed concentrations and time, 
correlation matrix for fixed vs. random effects, correlation matrix between parameters and 
covariates and normalised predictive distribution error (NPDE) 37.  
The validation of the final model was based on graphical and statistical methods, including 
visual predictive checks 38. Bootstrap was used to identify bias, stability and accuracy of the 
parameter estimates (standard errors and confidence intervals). The bootstrap procedures 
were performed in PsN v3.5.3 (University of Uppsala, Sweden) 39, which automatically 
generates a series of new data sets by sampling individuals with replacement from the 
original data pool, fitting the model to each new data set. 
 
Iron homeostasis in healthy individuals (basal ferritin turnover) 
To quantify serum ferritin changes in healthy individuals, data from 14 subjects were 
extracted from literature 34 and combined into a single dataset. Data are presented in Table 









where Kin is the basal zero-order production rate of ferritin and Kout is the basal first-order 
degradation rate of ferritin.  
 
Table 1. Summary of serum ferritin levels in healthy individuals: data is presented by study duration. 
 
 Serum Ferritin (g/L) 
Study duration Mean ± s.d Range (g/L) 
7 weeks (N=9) 49.67 ± 25.95 8.53 – 97.60 




Figure 2. Serum ferritin changes over time in healthy individuals. Individual profiles in 14 healthy 
individuals presented as mean (solid line) and 5th and 95th percentiles (dashed lines). Left panel: 
serum ferritin profiles during an observational period of 7 weeks (N=9). Right panel: serum ferritin 
profiles during an observational period of 24 hours (N=5).  
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Relationship between serum ferritin and cumulative blood units (effect of transfusions) 
Data containing serum ferritin levels in untreated patients were extracted and pooled from 
literature 35,40,41 into a single dataset (Figure 3, right panel). Relevant information regarding 
the study population mentioned in the published articles is summarized in Table 2.  
 
Table 2. Summary of serum ferritin levels and transfusion history in patients affected by transfusion-
dependent diseases not receiving iron chelation therapy.  
  Serum ferritin (g/L) Transfusion history (cum. blood units) 
Study N Mean ± s.d Range Mean ± s.d Range 
Overall 188 4271.55 ± 3003.76 353-18780 153.8 ± 106.42 4-502 
Worwood et al. 116 5023.4 ± 2512.38 445-14120 193.1 ± 107.4 4-502 
Letsky  et al. 24 4902.63 ± 4603.18 447.4-18780 116.5 ± 96.3 4-278 
George et al. 48 2694.64 ± 2694.64 353-9046 77.6 ± 43.05 13-224 
 
Figure 3. Comparison of the distributions of serum ferritin levels in healthy individuals (left panel) 





Information regarding the volume of blood per unit was only available for the work carried 
out by Worwood et al. (500 ml per unit) and by George et al. (350 ml per unit). To ensure 
that equal volume of blood per transfusion was taken into account for the entire cohort, 
cumulative amount of blood units was normalized to a volume of 500 ml per blood unit. 
Given the non-linear nature of the relationship between serum ferritin and cumulative blood 
units, an Emax model was tested to describe the relationship as described below: 
 





where, E0 represents baseline serum ferritin levels when no transfusion has yet occurred, 
Emax the maximum serum ferritin levels at saturation and Ebu50 the cumulative amount of 
blood units (BU) when 50% of saturation is reached.  
Ferritin data were log transformed for the analysis and the whole dataset was randomly 
divided into two subsets, resulting into 2/3 of the data used for the model building and 1/3 
of the data preserved for external validation. 
 
Integration of the effect of blood transfusions in the turnover model: disease model for 
iron overload  
Once the relationship between cumulative blood units and serum ferritin was quantified, it 
was our goal to integrate this information within the turnover model. Our intent was to 
translate the relationship into a rate that would affect the basal ferritin production rate. 
Given that information on time was not provided in the data used to quantify the 
relationship, and given that we were mainly interested in translating the population profile, 
we assumed a constant interval of three weeks between subsequent units of blood 
transfused. This is on average the case in patients affected by transfusion-dependent 
diseases 2,4,5,7,8. 
Assuming this constant time interval we performed a simulation-estimation analysis to 
quantify the impact of blood transfusions on the production rate of serum ferritin. The 
simulations were performed using the Emax model in the range of 5 to 450 cumulative blood 
units and subsequently the simulated data were fitted with the turnover model where basal 
Kin and Kout were fixed and a new production rate (CRT = conversion rate) was estimated 
(Figure 4). This rate was non-linearly correlated to actual ferritin levels according to the 
following equation: 
 
𝐶𝑅𝑇 = 𝑆𝐶𝐿 ×  𝑒−𝑆𝐻𝑃 ×𝐹𝐸𝑅𝑅𝐼𝑇𝐼𝑁 
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where SCL is a scaling factor and SHP is the shape factor of the correlation. The conversion 




= 𝐾𝑖𝑛 + 𝑪𝑹𝑻 − 𝐾𝑜𝑢𝑡 × 𝐹𝐸𝑅𝑅𝐼𝑇𝐼𝑁 
 




Figure 4. Stepwise integration of the effect of blood transfusions on serum ferritin levels in the 
turnover model developed on healthy subjects. Left panel: open circles represent the observed data 
and solid line represents the fitting of the relationship between cumulative blood units and serum 
ferritin levels. Right panel: negative relationship between serum ferritin conversion rate in the 
presence of chronic transfusion regimen and serum ferritin levels. The relationship has been derived 
from the one presented on the left panel assuming a constant time interval between consecutive 
blood units transfused. 
 
6.3 Results 
Iron homeostasis in healthy individuals (basal ferritin turnover) 
An indirect response model was developed to describe basal serum ferritin turnover in 
healthy individuals. The zero-order production rate constant (Kin) and the first-order 
degradation rate constant (Kout) were successfully estimated; inclusion of inter-individual 




bootstrap results are shown in Table 3. Goodness-of-Fit (GoF) (Figure 7, see Appendix) plots 
as well as Normalized Prediction Distribution Errors (NPDE) (Figure 8, see Appendix) confirm 
the suitability of the model in describing adequately the data. 
 
Table 3. Final model parameters for turnover model of serum ferritin in healthy individuals.  
Parameters Estimates Bootstrap (mean) CV (%) 
Kin (μg/day) 0.00625 0.00416 34.2 
Kout (day-1) 0.000137 0.0000875 32.7 
Eta on Kin 0.367 0.329 40.8 
Residual error 0.000658 0.000641 31.2 
 
Relationship between serum ferritin and cumulative blood units (effect of transfusions) 
An Emax model was used to describe the relationship between serum ferritin levels and 
cumulative blood units. Inter-individual variability was estimated on the Ebu50 parameters. 
The model allowed accurately quantifying the relationship; final parameter estimates are 
provided in Table 4 together with the estimates obtained with the external set of data. 
Goodness of Fit (Figures 9 and 11, see Appendix) plots as well as NPDE (Figures 10 and 12, 
see Appendix) reveal that the model provides a suitable description of the data.  
 
Table 4. Summary of estimated relationship between cumulative blood units and serum ferritin 
levels in patients affected by transfusion-dependent diseases not receiving iron chelation therapy. 
Parameters Estimates External Validation 
E0 (ug/L) 5.81 5.62 
Emax (ug/L) 9.17 8.88 
Ebu50 26.5 16 
Eta on Ebu50 0.554 0.63 
Residual error 0.0075 0.15 
 
Integration of the effect of blood transfusions in the turnover model: disease model for 
iron overload  
At first, ferritin levels corresponding to a range of cumulative blood units of 5 to 450 were 
simulated with the Emax model previously developed. Secondly, the data were fitted using 
an integrated model that consisted of the turnover model where basal Kin and Kout were 
fixed to the values estimated in the healthy population and an additive ferritin production 
rate (CRT) that was estimated during this process. The conversion rate (CRT) was non-
linearly correlated to actual ferritin concentration. Final parameter estimates are provided in 
Table 5, whereas a schematic representation of the model is shown in Figure 5.  




Table 5. Summary of final parameter estimates for the disease model of iron overload: integration of 
the effect of blood transfusions on serum ferritin levels in the turnover model developed on healthy 
subjects. 
Parameters Estimates 
Kin (μg/h) 0.000208 FIX 
Kout (h-1) 0.00000458 FIX 
SHP (h-1) 0.00026 
SCL (μg/h) 0.383 
Residual error 0.0014 
 
 
Figure 5. Disease model for iron overload. Kin and Kout represent respectively the basal zero order 
production rate and first order degradation rate of ferritin in healthy individuals. CRT represents the 
serum ferritin conversion rate in patients undergoing chronic transfusion therapy, which reflects the 
impact of the disease (blood transfusions) on serum ferritin levels. The dashed line represents the 
negative feedback that serum ferritin has on CRT. 
 
Given the nature of the simulation, it was only possible to quantify the mean population 
profile for the integrated model. Inter-individual variability was added in a systematic 
manner to evaluate whether the model would capture the variation in the original data. 
Visual predictive checks (with the inclusion of 50% variability on both SCL and SHP) show 











left panel). In addition, Figure 6 (right panel) shows simulated profiles of serum ferritin over 
a period of 10 years in a virtual patient not receiving iron chelation therapy. The simulations 
provide insights on how the impact of the disease changes when patients start at different 
baseline levels, and allow quantifying the true underlying disease progression. 
 
Figure 6. Visual predictive check of the disease model for iron overload and simulated mean serum 
ferritin profile in virtual patients not receiving iron chelation therapy. Left panel: VPC of the disease 
model for iron overload. Observed data are plotted using open circles; the black solid line represents 
the median of the simulated data; the dashed lines represent the 5th and 95th percentiles of the 
simulated data. Right panel: simulated ferritin profiles over a period of 10 years for a virtual patient 
not receiving iron chelation therapy. Each line represents a different ferritin baseline level: the solid, 
dashed (small), dotted, dashed-dotted, and dashed (big) lines represent 1000, 2500, 5000, 7500, and 
10000 ug/L baseline ferritin levels. 
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6.4 Discussion and Conclusion 
With this work we attempt for the first time to use a model-based approach in the field of 
transfusion-dependent diseases. An indirect response model was first developed in healthy 
subjects to account for the basal turnover of serum ferritin. Subsequently, the relationship 
between serum ferritin and cumulative blood units was quantified and integrated in the 
turnover model, and the non-linearity of the system was properly captured. Once the effect 
of the chronic transfusion regimen is introduced in the model, the contribution of the basal 
turnover of serum ferritin becomes negligible; the conversion rate (CRT) becomes the driving 
force of the changes in serum ferritin levels and gives a clear idea of the magnitude of iron 
overload in the absence of chelation therapy (Figure 6, right panel). As depicted in the same 
figure, the model allows exploring the natural course of the disease without treatment 
intervention; without such a model it would not be possible to appropriately quantify the 
true effect of iron chelation therapy. In addition, the nature of the model allows evaluating 
the drug effect of any available or future chelating agent.   
 
Limitations 
The lack of access to individual data did not allow a proper characterisation of the inter-
individual variability and/or of a thorough covariate analysis. On the contrary, we could 
appropriately quantify the mean population changes in disease progression.  
When integrating the Emax model with the turnover model, we assumed a constant time 
interval between subsequent units of blood transfused; the interval chosen was based on 
available literature data 2,4,5,7,8. Even though there is inter- and intra-patient variation in the 
transfusion regimen, we believe that the literature data support our assumption given that 
we could only evaluate the mean population profile of the integrated model. 
 
Conclusions 
In conclusion, despite some limitations due to incomplete availability of data a disease 
model was successfully developed in patients affected by severe iron overload that were not 
undergoing iron chelation therapy. The impact of blood transfusions on serum ferritin levels 
was quantified allowing a more mechanistic interpretation of the underlying disease 
progression. This model provides the basis for a more structured evaluation of therapeutic 
intervention in this patient population and gives the opportunity for further evaluation of 
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Figure 7. Goodness-of-fit plots for the turnover model in healthy individuals. Upper panels show the 
observed data (Obs) vs. population predictions (Pred) (left) and the observed data vs. individual 
predictions (IPred) (right). Lower panels show the conditional weighted residuals (CWRES) vs. 








Figure 8. NPDE summaries for the turnover model in healthy individuals. Upper panels show the QQ-
plot of the distribution of the NPDEs for a theoretical N (0, 1) distribution (left) and the histogram of 
the distribution of the NPDE together with the density of the standard normal distribution (right). 









Figure 9. Goodness-of-Fit plots of estimated relationship between cumulative blood units and serum 
ferritin levels in patients affected by transfusion-dependent diseases not receiving iron chelation 
therapy: model building. Upper panels show the observed data (Obs) vs. population predictions 
(Pred) (left) and the observed data vs. individual predictions (IPred) (right). Lower panels show the 









Figure 10. NPDE summaries of estimated relationship between cumulative blood units and serum 
ferritin levels in patients affected by transfusion-dependent diseases not receiving iron chelation 
therapy: model building. Upper panels show the QQ-plot of the distribution of the NPDEs for a 
theoretical N (0, 1) distribution (left) and the histogram of the distribution of the NPDE together with 
the density of the standard normal distribution (right). Lower panels show the NPDEs vs. time (left) 
and NPDEs vs. individual predictions (right). 
  





Figure 11. Goodness-of-Fit plots of estimated relationship between cumulative blood units and 
serum ferritin levels in patients affected by transfusion-dependent diseases not receiving iron 
chelation therapy: external validation. Upper panels show the observed data (Obs) vs. population 
predictions (Pred) (left) and the observed data vs. individual predictions (IPred) (right). Lower panels 









Figure 12. NPDE summaries of estimated relationship between cumulative blood units and serum 
ferritin levels in patients affected by transfusion-dependent diseases not receiving iron chelation 
therapy: external validation. Upper panels show the QQ-plot of the distribution of the NPDEs for a 
theoretical N (0, 1) distribution (left) and the histogram of the distribution of the NPDE together with 
the density of the standard normal distribution (right). Lower panels show the NPDEs vs. time (left) 
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Purpose: Our endeavour is to show the advantages of a model-based approach to identify key factors 
that play a role in transfusion-dependent iron overload. We use deferoxamine as a paradigm 
compound to assess the role of relevant covariates on the underlying disease progression. 
Methods: Data from clinical routine practice on 27 patients affected by β-thalassaemia major were 
used for the analysis. Serum ferritin was selected as the main endpoint of interest for the assessment 
of iron overload. Its time course was characterised by means of a hierarchical nonlinear mixed effects 
model, as implemented in NONMEM (7.2.0). 
Results: A turnover model best described serum ferritin changes over time, with the effect of blood 
transfusions introduced  as a change in  the ferritin conversion rate, whereas the effect of 
deferoxamine was described by a proportional change in the degradation rate constant (Kout). The 
inclusion of IOV (57.4 %) on the conversion rate resulted in a significant drop in the OFV (Δ 443) 
allowing a better description of the individual profiles. 
Conclusions: A model-based approach was successfully used to gather further insight into the 
dynamics of ferritin in transfusion-dependent iron overload. Given the choice of parameterisation, the 
model may be used as a tool to support clinical practice, including the evaluation of the dose 






ALT Alanine Aminotransferase 
AST Aspartate Aminotransferase 
Css Steady state concentration 
CMPL Treatment compliance 
DFO Deferoxamine 
FT4 Free T4 
IIV Inter-individual variability 
IOV Inter-occasion variability 
M&S Modelling and simulations 
NPDE Normalised predictive distribution error 
NTBI Non-Transferrin Bound Iron 
OFV Objective function value 
PKPD Pharmacokinetic-pharmacodynamic 
PRED Population prediction 
RBC Red blood cells 
TSH Thyroid-Stimulating Hormone 
VPC visual predictive check 




Transfusional iron overload 
Beta-thalassaemia major is a hereditary blood disorder and patients affected by this disease 
require regular red blood cell (RBC) transfusions to survive (1–7). Without the chronic 
transfusion regimen, patients would die before the third decade of life (2,4,5,7,8). Even 
though a significant improvement has been achieved in the management of the chronic 
transfusion regimen in the past decades, therapeutic intervention will eventually lead to a 
series of complications. Iron overload is the most common and relevant one and it is 
associated with several co-morbidities such as cardiac dysfunction, liver fibrosis, 
hypogonadism, hypothyroidism, hypoparathyroidism and diabetes mellitus (6,9,10). Cardiac 
disease caused by myocardial siderosis is the most relevant complication, causing death in 
71% of the patients affected by transfusion-dependent diseases (11). 
For complex processes such as iron overload, understanding of the dynamics of the disease 
and its progression is crucial to adequately evaluate the therapeutic intervention. This 
complexity is also characterised by the fact that the currently accepted biomarker, i.e., blood 
ferritin is not specific enough to distinguish the effect of transfusion from the influence of 
other pathological mechanisms such as inflammatory disorders, and/or liver status, which 
can equally affect the iron interchange between organs and the circulatory system (2,12–
14). Consequently, ferritin levels may not provide a direct link for total body or tissue specific 
iron accumulation at specific time points. On the other hand, changes in ferritin levels over 
time are still helpful for the management of the disease and maintaining serum ferritin 
below a threshold of about 2500 µg/L is a widely accepted therapeutic goal  (2,3,5–7). 
However, important clinical questions are not yet fully understood, e.g. how much time is 
required in order to observe a stable response or to reach clinically meaningful serum 
ferritin levels.  
 
Iron chelation therapy with chelating agent deferoxamine 
Given that human physiology does not have an innate mechanism that allows removal of the 
iron excess, treatment with iron chelators is therefore vital to prevent its accumulation and 
related complications (15–18). In the current investigation we attempt to characterise the 
(patho)-physiological response to the iron chelating agent deferoxamine as a paradigm 
compound for the assessment of iron dynamics using a model-based approach. 
Deferoxamine was the first iron chelator approved for human use and has been available for 
the treatment of iron overload for more than 35 years (2,6,15–19). It is an exadentate 
chelator that binds iron in a 1:1 ratio. The drug is rapidly absorbed after intramuscular and 
subcutaneous administration, but it cannot be absorbed orally. In the treatment of iron 
overload in patients affected by transfusion-dependent haemoglobinopathies several dosing 




cases deferoxamine is given as an 8 to 12 hour nightly subcutaneous infusion (5 to 7 days a 
week) (2,19–21). The serum protein binding is less than 10% and the drug undergoes the 
following metabolic reactions: transamination and oxidation; beta-oxidation; 
decarboxylation and N-hydroxylation. The average recommended daily dose varies between 
20 and 60 mg/kg and the drug has an half-life of 5.6 hours in patients (20–22).  
 
Deferoxamine binds free iron by preventing the uptake of NTBI (Non-Transferrin Bound Iron) 
into organs but is also acts within the cell where enters by endocytosis, stimulates the 
degradation of ferritin via lysosomes and subsequently binds the released iron. The iron 
bound to deferoxamine is then excreted in urine and faeces (2,6,21,23). 
Regardless of numerous limitations associated with the use of deferoxamine, such as poor 
compliance due to the parenteral administration, inadequate cardiac iron removal and 
auditory, ocular and neurological toxicities (6,16,18,19,24),  deferoxamine is still the most 
common used therapy for the treatment of iron overload. This widespread use has remained 
despite the presence of new oral iron chelators.  
 
Given the complexity of the issues highlighted above, our focus is to gain insight into key 
factors that play a role in iron overload; with the objective of quantifying the therapeutic 
effect of deferoxamine and identify potential covariates on model parameters describing the 
underlying disease progression. Furthermore, we propose how modelling and simulation 
(M&S) can be applied to support decision making in clinical practice,  providing a framework 
to predict changes in the disease status and resulting ferritin response following treatment 




The modelling analysis was performed using retrospective clinical data from three different 
Italian centres: Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari U.O. 
Pediatria Federico Vecchio; Azienda Ospedaliera Universitaria Policlinico di Sassari Clinica 
Pediatrica, ASL 1 D.H. per Talassemia; Azienda Ospedaliera di Padova Clinica di 
Oncoematologia Pediatrica. The study has been conducted in full conformance with the 
principles of the Declaration of Helsinki and with the local laws and regulations concerning 
clinical trials. The protocol and the informed consent documents have been formally 
approved by the relevant research ethics committee of each clinical site.  
 
27 patients affected by transfusion-dependent diseases, receiving deferoxamine as single 
drug for iron chelation therapy were considered eligible for the retrospective study. Patients 
receiving chemotherapy, and/or affected by other diseases that require additional blood 
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transfusions, and/or affected by unrelated endocrine dysfunctions were considered not 
eligible for the study. Baseline characteristics of the patient population are provided in Table 
1. Serum ferritin was the main endpoint of interest and was measured every two to three 
months; patients contributed with 40.2 observations on average (sd: 17), with a minimum of 
4 samples per year. With the same frequency, data on the following variables were collected 
during the study: height and body weight of the patients, as well as clinical data on TSH, FT4, 
AST, ALT, glucose, creatinine and ejection fraction. These were considered as potential 
covariates and were tested during the study to evaluate their influence on the changes in 
serum ferritin levels. 
 
Table 1. Baseline characteristics of the patient population 
 Units Median Range 
Age Years 14.6 6.8-19.9 
Weight Kg 46 17.5-71 
Height Cm 154 111-173 
TSH mIU/L 2.34 0.58-83.2 
FT4 ng/dL 1.05 0.73-1.43 
AST U/L 33 7-159 
ALT U/L 56 9-372 
Glucose mg/dL 91 52-444 
Creatinine mg/dL 0.6 0.2-1.12 
Ejection Fraction % 64 35-77 
Ferritin μg/L 2260 393-8500 
 
 
PK model deferoxamine 
As pharmacokinetic samples are not collected in clinical routine monitoring, the model was 
built using literature data (25) by fitting a mean pharmacokinetic profile in adults patients 
affected by transfusion-dependent haemoglobinopathies receiving deferoxamine as an 8 
hours subcutaneous infusion. A two compartment pharmacokinetic model with zero-order 
absorption (8 hours subcutaneous infusion) and first-order elimination processes provided 
an appropriate description of the average steady state concentration (CssAV) for the 






Figure 1. Performance of the pharmacokinetic model of deferoxamine. The circles represent the 
mean population deferoxamine concentrations reported in literature (23). The solid line represents 
model prediction.  
 
Assumptions were then made to allow the use of the model to predict exposure in the 
patient population: 1) the simulations were based on the dosing regimen information 
collected in the clinical centres and the reported changes to the regimen; and 2) in the 
absence of quantitative data on adherence to drug therapy, compliance was assumed 
equivalent to 100%. The role of compliance was assessed in a second phase and details on 
that are provided in the next paragraphs. Afterwards, fixed allometric scaling (exponent of 
0.75 on CL/F and 1.00 on V/F) was used to extrapolate CssAV in adolescents and children. 
Population prediction (PRED) were used to generate CssAV values in the population of 
interest. 
 
Disease model iron overload 
A disease model for iron overload in patients affected by transfusion-dependent diseases 
was previously developed by our group [unpublished results]. It consists of an indirect 
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response model where basal turnover of ferritin levels is depicted by a zero-order 
production rate (Kin) and a first-order degradation rate (Kout) and the disease component is 
described by an additive production rate (CRT) triggered by the transfusion regimen which 




= 𝐾𝑖𝑛 + 𝐶𝑅𝑇 − 𝐾𝑜𝑢𝑡 × 𝐹𝐸𝑅𝑅𝐼𝑇𝐼𝑁     Equation 1 
 
𝐶𝑅𝑇 = 𝑆𝐶𝐿 ×  𝑒−𝑆𝐻𝑃 ×𝐹𝐸𝑅𝑅𝐼𝑇𝐼𝑁       Equation 2 
 
where SCL is a scaling factor and SHP is the shape factor of the correlation. The population 
parameters of the disease model were kept fixed when performing the PKPD analysis of the 
retrospective clinical data. 
 
Modelling 
The software R (v.2.14.0) was used for statistical summaries as well as data manipulation 
and preparation for modelling purposes. Nonlinear mixed effects modelling was instead 
performed in NONMEM version 7.2 (Icon Development Solutions, USA). 
Model building criteria included: (i) successful minimisation, (ii) standard error of estimates, 
(iii) number of significant digits, (iv) termination of the covariance step, (v) correlation 
between model parameters and (vi) acceptable gradients at the last iteration. Comparison of 
hierarchical models was based on the likelihood ratio test. Goodness of fit was assessed by 
graphical methods, including population and individual predicted vs. observed 
concentrations, conditional weighted residual vs. observed concentrations and time, 
correlation matrix for fixed vs. random effects, correlation matrix between parameters and 
covariates and normalised predictive distribution error (NPDE) (26).  
Fixed and random effects were introduced into the model in a stepwise manner. Inter-
individual variability in the parameters was assumed to be log-normally distributed. A 
parameter value of an individual i (post hoc value) is therefore given by the following 
equation: 
 
θi = θTV * eηi 
 
in which θTV is the typical value of the parameter in the population and ηi is assumed to be 
random variable with zero mean and variance ω2. Residual variability, which comprises 
measurement and model error, was described with a proportional error model. This means 
for the jth observed concentration of the ith individual, the relation Yij: 
 





where Fij is the predicted concentration and εij the random variable with mean zero and 
variance σ2. W is a proportional weighing factor for ε. 
 
Different concentration-effect relationships (e.g., Emax model, linear model, etc.) were 
tested on the disease model presented in equation 1 to quantify the effect of deferoxamine 
on serum ferritin levels. CssAV levels, generated with the PK model described above were 
used in the drug model as a measure of deferoxamine exposure. The effect of deferoxamine 
(DFO) was introduced as proportional change in the degradation rate (Kout) of ferritin as 




= 𝐾𝑖𝑛 + 𝐶𝑅𝑇 − 𝐾𝑜𝑢𝑡 × 𝐹𝐸𝑅𝑅𝐼𝑇𝐼𝑁 × (1 + 𝐷𝐹𝑂)   Equation 3 
 
𝐷𝐹𝑂 = 𝑆𝐿𝑃 ×  𝑆𝐶𝑠𝑠𝐴𝑉        Equation 4 
 
where DFO is the effect of deferoxamine on the Kout of the disease model, SLP is the slope 
parameter of the concentration-effect relationship, and SCssAV is the steady state 
concentrations simulated with the deferoxamine PK model. 
In addition, the disease model parameters, the scaling (SCL) and the shape (SHP) factors 
presented in equation 2 were found to be non-linearly correlated to the actual disease 
status according to the following relationships: 
 





       Equation 5 
 





       Equation 6 
 
where SCLref and SHPref are the reference parameters in the population of interest, SCLi and 
SHPi are the individual parameters, FERRITINmed is the median ferritin value in the population 
of interest and θx is the estimated exponent of the relationship. 
The evaluation of the final model was based on graphical and statistical methods, including 
visual predictive checks (27). Bootstrap was used to identify bias, stability and accuracy of 
the parameter estimates (standard errors and confidence intervals). The bootstrap 
procedures were performed in PsN v3.5.3 (University of Uppsala, Sweden) (28), which 
automatically generates a series of new data sets by sampling individuals with replacement 
from the original data pool, fitting the model to each new data set. 
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Assessing the role of compliance 
At the initial stage of the model-building phase, the model was not able to appropriately 
describe the data (Figure 2), under the assumption that the patients represent a single 
population. However, two different profiles were observed in the data, which prompted us 
consider dichotomising the data into responders and non-responders. An arbitrary definition 
was used based on the observed ferritin levels: the responders showed very stable profiles 
around 2500 µg/L serum ferritin, whereas the non-responders showed very steep increases 
in ferritin levels and appeared not to be able to return to a less severe state of the disease. A 
mixture model improved the quality of the fitting, but did not allow an adequate 
characterisation of the individual profiles.  
 
 
Figure 2. Goodness-of-fit plots of the model without the inclusion of compliance. Upper panels show 
the observed data (Obs) vs. population predictions (Pred) (left) and the observed data vs. individual 
predictions (IPred) (right). Lower panels show the conditional weighted residuals (CWRES) vs. 
population predictions (left) and the CWRES vs time (left). 
 
We have therefore investigated other potential mechanisms and explanatory factors 




literature. Treatment compliance was found to be the major cause of differences in ferritin 
levels. In the papers by Gabutti et al. (29) and Galanello et al. (30) serum ferritin profiles are 
quite stable over the observational period (Figures 3 and 1 respectively) as in our responder 
group and compliance is in both cases higher than 95%. In other investigations (20,29,31) 
Kaplan-Meier analyses show the relationship between survival and treatment compliance, 
providing evidence of the fact that poor adherence has a crucial impact on the clinical 
outcome. In particular the work by Olivieri et al. (31) shows how survival can directly be 
linked to the observed ferritin levels.  
The absence of quantitative data on treatment compliance in our retrospective study did not 
allow us to directly select this variable to account for such differences, which represented a 
clear obstacle for the analysis. To overcome this issue we used the work carried out by 
Olivieri et al. (31) as a reference and we derived a new variable (CMPL) based on the 
percentage of observations for each patient above the threshold of 2500 µg/L ferritin. The 
new variable (CMPL) was introduced in the model as follows:  
 
𝐷𝐹𝑂 = 𝑆𝐿𝑃 ×  𝑇𝐶𝑠𝑠
𝐴𝑉        Equation 7 
 
𝑇𝐶𝑠𝑠
𝐴𝑉 =  𝑆𝐶𝑠𝑠
𝐴𝑉  × (1 − 𝐶𝑀𝑃𝐿)       Equation 8 
 
where DFO is the effect of deferoxamine, SLP is the slope parameter of the concentration-
effect relationship, and TCssAV are the “true” steady state concentrations after accounting 
for the impact of treatment compliance (CMPL). TCssAV are derived from the simulated 
steady state concentrations (SCssAV) corrected by treatment compliance as shown in 
equation 7. 
 
The implementation of treatment compliance provided a significant increase in the fitting 
performances of the model (as shown in Figures 3 and 4) and allowed a more accurate 
quantification of the therapeutic intervention.  
 




Figure 3. Goodness-of-fit plots of the final model. Upper panels show the observed data (Obs) vs. 
population predictions (Pred) (left) and the observed data vs. individual predictions (IPred) (right). 
Lower panels show the conditional weighted residuals (CWRES) vs. population predictions (left) and 







Figure 4. Individual plots of 9 randomly selected patients: observed data are plotted using blue 
circles; the black solid line represents the population prediction (Pred) and the red solid line 
represents the individual predictions (IPred). 
 
Model Simulations 
Simulations were performed to investigate the impact of different exposure levels and 
various compliance scenarios on the clinical evaluation of serum ferritin levels. Time to reach 
2500 μg/L serum ferritin (threshold between moderate and severe iron overload 
(2,6,20,31,32)) was chosen as a comparison measure between different scenarios. The 
differential equation solver ode15s from the software MATLAB (version R2010b) was used 
for the purpose of model simulations, whereas the software R (v.2.14.0) was used for 
graphical summaries. The ode15s which is a multistep solver and uses numerical 
differentiation formulas is particularly suitable for stiff systems (33,34).  
Three dosing regimens (30, 45 and 60 mg/kg/day for 5 days a week) were used to generate 
CssAV in a patient population with body weight ranging from 15 to 75 kg. This allowed 
evaluating the impact of different exposures on the endpoint of interest (time to reach the 
threshold). Each exposure level was then tested on patients starting at different baselines 
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ranging from 3000 to 12000 μg/L serum ferritin. In this set of simulations the exposure was 
assumed to be constant over time. 
 
In addition, simulations were used to evaluate the impact of various compliance scenarios 
on changes in ferritin levels. Our main interest in this case was to show how the model can 
be used prospectively in the clinical practice to evaluate a priori any given situation. To 
present and discuss the results of these simulations, given the large number of scenarios 
evaluated, we considered only a virtual patient of 45 kg receiving 45 mg/kg/day 
deferoxamine 5 days per week (representative of the mean patient in the population under 
investigation). The different scenarios investigated are presented in Table 2; compliance is 
stratified per 1 year, 6, 2 and 1 months.  
 
Table 2. Simulation scenarios for the evaluation of different compliance levels 
 
  Number of missed doses in the stratification period 




  Stratification 
 % of missed doses 1 year 1 year 6 months 2 months 1 month 
Scenario 1 10% 25 25 / 5 / 
Scenario 2 20% 50 50 25 10 5 
Scenario 3 30% 75 75 / 15 / 
Scenario 4 40% 100 100 50 20 10 
Scenario 5 50% 125 125 / 25 / 
Scenario 6 60% 150 150 75 30 15 
Scenario 7 70% 175 175 / 35 / 
Scenario 8 80% 200 200 100 40 20 
Scenario 9 90% 225 225 / 45 / 
Full adherence is equivalent to 250 doses per year 
 
The iterations were stopped if more than 5 years were needed to reach the threshold of 
2500 μg/L serum ferritin. As proposed in the work carried out by Piana et al. (35), the five 
scenarios selected try to cover different compliance patterns that may occur in the presence 
of a chronic regimen. Scenario 1 with single doses missed at random reflects poor quality of 
execution, whereas the other scenarios provide a range of options that reflect different 







The use of a disease model describing the impact of blood transfusions on serum ferritin was 
expanded to include the effects of chelation therapy. The effect of blood transfusions was 
introduced as a conversion rate on the production rate of ferritin and was found in the 
previous analysis to be inversely correlated to the disease status as shown in equation 1 and 
2. In addition, the disease model parameters, the scaling (SCL) and the shape (SHP) factors 
presented in equation 2 were found to be non-linearly correlated to the actual disease 
status.  Their inclusion in the model provided a significant decrease in the objective function 
value (OFV) and allowed a better description of the data. Furthermore, the inclusion of inter-
occasion variability (IOV = 57.4 %) on the conversion rate resulted in a significant drop in the 
OFV (Δ 443) allowing a better description of the individual profiles. 
 
Drug model 
The effect of deferoxamine (DFO) was introduced in a proportional way on the degradation 
rate (Kout) of ferritin. Furthermore, the implementation of treatment compliance as a factor 
on the exposure of deferoxamine improved considerably the data fitting and the model 
performance, as well as the inclusion of inter-individual variability (IIV) on the slope 
parameter, which reduced significantly the OFV and improved goodness of fit and visual 
predictive check (VPC) diagnostics. An overview of the final model parameters and bootstrap 
results is presented in Table 3.  
 
Table 3. Parameter estimates of the PKPD model of deferoxamine 
Parameter Estimate Bootstrap (mean) CV (%) 
Kin (mcg/h) 0.0002 (FIX) / / 
Kout (h-1) 0.0000045 (FIX) / / 
SHP (h-1) 0.00026 (FIX) / / 
SCL (mcg/h) 0.383 (FIX) / / 
Slope (mcg/conc) 4.81 5.16 15.7 
Error Proportional -0.173 -0.17 6.5 
DIS exp on SHP 1.29 1.08 57.4 
DIS exp on SCL 0.845 0.67 51.9 
IIV on Slope 0.082 0.105 80.9 
IOV on CRT 0.252 0.29 43.1 
 
Internal model validation diagnostics were satisfactory. Individual predicted profiles and 
goodness-of-fit plots as shown in Figures 3 and 4, as well as VPC (Figure 5) reveal that the 
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model provides an adequate and non-biased description of the data.  In addition, NPDE 
summaries (Figure 6) show that the discrepancy between predicted and observed values can 
be assumed to be normally distributed. 
 
 
Figure 5. Visual predictive check: observed data are plotted using grey circles; the red solid line 
represents the median of the observed data; the blue solid lines represent the 5th and 95th 
percentiles of the observed data. The red shaded area represents the 95th CI of the median of the 







Figure 6. NPDE: normalised prediction distribution errors. Upper panels show the QQ-plot of the 
distribution of the NPDEs for a theoretical N (0, 1) distribution (left) and the histogram of the 
distribution of the NPDE together with the density of the standard normal distribution (right). Lower 
panels show the NPDEs vs. time (left) and NPDEs vs. individual predictions (right). 
 
Model Simulations  
The impact of different exposure levels and various compliance scenarios on the clinical 
evaluation of serum ferritin levels was evaluated through model simulations. The results of 
the effect of different exposure levels in virtual patients characterised by different body 
weights and starting at different ferritin baseline levels are presented in Figure 7 for the 
following dosing regimen respectively: 30, 45 and 60 mg/kg/day for 5 days a week. Results 
clearly show that in the absence of an adequate exposure to the chelating agent an 
appropriate clinical response cannot be achieved. The model provides also the opportunity 
to evaluate a priori the most suitable dosing regimen to achieve a desired therapeutic goal. 
 





Figure 7. Time to reach a threshold of 2500 ug/L of serum ferritin based on different exposure levels 
in patients with different body weights (15 to 75 kg). The different panels show three scenarios 
where 30, 40 and 45 mg/kg dosing regimen have been evaluated. Each line represents a different 
starting baseline ferritin level (darker to lighter shows an increase in the starting baseline levels): 
square, circle, triangle with point up, plus, cross, diamond, triangle with point down, square cross, 
star and diamond plus represent respectively 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 





We have also investigated in one virtual patient of 45 kg receiving 45 mg/kg/day 
deferoxamine 5 days per week the impact of different compliance patterns in achieving a 
specific response, which was defined as time to reach the threshold of 2500 μg/L serum 
ferritin. Several conclusions can be derived from the results of the simulations: 1) if single 
doses are missed at random (reflecting poor quality of execution) (Figure 8 – scenario 1) as 
compared to doses missed consecutively (drug holidays) (Figure 8 – scenario 2) over a period 
of 1 year, a better and faster response is achieved; 2) if doses are missed consecutively over 
a given period of time, the shorter the period the better the clinical response as shown in 
Figure 8 – scenarios 2 to 5) in all the scenarios, if more than 60 % of the doses are missed 
(treatment compliance is lower than 40%) the therapeutic intervention is not effective; 
finally 4) a reduction in treatment compliance, especially when moving from 30 to 60% of 
missed doses clearly shows a significantly slower response indicating that even though the 
desired therapeutic outcome will be achieved the time to reach this goal might not be 
sustainable by the patient.  
 




Figure 8. Time to reach a threshold of 2500 mcg/L of serum ferritin based on different compliance 
scenarios (10 to 90 % of missed doses). The different panels show five scenarios where different 
compliance patterns have been evaluated (see table II). Each line represents a different starting 
baseline ferritin level (darker to lighter shows an increase in the starting baseline levels): square, 
circle, triangle with point up, plus, cross, diamond, triangle with point down, square cross, star and 
diamond plus represent respectively 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000 and 





A model-based approach was proposed here to understand the implications of iron 
chelation therapy with deferoxamine on ferritin levels in patients affected by transfusion-
dependent diseases. The complexity of the system requires an integrated approach that 
allows exploring the dynamics of the disease and its progression. A drug model was 
incorporated successfully into a disease model previously developed aimed at the 
characterisation of ferritin levels in this population. The model was evaluated using 
statistical and graphical criteria of goodness-of-fit and predictive performance measures as 
shown in table III and figures 3 to 6. The analysis reveals a strong effect of the disease status 
on the overall iron/ferritin conversion rate, and highlights also the role of treatment (drug 
exposure and compliance patterns) on the overall response and disease progression. In 
addition, the inclusion of IOV (57.4 %) allowed achieving a better description of individual 
profiles. Such a value of IOV appears to be influenced by larger intra-individual variability at 
higher serum ferritin levels where other mechanisms such as inflammatory disorders, and/or 
liver status play a role in determining the absolute ferritin value. Unfortunately, the lack of 
information on these variables allowed us only to take a stochastic approach for the 
quantification of such differences.  
 
Parameterisation of iron chelation 
Deferoxamine binds iron at different extracellular levels, and within the cell it targets 
lysosomal ferritin iron by stimulating ferritin degradation (23). Given that with the available 
data we could not distinguish among the different actions of deferoxamine, we decided to 
parameterise the drug effect as a proportional factor influencing the Kout of the turnover 
model. Furthermore, the same parameterisation would allow exploring the effect of other 
chelating agents: for example, oral chelators such as deferiprone and deferasirox also act 
intracellularly as deferoxamine, though targeting a different pathway (i.e., cytosolic ferritin 
iron) (23).  
 
Clinical application 
Model simulations were used to investigate the impact of different exposure levels and 
various compliance scenarios on serum ferritin levels. Results show that inadequate iron 
chelation therapy with sub-therapeutic exposure (Figure 7) as well as poor adherence to the 
assigned dosing regimen (Figure 8) would significantly increase the time required to achieve 
a desired clinical response, and in some cases (e.g., with treatment compliance lower than 
40%) patients would not achieve at all the therapeutic goal. Even though these results might 
seem rather obvious, we are aware that clinically relevant changes in serum ferritin levels 
are observed over a long period of time and often crucial decisions have to be made before 
the clinical evidence is available. This availability of this model shows an opportunity to 
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explore different scenarios that have been so far evaluated empirically in clinical practice. 
For example, model simulations allow evaluating whether a compromise between lower 
exposure, aimed at a possible reduction in acute side effects is compensated by acceptable 
increase in the time to achieve the therapeutic goal. Likewise, it may be possible to evaluate 
the importance of different compliance patterns for the available chelating agents, yielding a 
more quantitative estimate of the changes in ferritin levels and /or risk of clinical failure. This 




Some limitations must be discussed in the context of this analysis. First of all, we used a PK 
model developed on literature data, which allowed us using mean population data and 
derive individual information based only on fixed allometric scaling. A more structured 
analysis of the PK of deferoxamine would reduce the uncertainty around the simulated 
exposure and would allow us explaining the variability in PK that propagates into the 
pharmacodynamics. On the other hand, we believe that the approach taken allowed us to 
characterise differences in the pharmacokinetics that we would have not been able to define 
only with information on the dosing regimen; e.g., changes in size are accounted for based 
on allometric scaling. 
A second aspect is the role of compliance in the context of this analysis. The absence of 
quantitative data on treatment adherence in the population under investigation was a clear 
impediment. To overcome this issue we used the observed data to generate a variable that 
would allow us to have a gradient of treatment compliance. This decision was supported by 
the information available in the literature; we found clear evidence that high compliance 
leads to stable ferritin levels over time and that poor adherence to deferoxamine therapy is 
strongly correlated to a poor clinical outcome as nicely depicted in the work by Gabutti et al. 
(29) (Kaplan-Meier analysis presented in Figure 6). This was confirmed by a few other 
publications (20,30,31,36) and gave us the confidence that the approach taken would be 
robust enough to meet the purposes of this analysis. 
 
Conclusion 
In conclusion, we were able to gather further insights in the dynamics of a rather complex 
process such as iron overload using a model-based approach. Bearing in mind the limitations 
discussed and the relative level of uncertainty, the model has proven to be a useful tool to 
support decision making in clinical practice in the context of transfusion-dependent 
haemoglobinopathies. In addition, this approach will enable further evaluation of the dose 
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Aims: The evaluation of the safety profile during the development of a drug is a challenging 
undertaking, especially as the drug-specific adverse events may be intertwined with disease-related 
complications. Using iron chelation therapy as an example, we propose a model-based approach to 
integrate epidemiological and pharmacological data for the characterisation of the acute, long-term 
adverse events and the disease complications due to transfusion-dependent iron overload.  
Methods: Longitudinal data from a reference group of patients (n= 27) affected by β-thalassaemia 
major under chelation therapy with deferoxamine were evaluated in conjunction with literature data 
on the short-term safety profile of deferoxamine. Occurrence of the secondary co-morbidities 
hypothyroidism and diabetes mellitus was analysed based on a time to event approach in NONMEM 
v.7.2.0. In this analysis historical data were included as priors to reduce uncertainty in parameter 
estimates. Occurrence of the acute drug-specific adverse events arthralgia/myalgia and anaphylaxis 
were modelled as dose-dependent and dose-independent events. 
Results: The predicted incidence for hypothyroidism and diabetes based on the hazard models with 
mean (90% CI) was 6.3% (0-14.8) and 8.9% (0-18.5), respectively. For a 45 mg/kg/day dose the mean 
(95% CI of the mean) simulated incidences for anaphylaxis and arthralgia/myalgia were 0.154% 
(0.139-0.169) and 21.01% (20.85-21.17) respectively; other doses as well as different compliance 
patterns were evaluated both for drug-specific AEs and disease complications. 
Conclusions: A model-based approach provides the basis for a structured evaluation of the safety 
profile of drugs at different stages of development and for risk management, allowing integration of 
clinical and epidemiological data and consequently discrimination between the disease-related and 
the drug-related adverse events. Our simulations show that both chelation and transfusion history 
play a major role in determining the long-term adverse events and complications of disease. The 
findings also reveal a delicate balance between acute and long-term complications, indicating that 





In many chronic paediatric diseases such as transfusion-dependent haemoglobinopathies, 
where life-long red blood cell (RBC) transfusion is essential to survive (1–7), the direct and 
instantaneous therapeutic effectiveness needs to be balanced with long-term complications 
that depend both on the treatment intervention and the underlying disease progression. 
Two major aspects need to be considered when evaluating long-term effects: the disease 
progresses over time and may lead to disease specific complications and at the same time 
the frequency of drug-specific AEs may change over time or delayed, time-dependent AEs 
may be occur (8,9). Furthermore, in contrast to drug efficacy, even the short-term evaluation 
of drug-specific AEs can be extremely challenging, as data are often not available (e.g., a 
given event might not be observed during a clinical trial, especially if the incidence is 
relatively low) or not quantifiable due to recognised methodological issues (10–12). The two 
aspects very often overlap, making it rather difficult to discriminate the underlying cause. 
Lack of understanding of such an interaction may lead to inaccurate assessment of the safety 
profile of a drug. In fact, to fully characterise the safety profile, a variety of endpoints need 
to be considered in parallel, taking into account the correlations among them.  
 
Chronic iron overload 
Even though the management of the chronic RBC transfusion regimen and the availability of 
adequate iron chelation therapy have improved significantly in the last decades, patients 
with β-thalassemia will still experience a number of complications throughout their entire 
life (6,13,14).  
Among the disease related complications, iron overload is the most clinically relevant and it 
is associated with several co-morbidities such as cardiac dysfunction, liver fibrosis, 
hypogonadism, hypothyroidism, hypoparathyroidism and diabetes mellitus (6,13,14). 
Cardiac disease caused by myocardial siderosis is the most relevant one, causing death in 
71% of the patient population (15).  
In the absence of an innate mechanism to remove the excess of iron, treatment with iron 
chelators is vital to prevent its accumulation and to manage the related complications (16–
19). In addition to the disease related complications, the therapeutic intervention itself may 
also cause a number of undesired events (different for each iron chelator available on the 
market) that will play an essential role in the ability of the patient population not only to 
accept the intervention (poor adherence) but also to coexist with these complications for a 
life-long term. In this analysis we focus on the iron chelating agent deferoxamine (DFO), that 
is first-line therapy for transfusion-dependent diseases and has been available for the 
treatment of iron overload for more than 35 years (2,6,16–21). Among the various 
limitations of deferoxamine therapy recognised by clinicians and experts in the field 
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(6,17,19,22), compliance to the treatment plays a crucial role in the overall effectiveness of 
the treatment as well as the related complications. 
 
Using DFO for the treatment of iron overload as an illustrative example, we propose and 
evaluate the advantages of a model-based approach for the characterisation of the safety 
profile of a medicinal product. We also show how modelling allows integration of 
epidemiological (literature) and pharmacological data for the quantification of the acute 
(drug specific) and long-term (disease specific) AEs of iron chelation therapy. Lastly, we show 
how the effect of treatment compliance can be assessed and correlated to acute and long-
term events, disentangling the impact of inadequate chelation therapy from variable pattern 




To evaluate the model-based approach in the context of chronic iron overload we decided to 
select data in thalassaemic patients undergoing single therapy with deferoxamine and 
specifically collected data on incidence of hypothyroidism and diabetes mellitus. The choice 
of these two co-morbidities was made because they both are a clear consequence of the 
disease and no other influence of the drug therapy is expected except for the prevention of 
the complication itself. Furthermore, in the absence of clinical data on drug-specific AEs we 
simulated incidences for two extreme cases (i.e., arthralgia/myalgia as a very common AE 
and anaphylaxis as a rare AE) to assess their profiles after short- and long-term treatment. 
Specific details on the data are provided in the next few paragraphs. 
 
Clinical Data on hypothyroidism and diabetes mellitus 
The modelling analysis was performed using retrospective clinical data in 27 patients with β 
thalassaemia major from three different Italian centres: A.O. Universitaria Consorziale 
Policlinico di Bari U.O. Pediatria Federico Vecchio; A.O. Universitaria Policlinico di Sassari 
Clinica Pediatrica, ASL 1 D.H. per Talassemia; A.O. di Padova Clinica di Oncoematologia 
Pediatrica. The study has been conducted in full conformance with the principles of the 
Declaration of Helsinki and with the local laws and regulations concerning clinical trials. The 
protocol and the informed consent documents have been formally approved by the relevant 
research ethics committee of each clinical site.  
Clinical data were collected retrospectively for a maximum of ten years in 27 patients 
affected by transfusion-dependent diseases, receiving deferoxamine as single drug for iron 
chelation therapy. Baseline characteristics of the patient population are provided in Table 1. 
Patients contributed with 40.2 observations on average (sd: 17), with a minimum of 4 





Table 1. Baseline characteristics of the patient population (n=27) 
 Units Median Range 
Age Years 14.6 6.8-19.9 
Weight Kg 46 17.5-71 
Height Cm 154 111-173 
TSH mIU/L 2.34 0.58-83.2 
FT4 ng/dL 1.05 0.73-1.43 
AST U/L 33 7-159 
ALT U/L 56 9-372 
Glucose mg/dL 91 52-444 
Creatinine mg/dL 0.6 0.2-1.12 
Ejection Fraction % 64 35-77 
Ferritin μg/L 2260 393-8500 
 
Literature data on co-morbidities and drug specific AEs (data abstraction) 
A literature search has been performed to retrieve data on the incidence of hypothyroidism 
and diabetes mellitus in the thalassemic population. At first reports  from the  Central 
Bureau of Statistics, The Netherlands were used as reference for the background incidence 
of the two co-morbidities in the overall population (23). Subsequently, a comprehensive 
literature search was performed using MESH terms in PubMED, in which articles describing 
hypothyroidism and diabetes in thalassaemic patients were retrieved. Thirteen articles in 
total (15,24–32,32–34) were identified with relevant information on the incidence of both 
co-morbidities. The keywords used comprised the names of the co-morbidity in combination 
with β-thalassaemia major, transfusional iron overload, deferoxamine, and a combination of 
them. In parallel, a separate search was performed on publications showing supporting 
evidence for the use of serum ferritin levels as a predictor for the occurrence of the two co-
morbidities in thalassaemic patients (35–39). Of relevance is the finding that co-morbidity is 
with  higher incidence in  patients whose serum ferritin levels are consistently above 2500 
μg/L (35–39). This threshold represents the boundaries for a shift in  iron overload from  
moderate to a severe state (2,6,40–42). Given the level of detail provided by the authors,  
we  have focused on the work by Belhoul et al. who demonstrated in a group of almost 400 
patients a clear distinction in the incidence of hypothyroidism and diabetes mellitus in 
relation to a serum ferritin threshold of 2500 μg/L (38).  
 
Finally for the evaluation of drug specific adverse events (anaphylaxis and 
arthralgia/myalgia), estimates reported on the summary of product characteristics (SPC) of 
DFO (20) were used to simulate the events of interest. The pharmacological classification 
proposed by Wills and Brown was used to select drug specific adverse events based on their 
frequency, time of onset and the relation with dose (43). Arthralgia/myalgia was selected as 
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an example of a very common Type A (dose-dependent) AE with a frequency greater than 
1/10. In addition, anaphylaxis was identified as a rare, Type B (dose-independent) AE with a 
frequency between 1/10000 and 1/1000. 
 
Modelling 
Hazard models for hypothyroidism and diabetes mellitus 
The models for hypothyroidism and diabetes were developed based on the combination of 
literature and clinical data. Three steps were taken for the development of each model:  
 
1) An exponential hazard model was built based on literature data on the incidence of 
the co-morbidity in thalassaemic patients (disease effect) and in a healthy population 
(baseline);  
2) The estimated parameters were used as priors to estimate the hazard in the 
retrospective clinical data in thalassaemic patients;  
3) Literature data were used to incorporate the effect of serum ferritin levels as a 
covariate on the final hazard model. 
 
During step 1, a time to event analysis was performed for both hypothyroidism and diabetes 
by implementing an exponential hazard model in NONMEM v.7.2 (Icon Development 
Solutions, USA). The initial model was based on the epidemiology reports and literature data 
and consisted in the following relationship between hazard and survival:  
 
𝑆(𝑡) =  𝑒− ∫ ℎ(𝑡)𝑑𝑡
𝑡
0        Equation 1 
 
Where the hazard is h(t), and the survival (S) is a function of the cumulative hazard within 
the time interval 0 to t. The effect of disease was included as a covariate function (λdis) that 
would modify the background (initial) hazard (h0) as follows: 
 
ℎ(𝑡) =  ℎ0(𝑡) ∗ 𝑒
𝜆𝑑𝑖𝑠          Equation 2 
 
In step 2 the normal-inverse Wishart prior (NWPRI) option was used in NONMEM (44) to 
estimate the incidence of the co-morbidities in the data collected during the retrospective 
study in thalassaemic patients. In the presence of extremely sparse data the use of prior 
information was deemed pivotal to ensure unbiased estimate of the disease effect and to 
stabilise the model. 
 
Finally, in step 3  the work by Belhoul et al. (38) was used to justify the inclusion of serum 




demonstrate that ferritin can be considered as a predictive factor for the probability (hazard) 
of developing co-morbidity. The threshold of 2500 μg/L was used as reference value to 
dichotomise the data into two groups and ratio of the incidence of the co-morbidity in these 
groups was used to define the corresponding ratio in the hazard model. As shown in 
equation 2, the effect of the disease was described by two components depending on 
whether serum ferritin levels were above (λfrth) or below (λfrtl) the selected threshold: 
 
ℎ(𝑡) =  ℎ0(𝑡) ∗ 𝑒
𝜆𝑓𝑟𝑡ℎ+𝜆𝑓𝑟𝑡𝑙                Equation 3 
 
A summary of the model building steps and parameter estimates for the hazard models of 
deferoxamine for hypothyroidism and diabetes mellitus is provided in Table 3. 
 
Table 3. Model building steps and parameter estimates of the hazard model of deferoxamine for 
hypothyroidism and diabetes mellitus. 
Hypothyroidism 
Parameter Description Estimate 
Step 1: based on epidemiological and literature data 
h0 Baseline hazard 0.000496 
λdis Disease as a predictor 2.69 
Step 2: based on retrospective clinical data (step 1 used as prior) 
h0 Baseline hazard 0.000496 (FIX) 
λdis Disease as a predictor 1.86 
Step 3: based literature data (38) 
h0 Baseline hazard 0.000496 (FIX) 
λfrtl Disease when ferritin is 
below 2500 µg/L 
1.03 
λfrth Disease when ferritin is 
above 2500 µg/L 
2.58 
Diabetes mellitus 
Parameter Description Estimate 
Step 1: based on epidemiological and literature data 
h0 Baseline hazard 0.00036 
λdis Disease as a predictor 2.72 
Step 2: based on retrospective clinical data (step 1 used as prior) 
h0 Baseline hazard 0.00036 (FIX) 
λdis Disease as a predictor 2.54 
Step 3: based literature data (38) 
h0 Baseline hazard 0.00036 (FIX) 
λfrtl Disease when ferritin is 
below 2500 µg/L 
1.56 
λfrth Disease when ferritin is 
above 2500 µg/L 
3.33 
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Logistic models of acute drug specific adverse events 
In contrast to the data fitting procedures used to describe the incidence of co-morbidiies, 
drug-specific adverse events were evaluated by simulations using the information reported 
on the SPC of deferoxamine. 
Two approaches were used to simulate the incidence of a very common dose-dependent AE 
(arthralgia/myalgia) and a rare dose-independent AE (anaphylaxis).  In the first case, a 
logistic model with non-linear regression was developed correlating the drug levels a steady-
state with the probability of adverse events in an exposure-dependent manner. Steady-state 
concentrations were simulated based on a PK model, which is described in later in this 
section. The logistic model was implemented as follows: 
 




       Equation 4   
 
where Css is the deferoxamine steady state concentration, PC50 is the concentration 
corresponding to a 50% probability of experiencing the AE, and γ is the coefficient defining 
the shape of the relationship. Parameter values for PC50 and γ were fixed to 13 ug/ml and 
2.5, respectively, to ensure that simulated incidence levels correspond to the figures 
reported in the SPC. 
In the second case, a truncated normal distribution (with x > 0) was used in R to simulate a 
rare, dose-independent AE (anaphylaxis). The rnorm function (45) with mean equal to 0.5 
and standard deviation equal to 0.5 was used to generate the probabilities of experiencing 
the adverse event.  A severity of grade 2-3 was assumed for all AEs. However, for the 
purposes of this analysis no distinction was made between severity levels at the time of the 
event. Data was therefore summarised only as the overall frequency of AE. 
 
Role of compliance  
In a previous investigation we have highlighted the importance of treatment compliance for 
the effectiveness of drug therapy in patients with chronic iron overload [Chapter 7 of this 
thesis]. Poor adherence was found to have a major influence on the pharmacokinetics of the 
drug and subsequently on the desired clinical response. Compliance to treatment will 
therefore be one of the factors to be evaluated in the proposed simulation scenarios in 
order to assess its impact on the short- and long-term complications of iron chelation 
therapy.  
 
Evaluation scenarios: clinical trial and not-in-trial Simulations 
Simulations were performed to investigate the impact of different dose levels yielding to a 
range of exposure levels and various compliance scenarios on the onset and incidence of 




simulated for an overall period of maximum 10 years, where the 1st year is representative of 
a standard clinical trial and the subsequent years reflect a follow-up interval that has the 
objective of capturing real life conditions that may occur over a long-term period. 
Simulations were performed on a hypothetical patient population with similar demographic 
characteristics as the patients included in the retrospective clinical study (N=27) and were 
based on the models and final parameter estimates described above. Doses were adjusted 
according to changes in body weight at the scheduled visits. To ensure that uncertainty and 
variability in parameter estimates are accounted for, 250 simulations were performed for 
each individual in each of the scenarios described below. To facilitate visual representation 
of the simulated data, co-morbidity data were stratified by age in two major groups: above 
and below 12 years of age.  
 
Simulation of drug concentrations and serum ferritin levels 
A PK model and a PKPD model previously developed by our group [Chapter 7 of this thesis] 
were used to simulate deferoxamine exposure and serum ferritin levels. Deferoxamine 
concentrations (Css) were simulated based on a two compartment pharmacokinetic model 
with zero-order absorption and first-order elimination. Five dosing regimens (30, 40, 45, 50 
and 60 mg/kg/day for 5 days a week) were evaluated and used as input for the logistic 
model (evaluation of short-term effects). These data were also used for the prediction of 
serum ferritin profiles, as described by the PKPD model. The predicted ferritin levels were 
incorporated as a covariate factor in the hazard models to evaluate the long-term 
complications of chelation therapy. 
 
Clinical / Experimental conditions  
To ensure the availability of clinically relevant scenarios, different deferoxamine dosing 
regimens yielding to a range of exposure levels were tested on patients starting at three 
different baselines ferritin levels, namely 1500, 2500 and 3500 μg/L serum ferritin. This 
allowed further exploration of the correlation between ferritin levels and differences in 
compliance pattern. The three groups reflect well-defined populations of patients with poor 
chelation history (baseline at 3500 μg/L), patients with good chelation history (baseline at 
1500 μg/L) and patients with unknown chelation history (baseline around 2500 μg/L).  
In the initial set of simulations, exposure to deferoxamine was assumed to be constant over 
the course of treatment. In addition, it was assumed that all patients received the same 
dosing regimen: 45 mg/kg/day deferoxamine for 5 days a week. Treatment was maintained 
at constant dose levels for up to 10 years, under assumption of adequate or satisfactory 
response over time, even in those subjects showing initial ferritin levels above 3500 μg/L. 
Our main interest was to show how simulations can be used prospectively to evaluate long-
term complications. Moreover, we demonstrate how these scenarios can be used to explore 
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the impact of variable treatment compliance. The selected scenarios are presented in Table 
2.  
 
Table 2. Simulation scenarios for the evaluation of different patterns of compliance. 
  Number of missed doses in the stratification period 




  Stratification 
 % of missed doses 1 year 1 year 6 months 2 months 1 month 
Scenario 1 10% 25 25 / 5 / 
Scenario 2 20% 50 50 25 10 5 
Scenario 3 30% 75 75 / 15 / 
Scenario 4 40% 100 100 50 20 10 
Scenario 5 50% 125 125 / 25 / 
Scenario 6 60% 150 150 75 30 15 
Scenario 7 70% 175 175 / 35 / 
Scenario 8 80% 200 200 100 40 20 
Scenario 9 90% 225 225 / 45 / 
Full adherence is equivalent to 250 doses per year 
 
All the analyses described in the aforementioned paragraphs were peformed in NONMEM 
version 7.2 (Icon Development Solutions, USA), with exception of the rare dose-independent 
AE, which was performed in R. All data manipulation, graphical and statistical summaries 
were performed in R (v.2.14.0). 
 
8.3 Results 
Hazard models for hypothyroidism and diabetes mellitus 
Two survival models (exponential hazard) were developed for the quantification of 
hypothyroidism and diabetes in thalassaemic patients and used for prospective evaluation 
through model simulations. Figure 1 shows the predictions for hypothyroidism and diabetes, 
as compared to the available epidemiological and literature data, as described previously in 






Figure 1. Performance of the hazard model for hypothyroidism (top panel) and diabetes (bottom 
panel) based on modelling of historical data. Black circles represent observed literature data for 
baseline incidence of the co-morbidities in the overall population whereas blue circles represent the 
observed literature incidence for thalassaemic patients. The dashed lines show model predictions in 
blue with respect to the patient population and in black with respect to the baseline incidence. 
 
The results of the final model are presented in  Figure 2, (after step 3: inclusion of serum 
ferritin as a predictor of the co-morbidity), in which published literature (15,24,32,38,39,47) 
data was included as prior for the analysis of the available clinical data. The mean (90% CI) 
predicted incidence of hypothyroidism and diabetes was 6.3% (0-14.8) and 8.9% (0-18.5), 
respectively. Both models were considered adequate for simulation purposes. 




Figure 2. Validation of the hazard models for hypothyroidism (top panel) and diabetes (bottom 
panel).  Model predicted incidence (solid dark grey line) is compared to literature data (coloured 
dashed lines): Borgna-Pignatti et al (black); Belhoul et al (red); Mehrvar et al (blue); Aydinoc et al 
(yellow); Shamshirsaz et al (green); and Kyriakou et al (orange and purple). 
 
Clinical trial and not-in-trial simulations  
The results of the evaluation of drug and treatment compliance levels on long term disease 
progression are presented in Figure 3. Simulation of the incidence of hypothyroidism and 
diabetes in a virtual population of 27 patients are stratified by age groups (below or above 
12 years of age at start of treatment). In patients below 12 years of age a slight negative 
trend is observed indicating a reduction in the incidence of the co-morbidities with 
increasing dose levels; this is not the case in the other group where no significant changes 
are observed. Furthermore, a clear distinction in the incidence of both co-morbidities was 
observed for patients with different starting baseline ferritin levels. This finding highlights 





Figure 3. Effect of different exposure levels (x axes show different dosing regimens investigated in 
the simulation) on hypothyroidism, diabetes, arthralgia/myalgia and anaphylaxis in the population 
under investigation for an observational period of maximum 10 years. Top left and top mid panels 
show the simulations outcome for hypothyroidism after stratification of the patients into two age 
categories, i.e., below and above 12 years of age, respectively. Bottom left and bottom mid panels 
show the simulations outcome for diabetes in patients below and above 12 years of age, 
respectively. The dashed, solid and dotted-dashed lines represent respectively the three subgroups 
of patients with adequate, unknown and poor chelation history. The top right panel show the results 
for arthralgia/myalgia, whereas the bottom right panel gives the results for anaphylaxis. In all 
scenarios the dark grey lines represent the mean and the light grey lines represent the 95% 
confidence interval of the mean.  
 
On the other hand, the simulations describing the occurrence of acute,  drug-specific AEs the 
show the implications of dose-dependent and dose-independent adverse events, on the 
individual safety profile of each patient, with the incidence of myalgia/arthralgia increasing 
proportionally with the dose of deferoxamine.  
 
Given the interaction between treatment response, as determined by ferritin levels and 
adherence to the prescribed dosing regimen, we also included an evaluation of the impact of 
different compliance patterns. Results are shown in Figures 4, 5 and 6 for hypothyroidism, 
diabetes and arthralgia/myalgia and anaphylaxis, respectively. Similarly to what we have 
observed when evaluating the implications of different exposure levels, stratification of the 
ACUTE AND LONG-TERM UNFAVOURABLE EFFECTS OF IRON CHELATION THERAPY 
189 
 
data by age indicates an increase in the incidence of hypothyroidism and diabetes with 
decreasing levels of adherence in patients below 12 years of age (Figures 4 and 5 – left 
panels). Similar trends are observed among the different scenarios proposed.  In addition, 
stratification based on starting ferritin levels shows the importance of the patient’s 
treatment history for the prediction of long-term complications.  
When looking at arthralgia/myalgia (Figure 6 – left panels) the different scenarios are 
characterised by similar profiles, i.e., with increasing incidence of adverse events at 
increasing doses; but the magnitude of the effect is slightly altered at different levels of 
compliance. By contrast, no major differences are observed for the dose-independent AE 







Figure 4. Effect of different patterns of compliance on hypothyroidism in the population under 
investigation for an observational period of maximum 10 years. Left and right panels show results 
based on stratification of patients into two age categories, i.e., below and above 12 years of age, 
respectively. In all scenarios: the dashed, solid and dotted-dashed lines represent respectively the 
three subgroups of patients with adequate, unknown and poor chelation history; the dark grey lines 
represent the mean and the light grey lines represent the 95% confidence interval of the mean. The 5 
scenarios presented here are detailed in the methods and in Table 2. 





Figure 5. Effect of different patterns of compliance on diabetes in the population under investigation 
for an observational period of maximum 10 years. Left and right panels show results based on 
patient stratification into two age categories, i.e., below and above 12 years of age, respectively. In 
all scenarios: the dashed, solid and dotted-dashed lines represent the three subgroups of patients 
with adequate, unknown and poor chelation history; the dark grey lines represent the mean and the 
light grey lines represent the 95% confidence interval of the mean. The 5 scenarios presented here 






Figure 6. Effect of different compliance patterns on arthralgia/myalgia (left panels) and anaphylaxis 
(right panels) in the population under investigation for an observational period of maximum 10 
years. The solid, dashed (small), dotted, dotted-dashed, and dashed (large) lines represent the 
scenarios investigated from 1 to 5 respectively. In all panels the dark grey lines represent the mean 
and the light grey lines represent the 95% confidence interval of the mean. Mean and 95%-CI of the 
mean are presented in the top panels, whereas the bottom panels show only the mean value. 
 
8.4 Discussion and Conclusion 
A model-based approach was implemented to evaluate simultaneously the short- and long-
term unfavourable effects of iron chelation therapy. Epidemiological and pharmacological 
data have been combined to appropriately estimate the parameters of interest in the 
survival models. In contrast to traditional data meta-analysis, summary statistics is used to 
integrate data from different sources; here we rely on literature summaries to fit a 
population model for events whose incidence is relatively low to be derived from individual 
clinical trials. In fact, the epidemiological data was deemed essential for an unbiased 
quantification of the incidence of hypothyroidism and diabetes in the thalassaemic 
population. Both models were successfully validated, as shown in Figures 1 and 2.   
Whereas external model validation procedures could not be easily implemented for this type 
of analysis, basic diagnostics plots suggested that the model was sufficiently robust support 
its use for simulation purposes.  In fact, the use of literature summaries, i.e., point estimates, 
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as reference input data for fitting has been applied previously in a number of therapeutic 
areas in investigations with similar scope (48–50). 
 
Treatment as a disease modifying factor 
Our simulations show that long-term complications associated with inadequate chelation 
due to suboptimal dosing or poor compliance has major implications for patients in the 
lower age group, whereas almost no effect is observed for those patients in the higher age 
group. These results suggest that this phenomenon is partially masked by the baseline age of 
the population, which in turn reflects the chelation history of the patients. This is also 
evident by the difference in the overall incidence of the comorbidities among the three 
subgroups evaluated in each scenario, depending on their chelation history.  These findings 
are in agreement with previous report on the consequences and cost of noncompliance to 
iron chelation (51,52). In clinical practice, improvement of compliance with chelation 
therapy is considered the best prevention for hypothyroidism. Guidelines also recommend 
regular follow-up and optimising chelation therapy in patients showing sub-clinical 
hypothyroidism, i.e., basal levels of TSH 5 to 7 mUI/ml.  
 
In theory, our analysis suggests that changes in the treatment of patient at a late phase of 
the disease could potentially have little or no impact on the probability of developing 
hypothyroidism or diabetes. Hence, effective treatment at the start of chelation therapy may 
determine long-term onset of co-morbidities. Whilst the proposed simulations scenarios 
have been limited to a predefined set of compliance patterns with overall dose intake 
ranging from 10% (worst case scenario) to 90 % in patients with perfect adherence to 
treatment, literature data on deferoxamine reveals that mean compliance in patients ranges 
from 59 to 78 % (51). 
The proposed scenarios also provide an opportunity to assess prospectively the correlation 
between short- and long-term complications.  For instance, until now it is unclear whether 
changes in the dosing regimen can be implemented to provide benefit for a given patient in 
the short-term without significantly affecting the long-term disease progression. Such a 
correlation can be seen in the scenarios shown in Figures 3 to 5 for the long-term 
complications.  Focus of treatment is mostly on correcting for changes in ferritin levels, but 
dose rationale currently does not assess how different dose levels may lead to higher or 
lower incidence of long term co-morbidities. 
 
Limitations 
The simulation scenarios presented here represent a simplification of a complex therapeutic 
reality in which the nature and number of co-morbidities and drug-specific AEs are much 




selection of a subset of AEs has enabled us to demonstrate how inferences by modelling and 
simulation can be used to characterise the overall safety profile of a compound. 
Furthermore, our approach shows how to explore safety concerns pro-actively in a 
quantitative manner even in the absence of sufficient data from randomised clinical trials.  
We acknowledge, however, that the lack of available clinical data imposed the integration of 
epidemiological and literature data to develop the final models based on population 
summary data, which may mask some specific features of the disease or treatment at the 
individual patient level, especially if one takes into account potential correlations or 
interaction between covariates. Therefore, the impact of such an interaction, as well as of 
the correlation between endpoints could not be evaluated. The availability of more 
informative, individual patient data could have provided further support for our 
assumptions, but we do not anticipate that such data would alter the final conclusions from 
the proposed simulation scenarios.  
The shortcoming from individual data may have been compensated by the incorporation of 
time-dependent effects (and covariate factors), which allowed a clear distinction between 
disease-specific (long term) and drug-specific (short term) AEs. 
A possible weakness remains in that very few data were available from long term safety 
follow up studies including paediatric and adults. Such data might have provided better 
estimates of the parameters and covariate factors determining the timing and age of onset 
of co-morbidities. 
We also acknowledge that the stratification of AEs by their grade of severity would be more 
relevant in clinical practice. Here we have assumed a grade 2-3 for all simulated AEs to 
reduce the complexity of the scenarios. The same applies for the duration of the AEs and the 
clinical implications that the event would have for individual patients, such as dose titration 
over even change of chelator. This simplification was necessary to ensure that focus were 
given the time-dependencies associated with the long term consequences of inadequate 
chelation therapy (56,57).  
  
Perspectives 
In this analysis we showed that M&S provides the necessary tools to overcome the 
methodological and practical hurdles in the evaluation of the safety profile of a compound. 
We foresee the advantages of applying such an approach in the context of a full benefit-risk 
(BR) appraisal, where the lack of a systematic and more structured approach is 
acknowledged by different parties (58–62). Of particular relevance for the implementation 
of BR assessment, is the possibility of exploring rare dose-independent AEs. It is worth 
mentioning that in controlled trials and especially in paediatric trials, where limited numbers 
of patients are enrolled, these events might not even be observed.  We believe that in such 
cases, modelling & simulation enables the integration of available information (e.g., 
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extrapolation of adult data) to explore in a quantitative manner the implication of (clinically 
relevant) what-if scenarios (10,11).  
Despite the limited number of scenarios presented here, several aspects can be considered 
and analysed by clinical trial and not-in-trial simulations. Such a framework may allow 
common questions in paediatric research to be evaluated in a systematic way, especially 
those related to developmental growth or age, which may lead to changes in the incidence 
of AEs over time. Another important application is the assessment of  susceptibility of 




In summary, our investigation has illustrated the advantages of a model-based approach for 
the characterisation of the safety profile of drug in children.  The use of modelling and 
simulation does not only provide the basis for the  systematic integration of clinical and 
epidemiological data as a means  to overcome the limited data availability in this population, 
but also allows one to disentangle disease-specific from the drug-specific adverse events, 
which are often intertwined, but have different impact on  long-term outcome of treatment. 
Irrespective of the level of understanding or the mechanisms underlying adverse events, the 
availability of a simulation framework to evaluate the safety profile of a treatment offers a 
unique opportunity to explore scenarios which may not be feasible or even acceptable in 
real life, but which nevertheless provide insight into the role of the drug, the patient and the 
disease in the outcome of an intervention. Such information may be essential for accurate 







1.  Gibbons R, Higgs DR, Old JM, Olivieri NF, Swee Lay T, Wood WG. The Thalassaemia Syndromes 
- Fourth Edition. Blackwell Sci. 2001;  
2.  Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010 Jan;5:11.  
3.  Ginzburg Y, Rivella S. Β-Thalassemia: a Model for Elucidating the Dynamic Regulation of 
Ineffective Erythropoiesis and Iron Metabolism. Blood. 2011 Oct 20;118(16):4321–30.  
4.  Rebulla P. Blood transfusion in beta thalassaemia major. Transfus Med. 1995 Dec;5(4):247–
58.  
5.  Rebulla P, Modell B. Transfusion requirements and effects in patients with thalassaemia 
major. Lancet. 1991;337:277–80.  
6.  Rund D, Rachmilewitz E. Beta-Thalassemia. N Engl J Med. 2005;353:1135–46.  
7.  TIF. Guidelines for the clinical management of thalassaemia. 2008.  
8.  Edwards I, Aronson J. Adverse drug reactions: definitions, diagnosis, and management. 
Lancet. 2000;356(9237):1255–9.  
9.  Aronson J, Ferner R. Joining the DoTS: new approach to classifying adverse drug reactions. 
BMJ. 2003;327(7425):1222–5.  
10.  Fescharek R, Nicolay U, Arras-Reiter C. Monitoring and safety assessment in Phase I to III 
clinical trials. Dev Biol Stand. 1998;95:203–9.  
11.  Wahab I, Pratt N, Kalisch L, Roughead E. The detection of adverse events in randomized 
clinical trials: can we really say new medicines are safe? Curr Durg Saf. 2013;8(2):104–13.  
12.  Sheiner L. Learning versus confirming in clinical drug development. Clin Pharmacol Ther1. 
1997;61(3):275–91.  
13.  Cunningham MJ, Macklin E a, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major 
in North America. Blood. 2004 Jul 1;104(1):34–9.  
14.  Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio G, et al. 
Survival and complications in patients with thalassemia major treated with transfusion and 
deferoxamine. Haematologica. 2004;89(10):1187–93.  
15.  Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. 
Survival and complications in thalassemia. Ann N Y Acad Sci. 2005 Jan;1054:40–7.  
16.  Cappellini MD, Pattoneri P. Oral iron chelators. Annu Rev Med]. 2009 Jan;60:25–38.  
ACUTE AND LONG-TERM UNFAVOURABLE EFFECTS OF IRON CHELATION THERAPY 
197 
 
17.  Kwiatkowski JL. Oral iron chelators. Pediatr Clin North Am. 2008 Apr;55(2):461–82.  
18.  Musallam KM, Taher AT. Iron chelation therapy for transfusional iron overload: a swift 
evolution. Hemoglobin. 2011 Jan;35(5-6):565–73.  
19.  Shander A, Sweeney J. Overview of Current Treatment Regimens in Iron Chelation Therapy. 
US Hematol. 2009;2(1):56–9.  
20.  Novartis Pharmaceuticals UK. Deferoxamine summary of product characteristics.  
21.  Theil EC. Mining ferritin iron: 2 pathways. Blood. 2009 Nov 12;114(20):4325–6.  
22.  Bentur Y, Koren G, Tesoro A, Carley H, Olivieri N, Freedman MH. Comparison of deferoxamine 
pharmacokinetics between asymptomatic thalassemic children and those exhibiting severe 
neurotoxicity. Clin Pharmacol Ther. 1990 Apr;47(4):478–82.  
23.  CBS. Centraal Bureau voor de Statistiek. Available from: http://www.cbs.nl/nl-
NL/menu/home/default.htm 
24.  Aydinok Y, Darcan S, Polat A, Kavakli K, Nisli G, Coker M, et al. Endocrine Complications in 
Patients with Beta-thalassemia. J Trop Pediatr. 2002;48(February).  
25.  Gulati R, Bhatia V, Agarwal SS. Early Onset of Endocrine Abnormalities in ß-Thalassemia Major 
in a Developing Country. J Pediatr Endocrinol Metab. 2000 Jan;13(6):651–6.  
26.  Farmaki K. Hypothyroidism in Thalassemia. In: Springer D, editor. Hypothyroidism - Influences 
and Treatments. 2012. p. 97–110.  
27.  Ghader F, Kousarian M, Farzin D. High-dose deferoxamine treatment (intravenous) for 
thalassaemia patients with cardiac complications. East Mediterr Heal J. 2007;13(5):1053–9.  
28.  Fung EB, Harmatz PR, Lee PDK, Milet M, Bellevue R, Jeng MR, et al. Increased prevalence of 
iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J 
Haematol. 2006 Nov;135(4):574–82.  
29.  Lai ME, Grady RW, Vacquer S, Pepe A, Carta MP, Bina P, et al. Increased survival and reversion 
of iron-induced cardiac disease in patients with thalassemia major receiving intensive 
combined chelation therapy as compared to desferoxamine alone. Blood Cells Mol Dis. 
Elsevier Inc.; 2010 Aug 15;45(2):136–9.  
30.  Irshaid F, Mansi K. Status of Thyroid Function and Iron Overload in Adolescents and Young 
Adults with Beta- Thalassemia Major Treated with Deferoxamine in. Int J Biol life Sci. 
2011;7(1):47–52.  
31.  Maggio A, D’Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P, et al. Deferiprone versus 
Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical Trial. Blood Cells, 




32.  Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, et 
al. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter 
study in Tehran. BMC Endocr Disord. 2003 Aug 12;3(1):4.  
33.  Fung EB, Xu Y, Kwiatkowski JL, Vogiatzi MG, Neufeld E, Olivieri N, et al. Relationship between 
chronic transfusion therapy and body composition in subjects with thalassemia. J Pediatr. 
Mosby, Inc.; 2010 Oct;157(4):641–7, 647.e1–2.  
34.  Swaminathan S, Fonseca VA, Alam MG, Shah S V. The Role of Iron in Diabetes and Its 
Complications. Diabetes Care. 2007;30:1926–33.  
35.  Dmochowski K, Finegood DT, Francombe W, Tyler B, Zinman B. Factors determining glucose 
tolerance in patients with thalassemia major. J Clin Endocrinol Metab. 1993;77(2):478–83.  
36.  Li M, Peng SS, Lu M, Chang H, Yang Y, Jou S, et al. Diabetes Mellitus in Patients With 
Thalassemia Major. Pediatr blood cancer. 2014;61:20–4.  
37.  Chern JPS, Lin KL, Lu M, Lin D, Lin K, Chen J, et al. Abnormal Glucose Tolerance in Transfusion-
Dependent Beta-Thalassemic Patients. Diabetes Care. 2001;24:850–4.  
38.  Belhoul KM, Bakir ML, Saned M-S, Kadhim AM a, Musallam KM, Taher AT. Serum ferritin levels 
and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol. 
2012 Jul;91(7):1107–14. 
39.  Mehrvar a, Azarkeivan a, Faranoush M, Mehrvar N, Saberinedjad J, Ghorbani R, et al. 
Endocrinopathies in patients with transfusion-dependent beta-thalassemia. Pediatr Hematol 
Oncol. 2008;25(3):187–94.  
40.  Brittenham G, Griffith P, Nienhuis A, McLaren C, Young N, Tucker E, et al. Efficacy of 
deferoxamine in preventing complications of iron overload in patients with thalassemia 
major. N Engl J Med. 1994;331(9):567–73.  
41.  Modell B, Khan M, Darlison M. Survival in β-thalassaemia major in the UK: data from the UK 
Thalassaemia Register. Lancet. 2000;355(9220):2051–2.  
42.  Olivieri N, Nathan D, MacMillan J, Wayne A, Liu P, McGee A, et al. Survival in Medically 
Treated Patients with Homozygous β-Thalassemia. N Engl J Med. 1994;331:574–8.  
43.  Wills S, Brown D. A proposed new means of classifying adverse drug reactions to medicines. 
Pharm J. 1999;262:163–5.  
44.  Boeckmann AJ, Sheiner LB, Beal SL. NONMEM Users Guide - Part VIII. 2011.  
45.  R Core Team. The R stats package - The log normal distribution - https://stat.ethz.ch/R-
manual/R-patched/library/stats/html/Lognormal.html.  
ACUTE AND LONG-TERM UNFAVOURABLE EFFECTS OF IRON CHELATION THERAPY 
199 
 
46.  Chain ASY, Dieleman JP, van Noord, Charlotte Hofman A, Stricker BHC, Danhof M, 
Sturkenboom MCJM, et al. Not-in-trial simulation I: Bridging cardiovascular risk from clinical 
trials to real-life conditions. Br J Clin Pharmacol. 2013;76(6):964–72.  
47.  Kyriakou A, Skordis N. Thalassaemia and Aberrations of Growth and Puberty. Mediterr J 
Hematol Infect Dis. 2009;1(1).  
48.  Stroh M, Green M, Cha E, Zhang N, Wada R, Jin J. Meta-analysis of Published Efficacy and 
Safety Data for Docetaxel in Second-Line Treatment of Patients with Advanced Non-Small-Cell 
Lung Cancer. PAGE meeting. 2014.  
49.  Maringwa J, Cox E, Harnisch L, Gao X. Model-based meta-analysis of summary clinical 
outcome data in idiopathic pulmonary fibrosis (IPF). PAGE meeting. 2012.  
50.  Kathman S, Williams D, Hodge J, Dar M. A Bayesian population PK-PD model for 
ispinesib/docetaxel combination-induced myelosuppression. Cancer Chemother Pharmacol. 
2009;63(3):469–76.  
51.  Delea T, Edelsberg J, Sofrygin O, Thomas S, Baladi J, Phatak P, et al. Consequences and costs of 
noncompliance with iron chelation therapy in patients with transfusion-dependent 
thalassemia: a literature review. Transfusion. 2007;47(10):1919–29.  
52.  De Sanctis V, Soliman A, Elsedfy H, Skordis N, Kattamis C, Angastiniotis M, et al. Growth and 
endocrine disorders in thalassemia: The international network on endocrine complications in 
thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab. 
2013;17(1):8–18.  
53.  Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion-dependent thalassemia major 
patients may prevent or reverse ironoverload complications. Blood Cells Mol Dis. 
2011;47(1):33–40.  
54.  Toumba M, Sergis A, Kanaris C, Skordis N. Endocrine complications in patients with 
Thalassaemia Major. Pediatr Endocrinol Rev. 2007;5(2):642–8.  
55.  Xia S, Zhang W, Huang L, Jiang H. Comparative efficacy and safety of deferoxamine, 
deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized 
controlled trials. PLoS One. 2013;8(12).  
56.  Pakbaz Z, Fischer R, Treadwell M, Yamashita R, Fung E, Calvelli L, et al. A simple model to 
assess and improve adherence to iron chelation therapy with deferoxamine in patients with 
thalassemia. Ann N Y Acad Sci. 2005;1054:486–91.  
57.  Dasararaju R, Marques M. Adverse effects of transfusion. Cancer Control. 2015;22(1):16–25.  





59.  Food and Drugs Admnistration (FDA). Structured Approach to Benefit-Risk Assessment in Drug 
Regulatory Decision-Making - Draft PDUFA V Implementation Plan. 2013.  
60.  Liberti B, McAuslane N, Walker S. Progress on the Development of a Benefit / Risk Framework 
for Evaluating Medicines. Regul Focus. 2010;15:32–7.  
61.  Coplan P, Noel R, Levitan B, Ferguson J, Mussen F. Development of a Framework for 
Enhancing the Transparency , Reproducibility and Communication of the Benefit – Risk 
Balance of Medicines. Clin Pharmacol Ther. 2011;89:312–5.  
62.  Walker S, McAuslane N, Liberti L, Salek S. Measuring benefit and balancing risk: strategies for 
the benefit-risk assessment of new medicines in a risk-averse environment. Clin Pharmacol 
Ther. 2009;85:241–6.  
63.  Contopoulos-Ioannidis D, Giotis N, Baliatsa D, Ioannidis J. Extended-interval aminoglycoside 











Clinical Trial Simulations: accounting for 
exposure, disease progression and 









Model-based evaluation of benefit-risk 
balance in children 
 
F Bellanti, J Haddad, GC Del Vecchio, MC Putti, C Cosmi, A Ceci, A Maggio, J Horvath, M 
Danhof, and O Della Pasqua 
 
Ready for submission 
 
Summary 
Aims: In this manuscript we apply a model-based approach to complement evidence generation and 
support an integrated evaluation of benefit-risk balance. Multicriteria decision analysis is used as a 
reference method for the benefit-risk analysis of chelation therapy for chronic iron overload in 
children. Thalassaemia was selected as a paradigm disease with the objective of assessing the impact 
of long term effects on the dose rationale for the paediatric population. 
Methods: Clinical trial simulations and not-in-trial simulations were performed to characterise the 
time course of five clinical endpoints/markers deemed relevant for the evaluation of iron chelation 
therapy in paediatric patients affected by chronic iron overload.  Simulations were based on 
hierarchical models previously developed using available clinical and literature data on deferoxamine. 
Summary statistics were used as input for multi-criteria decision analysis using the software D-Sight.  
For comparison purposes, deferoxamine, as a fixed dose of 45 mg/kg/day, was used as a reference 
scenario. A range of alternative dosing regimens and treatment follow-up periods up to 5 years were 
then evaluated, including fixed doses, weight-banded and ferritin-guided individualised regimens.  
Results: The results of the MCDA show that fixed dosing regimens reach similar weighted scores in a 
typical phase III trial scenario.  However the contribution of the different criteria varies considerably 
amongst the five endpoints. In addition, differences in the pharmacokinetics and pharmacodynamics 
of children below 20 kg and in patients with serum ferritin levels below 2500 µg/L suggest that these 
subgroups may benefit from alternative regimens. The differences in these groups appear to hold 
throughout the 5-year follow-up scenario, although the overall weighted scores decrease and the 
differences among treatment options are less evident.  
Conclusions: In contrast to the evidence obtained during a phase III trial, the use of a model-based 
approach reveals that children below 20 kg and patients with ferritin levels below 2500 µg/L may 
achieve a similar BR score with higher and lower doses, respectively. Our analysis also shows the 
feasibility of integrating PKPD relationships into BR methodologies such as MCDA, allowing for a 
more clear, transparent and systematic assessment of the BRB of a medicinal product. Of relevance 
for paediatric diseases is the possibility to explore BRB beyond the duration of treatment in a clinical 
trial. Moreover, it illustrates how evidence synthesis can be complemented by simulated data, 
enabling the evaluation of options and scenarios which may not be available from empirical 





Approval of new medicines for the paediatric population is based on the evidence regarding 
the efficacy and safety profile obtained throughout clinical development (1–4). However, a 
quantitative assessment of the benefit-risk balance (BRB) of a drug is usually not performed 
by sponsors or regulatory authorities at the moment of first marketing authorisation (5). 
Currently, quantitative assessment of the BRB remains a post-marketing endeavour, taking 
into account the emerging evidence from the therapeutic use of the drug in larger 
population and thereby mitigating some of the uncertainties associated with the limited 
data available at the time of launch.  Interest towards the contribution of quantitative 
methodologies for BR assessment has increased considerably in the past years, with 
different stakeholders recognising the need for a more standardised framework, that 
includes higher transparency and consistency(6–14). Among the  numerous approaches for 
quantitative BR analysis, it appears that the lack of transparency can be addressed by the 
development of multi-criteria decision analysis (MCDA) (6,14–21). Nonetheless, this and 
other methods rely on the assumption that a systematic review of empirical evidence arising 
from randomised clinical trials and observational studies  data provides an accurate, 
unbiased picture of a drug’s efficacy and safety.  
This assumption though, may not be valid for a number of reasons.  First, it should be noted 
that for many drugs the evidence required to support regulatory submission does not arise 
from the overall target population, as data is constrained by inclusion and exclusion criteria 
which may not be applicable during the therapeutic use of the medicinal product. In 
addition, little is done to disentangle the contribution of treatment on disease progression 
from external confounding factors on treatment response. Furthermore, the information 
collected in the context of pivotal clinical trials may not provide evidence that dose 
selection, dosing regimen, and treatment duration are truly optimal. Current approaches 
provide a solution to these issues only on the basis of data accumulation from larger clinical 
trials (before drugs approval is obtained) or from data obtained in post-marketing phases. In 
the past years, model-based drug development has proven to be an important resource in 
pharmaceutical research and may be an extremely helpful tool for projecting or 
hypothesising based on assumptions in anticipation of further data collection (22–25). Its 
value is particularly relevant in paediatric drug development where M&S can be used as a 
tool to characterise pharmacokinetic-pharmacodynamic relationships and support further 
understanding of the efficacy and safety profile of old and new drugs (22,24). In this 
manuscript, we propose a model-based approach to complement evidence generation for an 
integrated evaluation of BRB and provide an opportunity for a comprehensive evaluation 
before the first marketing approval. Chronic iron overload will be used as a paradigm disease 
with the objective of assessing the impact of long term effects on the dose rationale for the 
paediatric population. 
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Chronic iron overload is a consequence of chronic blood transfusions in patients affected by 
transfusion-dependent diseases such as beta-thalassaemia major (26–33). These patients 
experience a number of complications such as cardiac dysfunction, hypogonadism, 
hypothyroidism and diabetes mellitus due to tissue specific iron accumulation (27,28,30,32). 
In order to keep iron levels under control, these patients undergo therapy with iron 
chelators, which present a number of unfavourable effects, and along with disease-related 
complications affect the patients’ quality of life (34). To provide an assessment of BRB as 
close as possible to clinical practice in this indication, we have selected deferoxamine as a 
reference compound. Deferoxamine is the currently considered as first line therapy for iron 
overload (34–36). However, we would like to stress that the context of the exercise is purely 
illustrative and is not intended to modify or provide recommendations about its benefit-risk 
profile.  
 
Instead, our objective is to show how integration of modelling and simulation with 
quantitative methods such as MCDA can be used to complement evidence generation for 
diseases or conditions in which data arising from clinical development may be limited or 
insufficient to address clinical and regulatory questions at the time of marketing 
authorisation. We focus on the opportunities for incorporating pharmacokinetic-
pharmacodynamic relationships into the evaluation of the dose rationale and reducing the 




All the data used in the analysis were simulated using pharmacokinetic, pharmacodynamic 
and disease models previously developed by our group. Five clinical endpoints were used for 
the evaluation of the BR framework for iron chelation therapy. A brief description of the 
selected of efficacy and safety endpoints is provided below:  
 
1. Serum ferritin level was selected as a measure of total body iron accumulation. 
Simulated data describing ferritin levels over time were included in the analysis as 
number of responders. A responder was defined as follows: a 20% reduction from 
baseline after 1 year of treatment for patients with baseline serum ferritin of 2500 
µg/L or more; any decrease of serum ferritin levels or an increase, if that increase is 
less than 15% of the baseline as long as it does not result in levels above 2500 µg/L, 
for patients with baseline serum ferritin less than 2500 µg/L. Inclusion criteria at the 
start of treatment is described in the following paragraphs.  
2. Hypothyroidism is a complication of the disease and its prevention was considered a 




hypothyroidism was used as a measure of the progression of the disease. The 
reduction of its incidence is an overall favourable effect of drug therapy. 
3. Diabetes mellitus is a complication of the disease and its prevention was considered 
a benefit of the chelation therapy. Simulated data describing the incidence of 
diabetes was used as a measure of the progression of the disease. The reduction of 
its incidence is an overall favourable effect of drug therapy. 
4. Arthralgia and myalgia are a consequence of the chelation therapy by deferoxamine. 
This is a very common and dose-dependent AE of the iron chelator deferoxamine. It 
was simulated in terms of the incidence of arthralgia/myalgia in individual patients 
over the course of treatment.  
5. Anaphylaxis is a rare dose-independent AE of the iron chelator deferoxamine. 
Simulated data reflected the incidence of anaphylaxis in individual patients. The 
occurrence of anaphylaxis would represent a drop-out from the study or switch to an 
alternative treatment, nonetheless, given the very low incidence patients’ data were 
kept for the evaluation of the other endpoints.  
 
The pharmacokinetic, pharmacodynamic and disease models were hierarchical models, with 
stochastic parameters describing within and between-subject variability. NONMEM v.7.2 and 
R software were used for simulation purposes as well as for graphical and statistical 
summaries. For the simulation of serum ferritin profiles a turnover model was previously 
built by our group, characterised by a disease model that accounts for the effect of the 
chronic transfusion regimen and by a drug model that accounts for the effect of iron 
chelators in reducing serum ferritin levels [Chapter 7 of this thesis]. For the simulation of the 
incidence of hypothyroidism and diabetes, two exponential hazard models were developed 
in which serum ferritin was included as a predictor of the instantaneous hazard [Chapter 8 of 
this thesis].   
 
For the evaluation of drug-specific adverse events, a logistic model with nonlinear regression 
affected by changes in deferoxamine exposure was used to describe the incidence of 
arthralgia/myalgia in dose-dependent manner; whereas a truncated normal distribution was 
used in R to simulate anaphylaxis events in a dose-independent manner. 250 simulations 
were performed for each individual to account for inter- and intra-individual variability in the 
thalassemic population.  An overview of the equations used to describe the response 
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Table 1. Models used for the simulations  
Model and equations Description 
Deferoxamine PK model 
𝑑𝐴(1)
𝑑𝑡
= 𝐴(2)  × 𝑄 𝑉2⁄ − 𝐴(1)  × 𝑄 𝑉1⁄ − 𝐴(1) × 𝐶𝐿 𝑉1⁄  
𝑑𝐴(2)
𝑑𝑡
= 𝐴(1)  × 𝑄 𝑉1⁄ − 𝐴(2)  × 𝑄 𝑉2⁄  
2 compartment PK model with zero-
order absorption (8 hours subcutaneous 
infusion) and first-order elimination 
processes. Fixed allometric scaling 
(exponent of 0.75 on CL/F and 1 on V1/F 
and V2/F) is used to extrapolate 
exposure in adolescents and children 
Deferoxamine PKPD model 
𝑑𝐹𝐸𝑅𝑅𝐼𝑇𝐼𝑁
𝑑𝑡
= 𝐾𝑖𝑛 + 𝐶𝑅𝑇 − 𝐾𝑜𝑢𝑡 × 𝐹𝐸𝑅𝑅𝐼𝑇𝐼𝑁 
× (1 + 𝐷𝐹𝑂) 
 
𝐶𝑅𝑇 = 𝑆𝐶𝐿 ×  𝑒−𝑆𝐻𝑃 ×𝐹𝐸𝑅𝑅𝐼𝑇𝐼𝑁 
 
𝐷𝐹𝑂 = 𝑆𝐿𝑃 × 𝑆𝐶𝑠𝑠𝐴𝑉 
Kin  = zero-order production rate  
Kout = first-order degradation rate 
CRT = disease component, additive 
production rate triggered by the 
transfusion regimen which was found to 
be non-linearly correlated to the disease 
status where SCL is a scaling factor and 
SHP is the shape factor of the correlation 
DFO = deferoxamine effect where SLP is 
the slope parameter of the 
concentration-effect relationship, and 
SCssAV is the steady state concentrations 
Diabetes and Hypothyroidism hazard model 
𝑆(𝑡) =  𝑒− ∫ ℎ(𝑡)𝑑𝑡
𝑡
0  
ℎ(𝑡) =  ℎ0(𝑡) ∗ 𝑒
𝜆𝑓𝑟𝑡ℎ+𝜆𝑓𝑟𝑡𝑙     
The hazard is h(t), and the survival (S) is a 
function of the cumulative hazard within 
the time interval 0 to t. 
The effect of the disease is described by 
two components depending on whether 
serum ferritin levels are above (λfrth) or 
below (λfrtl) the threshold of 2500 μg/L 
Arthralgia/myalgia logistic model 





Css is the deferoxamine steady state 
concentration, PC50 is the concentration 
corresponding to a 50% probability of 
experiencing the AE, and γ is the 






Phase III trial design 
A phase III trial of the duration of 1 year was simulated in paediatric thalassaemic patients 
undergoing chelation therapy with deferoxamine at a fixed dose of 45 mg/kg/day for 5 days 
a week. A sample size of 150 patients was selected with about 30 patients aged 2 to 6 years, 
70 aged 6 to 12 years and 50 aged 12 to 17 years. Patients’ demographics were as follows 
(median and range): age 10 years (2-17), body weight 32 kg (12-62), 50% males and baseline 
ferritin levels 3000 µg/L (1000-8500). A graphical representation of the simulated serum 
ferritin profiles for the 1 year study is shown in Figure 1, whereas a summary of the 
remaining endpoints is presented in Table 2. 
 
Figure 1. Simulated serum ferritin profiles over a period of 1 year for the Phase III trial in 
thalassaemic paediatric patients. The solid black line represents the median, whereas the dashed 
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Table 2. Summary statistics of the simulated phase III trial 
Endpoint Units Mean LCI1 RCI2 SD 5 P3 95 P4 
Incidence of Hypothyroidism % 3,26 3,07 3,45 1,54 0,67 6 
Incidence of Diabetes % 4,9 4,69 5,11 1,69 2,67 8 
Incidence of Arthralgia/Myalgia % 64,3 63,84 64,76 3,71 57,63 70 
Incidence of Anaphylaxis % 0,63 0,59 0,66 0,28 0,13 1,07 
1 Left confidence interval of the mean 
2 Right confidence interval of the mean 
3 5th percentile 
4 95th percentile 
 
Complementary simulation scenarios 
A number of alternative scenarios were simulated along with the phase III trial. A sample size 
of 150 patients (as commonly tested in phase III protocols for chronic iron overload in 
children) per treatment arm was selected also for the alternative scenarios. Even though a 
standard phase III trial in this patient population would last on average 1 year, we have 
simulated data for a period of 10 years to assess the changes in the long-term outcomes, 
with a number of 5 observations per year. Patients’ demographics were similar to the one 
used for the phase III trial. In the end two scenarios were selected and used for the BR 
analysis, namely data simulated over a 1 year and a 5 year period. Summary statistics for the 
simulated data are presented in Tables 3 and 4 (see Appendix). Different dosing algorithms 
were tested and used as treatment options for the BR analysis; the different regimens are 
presented in Table 5. Along to the fixed dosing regimen of 45 mg/kg/day (5/7) used as a 
reference scenario (phase III trial), a range of different fixed doses were tested as well as 





Table 5. BR analysis scenarios 
Input for standard 
MCDA analysis 
Input for integrated PKPD and MCDA analysis 
Phase III data based on a 
fixed dose of  
45 mg/kg/day 5/7 
Scenario Alternative options 
1: Fixed dosing regimens 30, 40, 50 and 60 mg/kg/day 5/7 
2: Weight banded dosing regimens 
Kg < 20: 60 mg/kg/day 5/7 
20-40 kg: 50 mg/kg/day 5/7 
Kg > 40: 45 mg/kg/day 5/7 
3: Ferritin guided dosing regimens 
Ferritin < 2500 µg/L: 40 
Ferritin 2500-5000 µg/L: 45 
Ferritin > 5000 µg/L: 55 
 
 
Multi-criteria decision analysis 
The MCDA analysis was performed with the software D-Sight (D-Sight Brussels, Belgium) 
which uses the PROMETHEE (Preference Ranking Organization Method for Enrichment 
Evaluation) methods (37–40). The different stages of the analysis are summarised in Table 6 
(17,18). Summary statistics of the simulated data discussed above were introduced in the 
MCDA software for the analysis. Mean and confidence intervals of the clinical endpoints for 
the different treatment arms and subgroups were used as input for the analysis (MCDA 
criteria).   
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Table 6. MCDA stages (adapted from Dogson et al.) 
Stage Description 
1 - Establish the decision context Establish aims of the MCDA, and consider 
the context of the appraisal 
2 - Identify the options to be appraised Define the options that will be evaluated in 
the appraisal 
3 - Identify objectives and criteria Identify criteria for assessing the 
consequences of each option and organise 
criteria into a value tree 
4 - Scoring Assess the expected performance of each 
option against the criteria; and assess the 
value associated with the consequences of 
each option for each criterion 
5 - Weighting  Assign weights for each of the criterion to 
reflect their relative importance to the 
decision 
6 - Derive an overall value Calculate overall weighted score by 
combining weights and scores for each 
option 
7 - Results Examine the results and the contribution of 
individual criterion to the overall score 
8 - Sensitivity analysis Assess the influence of other preferences or 
weights on the overall ordering of the 
options 
 
Expert input: value tree and weights elicitation 
The analysis was conducted with a group of experts including: 1 former member of the PDCO 
(Paediatric Committee), 3 haematologists/paediatricians, 1 clinical trial expert, 1 statistician 
and 1 clinical pharmacologist.  
Discussions with experts lead to the definition of the final value tree (a tree-like graph of the 
different criteria), as well as to the characterisation of the preference values for the criteria 
selected and the relative weights for the different criteria or weights elicitation (stages 4 and 
5 of the MCDA analysis). The outcome of this process reflects the risk perception of the 
different stakeholders and has the objective of providing an adequate and unbiased risk 
assessment before the processing of the data is performed.  
The final value tree is presented in Figure 2 and includes already the contribution of the 
relative weights assigned by the experts (weights elicitation), whereas Figure 3 shows an 
example of two utility functions defined for serum ferritin response (non-linear) and 







Figure 2. Final value tree and relative weights for the different criteria after discussion with experts. 
Favourable effects (FE) and unfavourable effects (UFE) were given the same importance whereas 
among the FE and UFE, diabetes and anaphylaxis were given the major importance respectively.  
 
  







Figure 3. Assessed preference values for two criteria based on the discussion with experts. Panel A 
shows the non-linear utility function defined for ferritin response, whereas panel B shows the linear 
utility function defined for arthralgia/myalgia. On the y axis the score is presented in percentage (%). 
 
With respect to the weights elicitation: as shown in Figure 2, the same importance was given 
to all favourable effects (FEs) against all unfavourable effects. Among the FEs, prevention of 




hypothyroidism; whereas the last two had equal importance as compared to each other. 
Finally, among the unfavourable effects (UFEs), greater relevance was given to anaphylaxis 
given the seriousness of the event. In addition, a brief summary of the discussion on the 
assessment of the preference values is provided below: 
 
1. Ferritin response: a nonlinear increase was selected for this criterion reflecting an 
optimal response above 90% and a poor response below 80% as depicted in figure 3 
(panel A). 
2. Hypothyroidism: a linear decrease is expected to be sufficient to characterise the 
differences among the options under evaluation as hypothyroidism is considered 
relatively tolerable by the experts. 
3. Diabetes mellitus: experts have defined an incidence above 5% as not acceptable. A 
non-linear utility function has been selected to characterise differences among the 
proposed options. 
4. Arthralgia/Myalgia: a linear decrease (Figure 3, panel B) was considered sufficient to 
capture the differences among the options proposed as a high rate of the AE can still 
be tolerated according to the experts’ opinion. 
5. Anaphylaxis: a very steep non-linear decrease has been selected for anaphylaxis 
given the seriousness of the AE.  
 
Calculation of the overall weighted score 
With the information on preference values and relative weights, the final step was to 
calculate the overall weighted score for each option (stage 6 of MCDA). The outcome of this 
calculation is simply the weighted average of its scores on the different criteria. The final 
score is generated using the following equation: 
 
𝑆𝑖 =  𝑤1𝑠𝑖1 + 𝑤2𝑠𝑖2 +  … +  𝑤𝑛𝑠𝑖𝑛     Equation 1 
 
where the overall weighted score (S) for an option i will be given by the sum of all the 
individual scores (s) of each criterion multiplied by the assigned weight (w). 
 
Assumptions 
We assume that the incidence of these effects is not random, in contrast to current 
approaches that regard the various endpoints as independent of each other. We captured 
mechanistic correlations across the various endpoints as described in the equations of table 
1, except for anaphylaxis which is a dose-independent AE. For the evaluation of 
unfavourable effects we have selected frequency as the only dimension of interest for this 
analysis, without taking into account severity or duration, i.e. assuming a grade 2-3 for all 
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AEs. We recognise that in clinical practice, severity and duration have an essential role in the 
evaluation of the BR balance and therefore should be accounted for. Furthermore, when a 
fixed dosing regimen was evaluated during the 1 year trial we maintained a fixed regimen 
also during the follow-up years and in the same manner, independently of patients’ 
response to therapy, no switch therapy was considered. On top of that, treatment 
compliance was assumed to be optimal in this exercise and subsequently the observed 
differences are essentially due to variability in pharmacokinetics. We acknowledge the 
importance of these factors, nonetheless, we chose to reduce the complexity to better 
illustrate the advantage of the approach without influencing its validity. 
 
9.3 Results 
The results of the multi-criteria decision analysis are presented in Figures 4 and 5, for the 1 
year clinical trial and 5 year treatment follow-up, respectively. Figure 4 shows that the fixed 
dosing regimens have a similar weighted score; except for the 30 mg/kg regimen (score of 
29.28) where the lowest score is achieved. Even though the overall score is similar the 
contribution of the different criteria is differs considerably amongst the five endpoints, with, 
as expected, ferritin response that tends to increase at increasing doses counteracted by the 






Figure 4. Criteria contribution for the 1 year scenario. The overall weighted score is presented for the 
different options (the higher the score the better the overall performance of the option appraised). 
Individual criteria contribution are displayed for each option: light blue, dark red, green, dark blue 
and blue represent respectively ferritin response, arthralgia/myalgia, anaphylaxis, diabetes and 
hypothyroidism. 
 
Figure 5. Criteria contribution for the 5 year scenario. The overall weighted score is presented for the 
different options (the higher the score the better the overall performance of the option appraised). 
Individual criteria contribution are displayed for each option: light blue, dark red, green, dark blue 
and blue represent respectively ferritin response, arthralgia/myalgia, anaphylaxis, diabetes and 
hypothyroidism. 
 
The results of the MCDA show that fixed dosing regimens reach similar weighted scores in a 
typical phase III trial scenario.  However the contribution of the different criteria varies 
considerably amongst the five endpoints. In addition, differences in the pharmacokinetics 
and pharmacodynamics of children below 20 kg and in patients with serum ferritin levels 
below 2500 µg/L suggest that these subgroups may benefit from alternative regimens. The 
differences in these groups appear to hold throughout the 5-year follow-up scenario, 
although the overall weighted scores decrease and the differences among treatment options 
are less evident. From the 5-year treatment follow up is also clear that the acute effects 
become clinically less relevant; in addition, the differences among the individual 
contributions of each criterion tend to disappear. For example, in a five year period different 
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doses lead to a similar response in serum ferritin. Yet, such changes are achieved at very 
different rates. 
 
9.4 Discussion and conclusion 
MCDA results 
Before any quantitative BR evaluation is performed, the integration of multiple models is 
essential and allows to 1) complementing the existing data to support the decision to be 
taken and possibly determining whether personalised medicine would be of any benefit for 
the patient population; 2) optimising the input data for the BR analysis; and 3) quantifying 
the relevant correlations among different endpoints that are currently still evaluated in an 
independent manner. 
Assuming that the scenarios presented here are part of a real clinical case, the therapeutic 
conclusion derived from this analysis may be the following: children below 20 kg may benefit 
from a higher dose (60 mg/kg/day) at least in an early phase of the disease, and patients 
with controlled serum ferritin levels below 2500 µg/L may achieve a similar BR score with a 
lower dose (40 mg/kg/day),  as compared to the evidence arising from the phase III trial data 
(fixed 45 mg/kg/day). A model-based approach allows one to understand the implications of 
doses that have not been formally tested and the impact they have on benefit and risk. The 
approach also enables one to take into account clinical and feasibility elements that were 
not considered in the clinical protocols. In addition, the possibility to explore beyond the 
standard duration of a phase III trial allows understanding how long-term outcomes may 
affect the BR scores and anticipate whether any changes can be expected in the BR balance 
of the drug.  
 
Limitations 
It is important to emphasise that it was not our intent to modify in any way the current BR 
balance of deferoxamine; our goal was to demonstrate how model-based MCDA can be used 
to personalise drug therapy by incorporating various alternatives and virtual sub-populations 
in the analysis. The complexity of chronic iron overload is much higher than the one depicted 
in this manuscript in many ways: e.g., other disease-related complications, such as cardiac 
complications, have a higher relevance in the evaluation of iron accumulation; drop-out 
rates that occur in a real clinical setting have not been considered during this  analysis; and 
last but not least the role that treatment compliance (especially for deferoxamine) has on 
the clinical evaluation of iron overload is extremely important. Having acknowledged that, 
an exercise with less complexity provides a better framework for illustrating how modelling 





Even though in the recent years PKPD modelling has been proposed in conjunction with 
clinical utility approaches (41,42), in this manuscript we integrate for the first time PKPD 
modelling with multi-criteria decision analysis (MCDA) to overcome the issues discussed in 
the introduction.  
Furthermore, we learned from this exercise that given the complexity that usually 
characterises the BR evaluation of drugs, a quantitative and integrated approach is essential 
to reduce the uncertainty of the analysis and to increase the understanding of the BRB. This 
is particularly true in the paediatric context where not only the BRB is not constant over time 
(in particular in chronic diseases, as in the example discussed here), but also the lack of 
available data does not allow performing an appraisal that is representative of real life 
population (22–24,43,44). Complementing evidence generation (i.e., real data) with virtual 
scenarios and alternative treatment and protocol options (clinical and feasibility elements 
such as study design, inclusion and exclusion criteria, etc.) using clinical trial simulations 
and/or not-in-trial simulations provides an opportunity to accomplish two major goals: 
achieving a better and more comprehensive understanding of the BRB possibly before a drug 
reaches the market and evaluating the BRB in sub-groups providing the basis for the 
assessment of personalised therapy. This is an element often overlooked in that 




In conclusion, we have successfully complemented evidence generation using PKPD 
modelling to the use of MCDA for BR assessment in a paediatric disease. We strongly believe 
that such an approach is essential for a more structured evaluation of the BR balance of any 
intervention, especially if mechanism-based modelling and pharmacokinetic-
pharmacodynamic relationships are used to support such scenarios. Of relevance for 
paediatric diseases is the possibility to explore BRB beyond the duration of treatment in a 
clinical trial.  
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Table 3. Summary statistics of the simulated data for the 1 year scenario 




Ferritin response % 89,44 89,12 89,76 2,56 85,33 93,33 
Incidence of Hypothyroidism % 3,26 3,07 3,45 1,54 0,67 6 
Incidence of Diabetes % 4,9 4,69 5,11 1,69 2,67 8 
Incidence of Arthralgia/Myalgia % 64,3 63,84 64,76 3,71 57,63 70 
Incidence of Anaphylaxis % 0,63 0,59 0,66 0,28 0,13 1,07 
Fixed 
dose 30 
Ferritin response % 77,7 77,32 78,08 3,05 72,67 82,67 
Incidence of Hypothyroidism % 3,33 3,13 3,52 1,56 0,67 6 
Incidence of Diabetes % 5,02 4,81 5,22 1,66 2,67 7,33 
Incidence of Arthralgia/Myalgia % 34,5 34,08 34,92 3,36 28,67 39,7 
Incidence of Anaphylaxis % 0,67 0,62 0,69 0,29 0,19 1,14 
Fixed 
dose 40 
Ferritin response % 86,77 86,42 87,11 2,79 82,67 91,03 
Incidence of Hypothyroidism % 3,18 2,99 3,37 1,5 0,67 6 
Incidence of Diabetes % 4,75 4,54 4,96 1,66 2 7,7 
Incidence of Arthralgia/Myalgia % 54,47 54 54,95 3,82 48 60,67 
Incidence of Anaphylaxis % 0,67 0,59 0,65 0,27 0,13 1,06 
Fixed 
dose 50 
Ferritin response % 91,78 91,51 92,05 2,18 88 95,33 
Incidence of Hypothyroidism % 3,13 2,94 3,31 1,5 0,67 5,33 
Incidence of Diabetes % 4,77 4,55 4,98 1,71 2 7,33 
Incidence of Arthralgia/Myalgia % 70,83 70,43 71,24 3,28 64,67 76 
Incidence of Anaphylaxis % 0,66 0,62 0,69 0,28 0,27 1,07 
Fixed 
dose 60 
Ferritin response % 96,47 96,3 96,65 1,44 94 98,67 
Incidence of Hypothyroidism % 3,19 3,01 3,38 1,52 0,67 6 
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Incidence of Diabetes % 4,71 4,51 4,92 1,69 2 7,33 
Incidence of Arthralgia/Myalgia % 82,82 82,44 83,19 3,02 78 87,33 
Incidence of Anaphylaxis % 0,65 0,62 0,68 0,28 0,26 1,14 
Weight < 
20 kg 
Ferritin response % 94,15 93,7 94,61 3,65 88,24 100 
Incidence of Hypothyroidism % 1,74 1,47 2,01 2,18 0 5,88 
Incidence of Diabetes % 2,42 2,12 2,73 2,47 0 5,88 
Incidence of Arthralgia/Myalgia % 73,06 72,21 73,91 6,88 61,76 85,29 
Incidence of Anaphylaxis % 0,66 0,62 0,69 0,29 0,27 1,20 
Weight 
20-40 kg 
Ferritin response % 91,57 91,16 91,97 3,27 85,25 96,72 
Incidence of Hypothyroidism % 2,72 2,46 2,98 2,11 0 6,56 
Incidence of Diabetes % 4,23 3,9 4,56 2,68 0 8,2 
Incidence of Arthralgia/Myalgia % 68,05 67,38 68,72 5,41 60,66 77,05 
Incidence of Anaphylaxis % 0,67 0,63 0,71 0,30 0,27 1,20 
Weight > 
40 kg 
Ferritin response % 92,29 91,91 92,67 3,05 87,27 96,36 
Incidence of Hypothyroidism % 4,47 4,1 4,83 2,91 0 9,09 
Incidence of Diabetes % 6,47 6,07 6,86 3,19 1,82 10,91 
Incidence of Arthralgia/Myalgia % 71,49 70,77 72,22 5,85 61,82 81 
Incidence of Anaphylaxis % 0,62 0,59 0,66 0,28 0,13 1,07 
Ferritin < 
2500 
Ferritin response % 93,83 93,35 94,3 3,83 86,49 100 
Incidence of Hypothyroidism % 3,06 2,67 3,45 3,13 0 8,11 
Incidence of Diabetes % 4,29 3,9 4,69 3,19 0 10,81 
Incidence of Arthralgia/Myalgia % 56,42 55,44 57,4 7,93 43,24 67,57 
Incidence of Anaphylaxis % 0,64 0,61 0,68 0,28 0,27 1,20 
Ferritin 
2500-
Ferritin response % 93,66 93,33 93,99 2,65 88,75 97,37 




5000 Incidence of Diabetes % 4,94 4,61 5,26 2,64 1,32 9,21 
Incidence of Arthralgia/Myalgia % 62,4 61,68 63,12 5,82 53,22 71,05 
Incidence of Anaphylaxis % 0,65 0,61 0,68 0.28 0,26 1,60 
Ferritin > 
5000 
Ferritin response % 99,77 99,68 99,87 0,75 97,3 100 
Incidence of Hypothyroidism % 3,03 2,67 3,38 2,86 0 8,11 
Incidence of Diabetes % 4,99 4,55 5,44 3,59 0 10,81 
Incidence of Arthralgia/Myalgia % 75,85 75,03 76,67 6,6 64,86 86,49 
Incidence of Anaphylaxis % 0,65 0,62 0,68 0,27 0,27 1,07 
1 Left confidence interval of the mean 
2 Right confidence interval of the mean 
3 5th percentile 
4 95th percentile 
 
Table 4. Summary statistics of the simulated data for the 5 years scenario 




Ferritin response % 93,32 93,06 93,58 2,08 89,63 96,67 
Incidence of Hypothyroidism % 4 3,78 4,22 1,74 1,33 7,33 
Incidence of Diabetes % 5,82 5,59 6,05 1,84 3,33 9,33 
Incidence of Arthralgia/Myalgia % 97,13 96,97 97,29 1,32 94,67 99,33 
Incidence of Anaphylaxis % 0,66 0,65 0,68 0,13 0,45 0,87 
Fixed 
dose 30 
Ferritin response % 83,97 83,65 84,3 2,61 79,33 88,37 
Incidence of Hypothyroidism % 4,57 4,34 4,81 1,87 1,63 8 
Incidence of Diabetes % 6,61 6,37 6,84 1,93 3,33 10 
Incidence of Arthralgia/Myalgia % 80,6 80,22 80,97 3,04 75,33 85,33 
Incidence of Anaphylaxis % 0,64 0,63 0,66 0,13 0,45 0,85 
Fixed 
dose 40 
Ferritin response % 90,24 89,97 90,5 2,13 86,67 93,33 
Incidence of Hypothyroidism % 4,04 3,83 4,25 1,72 1,33 7,33 
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Incidence of Diabetes % 5,94 5,71 6,18 1,89 3,33 9,33 
Incidence of Arthralgia/Myalgia % 94,11 93,89 94,33 1,77 91,33 96,67 
Incidence of Anaphylaxis % 0,65 0,63 0,66 0,12 0,45 0,86 
Fixed 
dose 50 
Ferritin response % 95,44 95,24 95,64 1,6 92,67 98 
Incidence of Hypothyroidism % 3,83 3,61 4,04 1,73 1,33 6,67 
Incidence of Diabetes % 5,61 5,38 5,84 1,83 2,67 8,67 
Incidence of Arthralgia/Myalgia % 98,24 98,12 98,36 0,97 96,67 100 
Incidence of Anaphylaxis % 0,67 0,65 0,68 0,14 0,44 0,91 
Fixed 
dose 60 
Ferritin response % 98,2 98,07 98,33 1,04 96,67 100 
Incidence of Hypothyroidism % 3,82 3,61 4,04 1,72 1,33 6,67 
Incidence of Diabetes % 5,55 5,33 5,78 1,82 2,67 8,67 
Incidence of Arthralgia/Myalgia % 99,59 99,53 99,66 0,53 98,67 100 
Incidence of Anaphylaxis % 0,66 0,64 0,67 0.14 0,45 0,93 
Weight < 
20 kg 
Ferritin response % 96,05 95,65 96,45 3,24 91,18 100 
Incidence of Hypothyroidism % 2,62 2,29 2,96 2,73 0 7,5 
Incidence of Diabetes % 3,41 3,03 3,8 3,09 0 8,82 
Incidence of Arthralgia/Myalgia % 98,38 98,13 98,63 2,02 94,12 100 
Incidence of Anaphylaxis % 0,66 0,64 0,68 0,13 0,45 0,90 
Weight 
20-40 kg 
Ferritin response % 94,67 94,33 95,01 2,77 90,16 98,36 
Incidence of Hypothyroidism % 3,39 3,1 3,68 2,35 0 8,2 
Incidence of Diabetes % 5,28 4,92 5,63 2,87 1,64 9,84 
Incidence of Arthralgia/Myalgia % 98,09 97,87 98,3 1,7 95,08 100 
Incidence of Anaphylaxis % 0,64 0,63 0,66 0,13 0,43 0,88 
Weight > 
40 kg 
Ferritin response % 95,24 94,89 95,58 2,79 90,91 100 




Incidence of Diabetes % 7,27 6,85 7,69 3,41 1,82 12,73 
Incidence of Arthralgia/Myalgia % 98,36 98,15 98,58 1,73 94,55 100 
Incidence of Anaphylaxis % 0,65 0,64 0,67 0,13 0,45 0,88 
Ferritin < 
2500 
Ferritin response % 92,64 92,12 93,15 4,14 86,49 98,78 
Incidence of Hypothyroidism % 3,56 3,16 3,96 3,23 0 8,11 
Incidence of Diabetes % 4,96 4,53 5,39 3,46 0 10,81 
Incidence of Arthralgia/Myalgia % 96,86 96,49 97,24 2,99 91,89 100 




Ferritin response % 97,99 97,8 98,19 1,59 94,74 100 
Incidence of Hypothyroidism % 3,97 3,68 4,26 2,34 0 7,89 
Incidence of Diabetes % 5,66 5,32 6 2,73 1,32 10,53 
Incidence of Arthralgia/Myalgia % 96,96 96,72 97,19 1,89 93,42 100 
Incidence of Anaphylaxis % 0,65 0,64 0,67 0,14 0,43 0,88 
Ferritin > 
5000 
Ferritin response % 99,95 99,9 99,99 0,38 100 100 
Incidence of Hypothyroidism % 3,75 3,36 4,14 3,12 0 8,11 
Incidence of Diabetes % 5,96 5,47 6,45 3,95 0 13,51 
Incidence of Arthralgia/Myalgia % 97,99 97,73 98,25 2,08 94,59 100 
Incidence of Anaphylaxis % 0,66 0,64 0,67 0,13 0,43 0,85 
1 Left confidence interval of the mean 
2 Right confidence interval of the mean 
3 5th percentile 






















Model-informed assessment of the benefit-
risk profile of medicines for children  
 
Summary, conclusions and perspectives 
 
Growing awareness about the relevance of formal evaluation of the efficacy and safety in 
children has resulted into important changes in the legislation defining the requirements for 
the approval of medicines for children (1–4). In parallel to these developments, 
methodological advancements have taken place in terms of the level and type of evidence 
required to establish the so-called benefit-risk profile of an intervention (5–8). Whilst a 
considerable number of approaches have been evaluated over the last decade, their 
utilisation has often been limited to post-approval data. Most importantly, they summarise a 
fait accompli, i.e., the evidence is gathered after the facts. 
Whilst risk management and mitigation measures are intrinsic components of a risk 
management plans (5–8), current approaches do not provide a quantitative framework for 
regulators, clinical scientists and drug developers on how to integrate knowledge about 
drug- and disease-specific properties, thereby enabling the prediction of treatment response 
across a range of possible scenarios before evidence is generated. The availability of such a 
framework would not only permit optimisation of risk management plans, it would also 
represent a more robust basis for addressing clinical and scientific questions during drug 
development and at the time of approval.  
 
Throughout this thesis we have focused on the advantages of introducing quantitative 
clinical pharmacology concepts, and more specifically modelling and simulation, as an 
ancillary tool for evidence generation and evidence synthesis. We have illustrated how 
model-based predictions can be used in conjunction with established benefit-risk 
methodologies to support the decision-making process underpinning the approval of 
paediatric medicines. The examples used in previous chapters also offer insight into the 
deficiencies associated with data generation and unravel opportunities for the optimisation 
of clinical protocols in children.  
 
Two main features need to be highlighted, which differentiate the work proposed here from 
previous research in paediatric clinical pharmacology. In contrast to previous work in which 




single endpoint, it is the first time that multiple drug-disease models are implemented in 
parallel, taking into account eventual correlations between measures of efficacy and safety. 
This represents an important advancement in the way one assesses treatment response i.e., 
not as a primary endpoint in a clinical protocol, but rather as a means to characterise 
disease- from drug-specific properties, thereby providing a parametric representation of the 
efficacy and safety profile of an intervention. A second feature of our work is the 
application of clinical trial and not-in-trial simulations as complement to data obtained from 
clinical trials. Here simulated data (i.e., imputations) from virtual scenarios were intertwined 
with real data and used as input for the multi-criteria decision analysis. An immediate 
advantage of the approach is the possibility of exploring in a quantitative manner the 
benefit-risk profile of a medicinal product in situations which have not been tested prior to 
its approval. This aspect is particularly relevant for the evaluation of medicines for children, 
for whom limited evidence can be generated and physiological processes associated with 
maturation and growth may affect the benefit-risk balance. 
 
The aforementioned features were embedded across the different chapters, where 
chelation therapy associated with iron overload is used to illustrate the implementation of 
the proposed framework. Here we present an overview of the results and conclusions from 
these investigations, emphasising the contribution of modelling and simulation as a tool for 
more effective data generation, evidence synthesis and decision making regarding the 
evaluation of paediatric medicines. 
  
Our work is based on the premise that when a drug is granted its first marketing 
authorisation the decision is based only on the evidence generated throughout the drug 
development phases in the target paediatric population (1,3,2,4). However, at this stage no 
quantitative evaluation is performed of the benefit-risk balance (BRB); usually a full BR 
appraisal takes place during the post-marketing phase, when additional evidence arises from 
clinical practice as well as from additional randomised controlled trials.  Clearly, this 
situation is not ideal, as it imposes a reactive rather pro-active attitude towards benefit-risk. 
Despite the acknowledgement by different stakeholders about the need for a more 
consistent, transparent framework to support (decision-making for) the approval of new 
medicines (9–12)., inferential methods by modelling and simulation have been ignored or 
have limited role as a statistical analysis tool. Thus far little has been done to enable the use 
of inferential methods by modelling and simulation as an integrative tool for evidence 
synthesis and benefit-risk assessment.   
 
In chapter 1, we review the available literature on benefit-risk evaluation to identify suitable 
methods for the development of the proposed framework. In spite of the vast number of 
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methodologies (both qualitative and quantitative) are available in the public domain, the 
majority of them are not appropriate for a more general application (13–15).   
Among other things, we highlight the relevance of quantitative methods as enablers or keys 
to the answer to clinical, regulatory and scientific questions regarding the benefits and risks 
of an intervention.  Growing consensus suggests that a combined approach involving 
qualitative and quantitative methods is required to ensure meaningful evaluation and 
interpretation of benefit and risk data.  Here we identify MCDA as the method of choice for 
further integration with mechanism-based modelling and simulation. Despite its limitations 
in the way uncertainty is handled, MCDA offers the opportunity to evaluate a 
multidimensional aspects drug and disease which arise in drug development and in the 
clinical practice. In revisiting the drug approval process and the requirements for paediatric 
drug development, it becomes evident that the use of drug-disease modelling and 
simulation represents a formal extension of the clinical pharmacology concepts into the 
realm of evidence synthesis and evaluation of novel therapeutic agents. This advancement 
can be compared to the introduction of receptor pharmacology in drug discovery, which 
replaced empirical evidence from experimental protocols (16–18). Then receptors were just 
a concept, not a substrate, whose properties could be used to understand drug properties 
and optimise the development of novel molecules.  Similarly, today response scenarios in 
virtual patients are still seen as concepts, rather than as substrates that can be used for 
further characterisation of the benefit-risk profile. 
 
Having identified a suitable methodology enabled us to formalise the scope and intent of the 
investigations described in the subsequent chapters of this thesis.  In fact, in chapter 2 we 
introduce details on the implementation of a framework in which MCDA is applied in an 
integrated manner with modelling and simulation. The primary intent of the framework is to 
have a tool for more effective data generation, evidence synthesis and better decision 
making.  Focus is given to the opportunities for optimising data generation in children and 
most importantly to the possibility of integrating knowledge by mechanism-based 
parameterisations, which enable us to discriminate between drug- and disease-specific 
properties. The implementation of these concepts is illustrated by the use of clinical trial and 
not-in-trial simulations to complement data generation and improve benefit-risk 
assessment. For the sake of clarity, the proposed work is presented into three separate 
sections in this thesis. In section 2, attention is paid to importance of data quality in the 
context of paediatric bridging studies and the implications for the estimation of the 
parameters of interest in subsequent steps, i.e., evidence synthesis. Our investigation also 
shows how critical pharmacokinetic data are for the selection of the dosing regimen in the 
target population. In section 3, we discuss the hurdles for the assessment of efficacy in 




making drug effects no more than a covariate factor for efficacy and safety.   We illustrate 
how treatment response can be characterised by integrating certain physiological measures 
(i.e., markers of pharmacology) with disease-related factors. In this context, it also worth 
mentioning that further insight into the mechanisms underpinning pharmacological effects 
provides a systematic approach to the evaluation of safety findings.  In fact, drug-disease 
models were developed for a series of clinically relevant outcomes, taking into account the 
physiological or pharmacological correlation between them.  The examples presented here 
also provide a first insight into the concept of knowledge propagation, not as a statistical 
prior, but as time variant and time-invariant parameter distributions. These predictive 
distributions are essential in the context of chronic diseases, as they enable prediction of 
long-term complications or changes in response due to physiological factors as well as 
patient behaviour. Finally, in section 4, we demonstrate how MCDA can be implemented in 
conjunction with modelling and simulation. The models developed in the previous sections 
are used to generate virtual responses in clinical trial and not-in-trial simulation scenarios, 
mimicking a Phase III efficacy trial and a long-term follow-up pharmacovigilance protocol. 
The availability of a range of scenarios which have not been evaluated in an empirical 
setting, including predictions of long-term changes in the benefit-risk profile, provides a 
more robust basis for decision making regarding the approval and risk management of 
medicines for children.  
 
10.1 Optimising evidence generation in paediatric trials 
One of the major issues in paediatric drug development is that ethical and practical 
constraints often limit the generation of evidence (19,20). This has implications for the 
subsequent use in the evaluation of the benefit-risk profile of an intervention.  In brief, there 
is an imperative for acquiring data with high quality and high informative value. Obviously, 
both the quality and informative value of data acquire in children cannot be taken for 
granted. Empirical experimental evidence based primarily on feasibility yields a potentially 
distorted picture of reality, in that drug-specific properties may not be disentangled from the 
role of disease-related factors and experimental design. 
 
Given the role of extrapolation and bridging in paediatric research, in chapters 3, 4 and 5 we 
demonstrate how knowledge integration can be use applied in conjunction with optimal 
design to evaluate which study protocol designs are more informative, whilst taking into 
account feasibility issues. Here we have focused on the sample size and sampling frequency 
required for obtaining accurate estimates of systemic exposure in children with < 6 years of 
age undergoing chelation therapy with deferiprone. 
The study was based on the assumption that pharmacokinetic properties can be bridged 
from adults and adolescents. Affected by transfusion-dependent diseases and therefore 
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provide evidence of the dosing regimen(s) that ensures comparable drug exposure across 
the overall patient population. Therefore in chapter 3 we developed a population 
pharmacokinetic model using available data in adults receiving oral doses of deferiprone as a 
100 mg/ml solution. Our results show how a model-based approach can be used to assess 
the effect of demographic and physiological factors on drug exposure and subsequently 
provide the basis for evaluating the design of prospective clinical trial protocols. Our analysis 
also illustrates how pharmacokinetic models can be used with a set of assumptions to 
explore the implications of factors such as co-morbidities, hepatic or renal impairment on 
drug exposure and consequently on dosing recommendations. In chapter 4, the population 
pharmacokinetic model describing the pharmacokinetics of deferiprone in adults and 
adolescents is used in conjunction with allometric scaling concepts to optimise the sampling 
algorithm for a prospective PK trial in children aged < 6 years. The analysis also provided an 
opportunity to assess the feasibility of reducing the number of patients per dose level. A 
sampling scheme with 5 samples post-dose per subject was found to be sufficient to ensure 
accurate characterization of the systemic exposure to deferiprone. Despite the assumptions 
regarding the changes in clearance and volume of distribution, our results reveal that the 
use of predefined (fixed) sampling schemes and sample sizes do not warrant accurate model 
structure and parameter identifiability in paediatric pharmacokinetic studies. Of importance 
is the accurate estimation of the magnitude of the covariate effects, as they may determine 
the dose recommendation for the population of interest.  Furthermore, the analysis shows 
that the optimisation of study design does not require necessarily the use of the final model 
for the population of interest; the combination between ED-optimisation and the 
information carried by a hypothetical model is sufficient to significantly increase the quality 
of the information collected in a prospective clinical trial. Finally, in chapter 5 we have 
performed the analysis of the pharmacokinetics of deferiprone in children aged < 6 years 
after administration of three different dose levels in the DEEP1 PK study (EudraCT, 2012-
000658-67). The analysis also demonstrates the value of optimised protocol design, in that 
pharmacokinetic parameter estimates are obtained with high precision and accuracy despite 
sparse sampling and small sample size (i.e., 18 evaluable children with 5 samples per 
patients). Based on bridging concepts, a dosing regimen was recommended to this 
population of young children that ensures comparable exposure to adults and adolescents. 
An oral dose of 75 mg/kg/day deferiprone results in median AUC values of 340.6 and 318.5 
µM/L*h in children and adults, respectively. Comparable values are also observed after a 
regimen of 100 mg/kg/day. Hence, a dosing regimen of 25 mg/kg t.i.d. should be used in 
children below 6 years, with the possibility of titration up to 33.3 mg/kg. The work carried 
out in this section allowed us to characterise the pharmacokinetics in the target population 
and supported the dose rationale for the subsequent assessment of the efficacy and safety 




From a methodological perspective, our findings highlight the role of parameter-covariate 
correlations to establish accurate dosing recommendations, i.e., pharmacokinetic studies in 
children involve more than simply generating data in a small group of children: it demands 
some level of stratification of the covariate factors. 
 
10.2 Integrated evaluation of efficacy and safety by modelling and 
simulation 
In addition to the requirement for high quality of data, accuracy and precision in the 
parameters of interest, the evaluation of pharmacodynamics, efficacy and safety imposes 
the assessment of the multidimensionality and the complexity of the clinical context in 
which the treatment is used. In contrast to pharmacokinetics, where measures of exposure 
are all derived from the underlying pharmacokinetic parameters, the analysis of 
pharmacodynamic data needs to account for multiple endpoints, many of which are 
correlated with each other. Drug-specific and system-specific parameters need to be 
considered in an integrated manner in order to characterise the efficacy and safety profile of 
a drug. As illustrated in the previous chapters of this thesis, PKPD models provide an 
opportunity to quantify such correlations and account for them when drawing conclusions 
about the benefit-risk profile of an intervention. To this end, the integration oncoming 
clinical data with prior knowledge (e.g. epidemiological data on background rates of 
expected co-morbidities; or knowledge acquired on a different disease, population or drug 
of the same class) becomes essential to describe the dynamics of disease and its progression 
and consequently determine long-term outcome. 
 
These concepts were illustrated for characterisation of the safety and efficacy profile of 
deferoxamine, which is currently the first line treatment for chronic iron overload in patients 
affected by transfusion-dependent diseases (21–24).  First, in chapter 6 we developed a 
disease model for chronic iron overload based on available literature data in untreated 
patients. For the first time, the relationship between serum ferritin levels and blood 
transfusions has been characterised in a parametric manner. A turnover model was 
implemented in which a time-varying parameter describes the ferritin conversion rate taking 
into account the transfusion history and disease progression. This model provides a more 
mechanistic interpretation of the pathophysiological changes associated with iron overload 
observed during the course of transfusions. Among other things, it allows us to address 
some unanswered clinical questions in thalassaemia, such as to estimate the time required 
to achieve response based on the serum ferritin levels at the start of treatment.  
This turn-over model was used as a starting point in chapter 7 for the evaluation of the 
chelating effects of deferoxamine, as determined by the changes in serum ferritin levels. 
Deferoxamine binds iron at different extracellular levels, and within the cell it targets 
SUMMARY, CONCLUSIONS AND PERSPECTIVES 
235 
 
lysosomal ferritin iron by stimulating ferritin degradation. The drug effect was therefore 
parameterised in the disease model as a proportional change in the degradation rate 
constant (Kout). Such a parameterisation can also be applied to the evaluation of other 
chelating agents. Most importantly, the availability of this model offers an opportunity to 
explore different scenarios that have been so far evaluated empirically in clinical practice. 
For example, it may be possible to evaluate the importance of different compliance patterns 
for the available chelating agents, and consequently, their impact on ferritin levels and /or 
risk of clinical failure. In fact, we found clear evidence that high compliance leads to stable 
ferritin levels over time and that poor adherence to deferoxamine therapy is strongly 
correlated to a poor clinical outcome 
We subsequently apply this drug-disease model as a framework for further optimisation of 
therapeutic interventions, whereby the impact of covariate factors such as dose, drug 
exposure, compliance, or disease status can be evaluated against short and long-term 
treatment outcome.  
 
As the assessment of the benefit-risk profile of a treatment requires quantitative descriptors 
of efficacy and safety, in chapter 8, we have complemented the work described in the 
previous chapter for safety endpoints. Whilst different dimensions of a symptom or sign may 
need to be considering when assessing its clinical relevance, here we have focused on 
incidence only.  This decision was purely based on didactic reasons, ensuring clarity about 
how modelling and simulation can be used to integrate different endpoints. Two survival 
models were developed to describe disease-specific complications, namely hypothyroidism 
and type II diabetes. Both co-morbidities evolve as a consequence of iron accumulation and 
as such can be causally correlated with ferritin levels. A hazard function including ferritin 
levels was found to be a predictor of the probability of the incidence of the co-morbidity. In 
addition two models were developed to characterise the incidence of acute drug-specific 
adverse events, namely arthralgia/myalgia and anaphylaxis. They reflect two typical features 
of the safety profile, in that the former refers to a frequent, dose-dependent event, whereas 
the latter a rare, dose-independent one. Of particular relevance for the implementation of 
BR assessment, is the possibility of exploring rare dose-independent AEs. The four models 
were used in parallel to assess the impact of different exposure levels and compliance 
patterns on short- and long-term complications of iron chelation therapy. It should be noted 
that such a comprehensive analysis would not have been possible without integration of 
epidemiological (literature) and pharmacological data. In doing so, we have ensured that 
interdependencies and correlations between the different endpoints under evaluation were 





10.3 Clinical Trial Simulations: accounting for exposure, disease 
progression and uncertainty in benefit-risk analysis 
As highlighted in the scope and intent of investigations, throughout this thesis we have 
defended the use of model-guided evidence generation and subsequent evidence synthesis 
for characterising the benefit-risk profile of medicines for children. Our results have 
demonstrated that empirical evidence is not necessarily accurate and that any attempt to 
establish the benefit-risk profile of an intervention at the time of its approval presupposes 
that the available data suffices to support such an assessment. This assumption may not be 
appropriate in a considerable number of cases.  In paediatric diseases one needs to consider 
that the natural time course of disease occurs in parallel to developmental (physiological) 
growth and maturation processes. By performing clinical trial simulations and not-in-trial 
simulations, intrinsic and extrinsic sources of variation as well as confounding factors can be 
appropriately evaluated and incorporated into the decision process. The approach also 
addresses the issue of uncertainty due to limited sample size in clinical trials. 
 
In chapter 9 MCDA is used in conjunction with simulation scenarios to evaluate the benefit-
risk profile deferoxamine in children with transfusion-dependent haemoglobinopathies. 
Here all five models developed in the previous section were used to simulate treatment 
response in virtual paediatric patients. Individual response data is obtained from a 1-year 
hypothetical phase III trial in conjunction with a follow-up safety study in which patients are 
evaluated up to 10 years after the start of the treatment. A reference scenario was proposed 
based on the currently approved dosing regimen of deferoxamine, i.e., 45 mg/kg/day (5/7). 
In this analysis, we have compared the results of the phase III trial with a range of alternative 
regimens and conditions, namely different fixed dose levels, weight-banded dosing regimens 
and ferritin-guided individualised regimens. The availability of simulated responses over a 
period of 10 years enabled us to assess the impact of long-term complications on the 
benefit-risk balance. Our approach clearly provides a more comprehensive evaluation of the 
implications of drug-specific and disease-specific factors on the overall benefit-risk profile of 
deferoxamine. Moreover, we show how interdependencies can be accounted for during the 
characterisation of long-term complications and how disease progression can be 
disentangled from drug-related events. The current findings open new avenues for a more 
structured evaluation of the BR balance of an intervention. It provides a framework for the 
integration of knowledge in a parametric manner, thereby 1) complementing the existing 
data to support the decision to be taken; 2) optimising the input data for the MCDA analysis; 
and 3) quantifying the relevant correlations among different endpoints and possibly 
determining whether personalised regimens would be of any benefit for the patient 
population.  
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10.4 Conclusions, recommendations and perspectives 
Throughout this thesis we have highlighted important limitations in the assessment of BR 
profile of a medicinal product in children, especially if applied at the time of approval. In 
contrast to current practice, PKPD modelling provides a robust, mechanism-based 
opportunity to complement the clinical data to be used in BR assessment. Whereas different 
methods have been developed with the intent of enabling a more quantitative appraisal of 
the benefit-risk profile, none of them fully address the aforementioned limitations. 
Nevertheless, the MCDA appears to possess the necessary features to assess BRB in a more 
systematic and transparent manner, with the potential for a full integration with PKPD 
modelling. Yet, it should be noted that the use of MCDA has an illustrative purpose in this 
thesis. In principle, our approach could be implemented in combination with other 
quantitative BR methodologies. The major challenge lies in the steps that take place before a 
BR evaluation is performed. Traditional endpoints do not necessarily capture sufficient 
information about the treatment and the p-value of a clinical trial is not predictive of 
effectiveness, losing its importance in the context of BRB.  This is compounded by the fact 
that ethical and practical constraints limit the level of clinical evidence that can be gathered 
in a randomised, controlled setting as well as by the effect of disease progression on the 
benefit-risk balance, especially in chronic conditions.  
In summary, we defend the need for a development and approval paradigm in which both 
evidence generation and evidence synthesis form the basis for approval.  Clinical events or 
the absence thereof are not spurious, random features of an intervention. They are greatly 
determined by the patient population, the context in which the treatment is assessed and by 
the dose rationale.  
 
Even though some examples are available in literature where M&S is proposed in 
combination with clinical utility measures in the context of BR assessment (25,26), this thesis 
represents the first analysis in which PKPD modelling has been fully integrated with MCDA. 
This approach enables regulators, sponsors, and clinical experts to:  
 
1. optimise study design, ensuring the quality of the data collected; 
2. integrate available information (e.g., epidemiological data) to support data analysis 
and models assumptions; 
3. simultaneously evaluate multiple endpoints and account for co-linearity and 
interdependencies and  







What have we learned? 
We have encountered a number of challenges that made the characterisation of treatment 
effects within a real-life clinical context rather complex. Currently, clinical data are 
generated for hypothesis testing and as such are focused on primary endpoints, not on the 
assessment of benefit-risk profiles. Often, the available were not sufficient to estimate all 
model parameters for each separate endpoint or to fully assess correlations between 
endpoints. Moreover, dose rather than exposure is still used as gold standard for defining 
treatment effects, ignoring the role of pharmacokinetics and covariate factors as explanatory 
variables for the variability in response. 
Firstly, these challenges allowed us to learn that M&S tools provide an opportunity to 
describe and quantify relevant aspects of paediatric diseases even in the absence of 
individual data by making use of available literature as well as prior knowledge, as presented 
in chapter 6. We have shown also that despite limited evidence regarding the safety profile 
of deferoxamine, such a limitation does not prevent us from exploring the implications of 
treatment based on the integration of data from epidemiological studies as well as from a 
different population in which the same compound or another one of the same 
pharmacological/molecular class has been used.  Secondly, we have shown the importance 
of defining a model for each endpoint to be evaluated in a BR analysis: an integrated 
approach with the use of multiple models is essential to characterise the multidimensionality 
of disease. Moreover, PKPD relationships cannot be ignored during the evaluation of the BR 
profile. Whereas this process was found to be resource-intensive and time-consuming, we 
have no doubt about its superiority in terms of establishing the true benefit-risk profile and 
enabling better decision making. It is also clear that implementation of the approach in a 
prospective manner requires efforts to be allocated as early as phase I. Finally, we have 
learnt that the clinical interpretation of benefit-risk estimators is fraught with a relatively 
large degree of uncertainty, varying considerably among the different stakeholders. These 
differences do not facilitate consensus regarding the consequences of an intervention.  M&S 
allows a reduction in this uncertainty thanks to the use of underlying PKPD relationships. 
Such relationships are causal in nature and as such provide a somewhat more objective 
readout of the different criteria and their relative consequences: exposure-response data 
can be used to guide the expert judgment and dismiss implausible correlations.  
Nevertheless, we are aware of the fact that subjectivity cannot and most likely will never be 
fully eliminated during the appraisal of the benefit-risk profile of a medicinal product. 
 
Requirements and recommendations 
In the next paragraphs, we aim at summarising how a model-based approach can be applied 
to future appraisals using MCDA as a quantitative method. The first point to consider is that 
the clinical data generated is not sufficient for a comprehensive BR evaluation. In table 1 a 
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visual overview of the elements that differentiate our proposal from current practices in 
benefit-risk assessment. The most important message from our work is that any available 
knowledge on the pharmacological properties as well as on the disease and its progression 
cannot be omitted from a more structured and comprehensive analysis of the benefit-risk 
profile.  
 
Table 1. Overview of the differences between the proposed model-based approach and the current 
approach for BR appraisals. CTS: Clinical Trial Simulations; NITS: Not In Trial Simulations. 
 
CURRENT APPROACH    MODEL-BASED APPROACH 
Clinical data from  






morbidities and AEs) 
Prior knowledge on: 
mechanism of action; 
disease progression; other 
drugs; other populations 
Evidence generated INPUT 
Evidence generated + virtual 
scenarios (CTS and NITS*) 
Tested dosing regimen vs. 
placebo or standard of care 
OUTPUT 
Alternative options: 
possibility to achieve 
personalised medicine 
 
The proposed approach is versatile in that it does not necessarily rely on the characteristics 
of MCDA. However, if we consider M&S in the context of MCDA, as described throughout 
this thesis, the chart shown in figure 1 can be used to illustrate what exactly changes in 
benefit-risk assessment. In figure 1, the different stages of MCDA are aligned to the 







Figure 1. Contributions of the proposed model-based approach to the different stages of MCDA.  
 
Future perspectives and conclusions 
The regulation of drugs is undergoing rapid worldwide change in response to the advances in 
pharmaceutical sciences, drug development, and changes in public expectations. The 
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interest towards BR assessment is expanding and more and more projects have started 
focusing on the use of a more structured and transparent process by combing ideas and 
inputs from different stakeholders (5–8,27,28). The major effort of these groups appears to 
be focused  on the following aspects (29–37):  
1. more systematic use of available clinical evidence;  
2. better graphical representation of the overall BRB;  
3. re-evaluation of the BRB during the whole life cycle of the drug based on data 




Figure 2. Process of the Public Health Benefit assessment. Adapted with permission from Massol et 
al. (38) 
 
Unfortunately, as depicted in Figure 2, it appears that today’s efforts rely primarily on data 
accumulation, making it central to the implementation of BR analysis. By contrast, we 
envisage the joint used of available data with drug-disease models as basis for clinical trial 
simulations (CTS) and/or not-in-trial simulations (NITS). The concept of extrapolating to real 
life population is not new and has been already applied and proposed in the context of 
safety management (39).  
Trials
Effective Dose











One major area that requires further development and discussion is uncertainty. While 
statistical uncertainty is captured well in most decision approaches, work remains to be 
done with regard to better articulating the consequences of any gaps in the efficacy and 
safety data (e.g., dropouts) and the level of evidence available on the benefit–risk profile. 
We acknowledge the fact that the models developed and used in this thesis carry a certain 
degree of uncertainty. Nevertheless, they allowed us to explore scenarios that could not be 
considered during drug development. They also provided answers to clinical questions (e.g., 
impact of long-term complications on the BRB of iron chelators) that could not necessarily 
be addressed directly in a real setting. Drug development and therapeutics will greatly 
benefit from a framework that describes how drug- and disease-specific properties interact 
with each other and ultimately determine the benefit-risk profile during development (i.e. 
randomised clinical trials) as well as during clinical use of the drug. 
 
Our approach could form the backbone for the recently proposed progressive licensing 
model, which was initiated by Health Canada to develop a drug regulatory system for the 
future (36). The progressive licensing model consists in sound scientific evidence and risk 
management. It is aimed at supporting access to promising new drugs and the continuous 
monitoring of safety, quality, and efficacy. It is being developed on the assumption that 
knowledge and experience can be gained from every stage of a drug's life cycle. A well-
designed regulatory framework should support the collection, analysis, and communication 
of knowledge and experience about a drug throughout its life cycle so that it can be used 
wisely. In addition, in contrast to network meta-analysis which relies in stochastic 
parameterisation of the trade-offs between risk and benefit, the use of drug disease models 
suits the same purpose using a biologically, clinically plausible parameterisation (40). 
 
In conclusion, it should be highlighted that models do not make decisions, people do. A 
collaborative effort between industry and regulators will be required to continue to advance 
the science of benefit–risk methodology, since, as we have argued above, there is no single 
or simple approach that would address all benefit–risk assessments. Eventually, we expect a 
set of common principles, standards and a toolbox of methods will emerge. Ultimately, 
patients, clinicians, drug developers and regulators need to acknowledge that decisions are 
better made when data are presented and communicated in a clear, systematic manner. 
PKPD modelling can complement evidence generation by providing stakeholders the 
opportunity to explore conditions that have not been experimentally tested at the time of 
BR analysis. Regardless of the limitations models and simulation scenarios may have, model-
based evaluation is likely to outperform gut feeling, which currently prevails in clinical 
decision-making.   
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Nederlandse samenvatting  
(Synopsis in Dutch) 
 
De evaluatie en de toelating van geneesmiddelen voor kinderen is voortdurend aan 
verandering onderhevig. Enerzijds is dat een gevolg van het toegenomen besef van het belang  
de effectiviteit en veiligheid van geneesmiddelen voor deze  doelgroep zo nauwkeurig 
mogelijk vast te stellen. Anderzijds is het een gevolg van  vooruitgang in stastische en klinische 
methodologien die het mogelijk maakt het baten-risico profiel steeds nauwkeuriger vast te 
stellen. Omdat het moeilijk is om voldoende onderzoeksresultaten te verkrijgen voor de 
toepassing van  geneesmiddelen voor kinderen, wordt vaak gebruik gemaakt van gegevens 
verkregen nadat een geneesmiddel is toegelaten (de zogenoemde ‘post-approval data’). 
Hierbij geldt een fait accompli, oftewel het bewijs is verzameld na de feiten.  
Op dit ogenblik is er geen kwantitatief raamwerk voor autoriteiten, klinische onderzoekers en 
bedrijven die geneesmiddelen ontwikkelen, op basis waarvan de bestaande kennis en 
informatie over zowel het geneesmiddel als de ziekte kan worden geïntegreerd  om daarmee 
de effectiviteit van het geneesmiddel te voorspellen voordat het onderzoek wordt gestart. 
Door een kwantitatief raamwerk op te stellen is het niet alleen mogelijk om het risico 
management plan te optimaliseren, het geeft ook houvast om tijdens het geneesmiddel 
ontwikkelingsproces wetenschappelijke en klinische vragen te beantwoorden. 
 
Het onderzoek beschreven in dit proefschrift is er op gericht om  op basis van kwantitatieve 
klinische farmacologische principes aanvullend bewijs te verkrijgen over de werkzaamheid van 
geneesmiddelen bij kinderen. Hiervoor is  modelering en simulatie van klinische 
farmacokinetische en farmacodynamische gegevens gebruikt. In hoofdstuk 1  laten we zien 
hoe voorspellingen op basis van een modelmatige aanpak kunnen worden gecombineerd met 
bestaande methodes voor het karakteriseren van het baten en risico profiel van en 
geneesmiddel.  Op basis daarvan verwachten we het besluitvormingsproces voor de toelating 
vangeneesmiddelen voor kinderen te verbeteren. Twee belangrijke zaken onderscheiden het 
onderzoek beschreven in dit proefschrift van eerder onderzoek in pediatrische klinische 
farmacologie. Wij hebben voor het eerst meerdere geneesmiddel-ziekte modellen 
tegelijkertijd geanalyseerd en gesimuleerd waarbij rekening werd gehouden met mogelijke 
correlaties tussen effectiviteit en veiligheid. Dit levert een belangrijke bijdrage aan de manier 
waarop het effect van een geneesmiddel wordt geanalyseerd; niet zozeer als primair eindpunt 
in een klinische studie, maar als middel om geneesmiddeleigenschappen te onderscheiden 




een geneesmiddelinterventie te beschrijven  met behulp van parameters. Het tweede 
belangrijke punt waar ons onderzoek aan heeft bijgedragen, is het gebruik van simulaties van 
effecten in klinische studies en in patiënten die gewoonlijk worden uitgesloten van deelname 
aan klinische studies, de zogenoemde “not-in-trial” populatie, als toevoeging aan de klinische 
gegevens. Hierbij worden gesimuleerde gegevens uit virtuele scenarios verweven met echte 
gegevens en vervolgens gebruikt als input voor MCDA (Multi Criteria Decision Analysis).  
MCDA wordt gezien als hulpmiddel bij het oplossen van vraagstukken waarbij de oplossing 
moet voldoenaan meerdere, mogelijks conflicterende eisen.  Het voordeel van deze aanpak is 
dat het mogelijk is om al voor de beoordeling en toelating  van een geneesmiddel, een 
kwantitatieve analyse te doen van het baten-risico profiel in situaties die niet getest zijn 
tijdens de ontwikkelingsfase(s). Dit is vooral van belang voor de evaluatie van geneesmiddelen 
voor kinderen, omdat er maar op zeer beperkte schaal gegevens verkregen kunnen worden 
uit deze populatie.  Daaranaast kan men rekening houden met de rol van  fysiologische 
processen zoals rijping en groei die op lange termijn de baten-risico balans van de behandeling 
kunnen beïnvloeden.  
 
De punten zoals zojuist besproken komen in de verschillende hoofdstukken van dit 
proefschrift aan de orde. Het voorgestelde raamwerk voor de toepassing van een 
modelmatige aanpak bij de toelatingsprocedure van geneesmidelen voor kinderen  wordt 
geïllustreerd aan de hand van de ontwikkeling van chelatietherapie voor ijzerstapelingsziekten 
als gevolg van herhaalde bloedtransfusie. 
 
 
11.1 Chronische ijzerstapeling door bloedtransfusie-afhankelijke 
hemoglobinopathien 
Bèta-thalassemie-major is één van de meest voorkomende bloedtransfusie-afhankelijke 
ziekten. Het is een erfelijke ziekte die door een sterk gereduceerd of volledig afwezige 
synthese van bèta-globine wordt veroorzaakt. Hierdoor wordt in het lichaam van patiënten 
met bèta-thalassemie-major onvoldoende en afwijkend hemoglobine (Hb) in de rode bloed 
cellen (RBC) aanmaakt. Ook daalt de productie van RBC waardoor deze patiënten 
bloedarmoede hebben. Daarom hebben patiënten met bèta-thalassemie-major regelmatig 
een bloedtransfusie nodig om te kunnen overleven. Alhoewel de behandeling met chronische 
bloedtransfusie sterk verbeterd is in de afgelopen jaren, zijn er nog steeds een groot aantal 
complicaties. Door de vele bloedtransfusies kan ijzerstapeling optreden en dit kan hartfalen, 
lever fibrose, suikerziekte en een verstoorde hormoon productie tot gevolg hebben. Omdat 
het menselijk lichaam zelf geen mechanisme heeft om een overschot aan ijzer af te voeren is 
een adequate ontijzering noodzakelijk om complicaties te voorkomen. Hiervoor worden 
ijzerchelatoren gebruikt die 1) voorkomen dat niet aan transferrine gebonden ijzer (NTBI) 
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wordt opgenomen door organen zoals hart en lever, 2) voorkomen dat intracellulair ijzer 
wordt opgenomen door ferritine, en 3) ijzer wegvangen van ferritine dat wordt afgebroken. 
Aangezien de rol van ferritine bij ijzerstofwisseling, wordt de ferritine concentratie in serum  
gebruikt als maat voor ijzerstapeling. Daarvoor geldt de aanname dat ferritine  aan de totale 
ijzerhoeveelheid in het lichaam gecorreleerd kan worden. Het bepalen van de serum ferritine 
concentratie is een eenvoudige en minimaal invasieve methode om de ijzerstapeling en het 
beloop van het effect van chelatietherapie te volgen.  
 
 
11.2 Optimalisatie van het verzamelen van gegevens bij 
geneesmiddelonderzoek in kinderen 
Klinisch onderzoek in kinderen is beperkt door zowel ethische als praktische oorzaken. 
Daarom  worden extrapolatie en overbruggingsconcepten vaak gebruikt als basis voor de 
evaluatie van geneesmiddelen in paediatrische indicaties.  Dit maakt het lastig om het baten-
risico profiel van een therapie op te stellen. Daarnaast moet men ook erop letten dat de 
gegevens die worden verzameld van voldoende kwaliteit zijn.  
Rekening houdend met  het bovenstaande hebben we iIn hoofdstukken 3, 4 en 5 beschreven 
hoe een klinisch studieprotocol de meeste informatie kan opleveren.  Hiervoor hebben we 
zowel de mogelijkheden van integratie van kennis als de praktische uitvoerbaarheid in 
overweging genomen. Onze belangrijkste doelstellingen waren om te onderzoeken hoe veel 
patiënten in een studie nodig zijn en hoe vaak bloedmonsters afgenomen moeten worden om  
de blootstelling aan een geneesmiddel nauwkeurig te bepalen.  Het optimalisatie concept is 
geïllustreerd  door  het vaststellen van de farmacokinetische eigenschappen van deferiprone 
in kinderen jonger dan 6 jaar. Door aan te nemen dat de farmacokinetiek  van deferiprone kan 
worden voorspeld op basis van gegevens verkregen uit klinisch onderzoek in volwassenen en 
in jongvolwassenen met bloedtransfusie-afhankelijke ziekten, kan het doseringsschema en 
dus de blootstelling gelijk worden gehouden voor de totale patiënten populatie. Op basis van 
beschikbare gegevens in volwassenen die werden behandeld met een orale dosis van 75 
mg/kg/day deferiprone hebben we in hoofdstuk 3 een populatie farmacokinetisch model 
ontwikkeld. Onze resultaten laten zien dat een modelmatige aanpak gebruikt kan worden om 
het effect van demografische en fysiologische factoren op het lotgeval van deferiprone te 
karakteriseren. Kennis omtrent de farmacokinetiek van deferiprone kan vervolgens 
geïntegreerd worden met statistische beginselen om nieuwe klinische studies te ontwerpen. 
De parameters die de farmacokinetiek van deferiprone beschrijven zijn in hoofdstuk 4 
toegepast in combinatie met allometrische schaling  om de optimale tijdstippen voor 
bloedafname te bepalen. Hieruit bleek dat het voldoende is om per patiënt 5 bloedmonsters 
af te nemen om de systemische blootstelling aan deferiprone nauwkeurig vast te stellen in 




de opzet van een klinische studie een definitief farmacokinetisch model ter beschikking te 
hebben.  De toepassing van  geextrapoleerde parameters bij optimalisatieprocedures in 
paediatrisch onderzoek is een aanzienlijk nieuw concept. In hoofdstuk 5 hebben we, uit data 
verkregen uit de DEEP1 PK studie (EurdraCT, 2012-000658-67), de farmacokinetiek van 
deferiprone in kinderen jonger dan 6 jaar geanalyseerd. Hieruit bleek de meerwaarde van een 
geoptimaliseerd protocol ontwerp erg duidelijk: de farmacokinetische parameters konden 
met grote precisie worden bepaald ondanks het kleine aantal patiënten (18 kinderen) dat in 
de studie was opgenomen en het kleine aantal bloedmonsters (5 per patiënt). Op basis van 
overbruggingsconcepten hebben we een doseringsschema voor deferiprone in kinderen 
jonger dan 6 jaar kunnen vaststellen zodat  de blootstelling aan deferiprone bij deze groep 
patiënten vergelijkbar is met die van volwassenen en jongvolwassenen. Samenvattend tonen 
deze resultaten aan, dat modelmatig ontworpen overbruggingsprotocolen robust zijn om de 
farmacokinetiek in en nieuwe doelgroep te karakteriseren. Bovendien,  kunnen deze 
resultaten de basis vormen voor het kiezen van de dosis en doseerschema voor het 
vervolgonderzoek waarin de effectiviteit en veiligheid van deferiprone in de doelgroep wordt 
bepaald. Vanuit een methodologisch perspectief blijkt  het dat de correlatie tussen 
farmacokinetische parameters en covariaten bepalend zijn om een nauwkeurige aanbeveling 
over de juiste dosering te kunnen maken. Oftewel: farmacokinetische studies in kinderen is 
meer dan data verzamelen in een kleine studiegroep, het identificeren van de covariaten op 
basis waarvan de variabiliteit in farmacokinetische parameters kan worden bepaald speelt 
hierbij een grote rol.  
 
 
11.3 Geïntegreerde evaluatie van effectiviteit en veiligheid door 
modelering en simulatie 
Voor het bepalen van de effectiviteit en veiligheid van een geneesmiddel  is meer nodig dan 
een betrouwbare meting en een precieze bepaling van relevante eindpunten  en parameters. 
Daarvoor dienen de complexiteit van de ziekte en de onderliggende klinische context ook 
meegenomen te worden.  In tegenstelling tot een farmacokinetische analyse waarbij de mate 
van blootstelling direct uit enkele parameters wordt bepaald, zijn er bij het bepalen van de 
farmacodynamiek vaak meerdere eindpunten nodig, die ook onderling een samenhang met 
elkaar hebben. Om de effectiviteit en veiligheid van een geneesmiddel te kunnen vaststellen 
moet een onderscheid worden gemaakt tussen de geneesmiddel-specifieke parameters en de 
ziekte-specifieke parameters. In de voorafgaande hoofdstukken van dit proefschrift hebben 
we laten zien dat PKPD modellen gebruikt kunnen worden om de correlatie tussen de 
geneesmiddel- en ziekte-specifieke parameters te karakteriseren. Daardoor is het ook  
mogelijk om met deze correlatie rekening te houden  wanneer het baten-risico profiel van een 
geneesmiddel wordt opgesteld.  




Als men de lange termijn uitkomsten van een behandeling  tracht te voorspellen is het 
essentieel om  nieuwe onderzoeksgegevens over de dynamiek en het verloop van een ziekte 
te integreren met bestaande kennis. De bestaande kennis kan worden verkregen of afgeleid 
uit oa. epidemiologische gegevens over  verwachte co-morbiditeit(en), uit andere 
ziektemodellen of patiëntengroepen, of uit geneesmiddelen uit dezelfde klasse.   
Om deze concepten te illustreren hebben we de effectiviteit en veiligheid van deferoxamine 
gekarakteriseerd. Deferoxamine is een ijzerchelator die op dit moment als eerstelijns therapie 
bij chronische ijzerstapeling wordt voorgeschreven. In eerste instantie hebben we in 
hoofdstuk 6 een ziektemodel voor chronische ijzerstapeling ontwikkeld op basis van 
literatuurgegevens die  de jizer homeostase in onbehandelde patiënten beschrijft. In dit 
“turnover” model, hebben we gebruik gemaakt van een tijdsafhankelijke parameter die de 
omzettingssnelheid van ferritine weergeeft waarbij rekening werd gehouden met 
bloedtransfusies en ziekte progressie. Dit model sluit een mechanistische benadering om van 
de pathofysiologische veranderingen als gevolg van ijzerstapeling door herhaalde 
bloedtransfusie. In hoofdstuk 7 is dit ziektemodel gebruikt om op basis van  van veranderingen 
in serum ferritine concentraties, het effect van deferoxamine te bepalen. Daardoor kunnen 
verschillende scenario’s gesimuleerd worden waar dit tot nu toe slechts empirisch konden 
worden bepaald. Het is bijvoorbeeld mogelijk om de invloed van patiënt-trouw  voor de 
verschillende ijzerchelatoren te simuleren en daarbij het effect op de ferritine concentratie in 
serum te bepalen. Daaruit kan men oa de klinische respons en het succes of faal van  de 
behandeling te voorspellen. Dit geneesmiddel-ziekte model hebben we vervolgens toegepast 
als raamwerk voor de optimalisatie van de respons op ijzerchelatoren. Hierbij kunnen 
covariaten zoals dosering, blootstelling, patiënt-trouw, stadium van de ziekte worden afgezet 
tegen korte- en lange termijn uitkomsten.  
 
Omdat het voor het bepalen van het baten-risico profiel van een geneesmiddel van belang is 
om niet alleen de werkzaamheid te bepalen, hebben we in hoofdstuk 8 ook de veiligheid 
(bijwerkingen en ziektecompicaties) ook door middel van parametrische methodes 
samengevat. Hiervoor hebben we twee overlevings-modellen ontwikkeld om hypothyroidie 
en diabetes mellitus als ziekte-specifieke complicaties te kunnen beschrijven. Zowel diabetes 
als hypothyroidie zijn een co-morbiditeit van ijzerstapeling en kunnen daarom worden 
gecorreleerd aan de ferritine concentratie in serum. Een risico functie waarbij rekening 
gehouden werd met de ferritine concentratie bleek het ontstaan van de co-morbiditeiten te 
kunnen voorspellen. Daarnaast hebben we twee modellen ontwikkeld om de incidentie van 
gewrichts- en spierpijn en overgevoeligheidsreacties, twee acute en geneesmiddel-specifieke 
bijwerkingen van ijzerchelatoren, te kunnen karakteriseren. Deze vier modellen werden 




lange termijn complicaties van ijzerchelatie therapie te onderzoeken. Hierbij dient te worden 
opgemerkt dat deze uitvoerige analyse alleen mogelijk was door de integratie van gegevens 
uit epidemiologische en klinisch farmacologische studies. Hierdoor hebben we zowel de 
correlatie tussen als de tijdsafhankelijkheid van de verschillende eindpunten op een 
kwantitatieve manier kunnen meewegen in onze analyse.    
 
 
11.4 Simulatie van klinische studies als basis voor de baten-risico 
analyse  
Het doel van ons onderzoek is om de meerwaarde van modelering en simulatie voor het 
genereren van zo een realistisch mogelijk baten-risico profiel voor geneesmiddelen voor 
kinderen. Met het onderzoek beschreven in dit proefschrift willen we aantonen dat het bewijs 
dat empirisch verkregen wordt niet altijd accuraat is. En dat de aanname dat de gegevens die 
beschikbaar zijn op het moment van goedkeuring voldoende zijn om een baten-risico profiel 
voor een nieuw geneesmiddel op te stellen, ook niet altijd klopt. Door gebruik te maken van 
simulatie van de effecten verkregen uit klinische studies en in individuen die gewoonlijk 
worden uitgesloten van deelname aan klinische studies (“not-in-trial” simulaties), is het 
mogelijk om rekening te houden met intrinsieke en externe variabiliteit, zoals bijvoorbeeld 
verschillen in blootstelling en  ziekte progressie. Ook is het mogelijk om eventueel verstorende 
factoren te analyseren zodat hiermee rekening gehouden kan worden in het besluitvormende 
proces. Deze aanpak maakt het ook mogelijk om onzekerheden door het kleine aantal 
patiënten (en/of bloedmonsters) in de klinische studies uit te sluiten. 
 
In hoofdstuk 9 hebben we het baten-risico profiel voor deferoxamine bij kinderen met een 
bloedtransfusie-afhankelijke hemoglobinopathie geëvalueerd door gebruik te maken van 
MCDA technieken in combinatie met gesimuleerde scenario’s, waarbij virtuele patienten op 
verschillende manieren worden behandeld. In onze analyse hebben we de resultaten van een 
standaard fase III studie vergeleken met de gesimuleerde resultaten van verschillende 
behandeling condities en doseringsschema’s voor deferoxamine. Op deze manier konden we 
de gevolgen van lange-termijn complicaties op het baten-risico profiel  kwantificeren. Deze 
resultaten laten zien dat het mogelijk is om het baten-risico profiel van een geneesmiddel op 
een meer gestructureerde manier te evalueren voordat data omtrent de effectiviteit van de 
behandeling wordt verkregen. Bovendien laat ons onderzoek een raamwerk zien waarbij 
bestaande kennis over de ziekte, patiënten populatie en het geneesmiddel wordt 
geïntegreerd als parametrische verdelingen in een groep modellen. Dit heeft een drietal 
voordelen: 1) bestaande gegevens worden aangevuld om zo de besluitvorming te verbeteren; 
2) de input voor de MCDA wordt geoptimaliseerd; en 3) dankzij het vastellen van relevante 
correlaties tussen verschillende eindpunten wordt het mogelijk om te evalueren of een 
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bepaalde dosis of doseringsschema een voordeel heeft voor de gehele patiënten populatie of 
alleen maar voor een deel daarvan. Op basis van zulke scenario’s kan besloten worden of een 
gepersonaliseerde therapie zinvol, wenselijk of onnodig is voor de betrokken patiënten.  
 
11.5 Discussie, conclusies en aanbevelingen 
In dit proefschrift hebben we laten zien dat de huidige manier om een baten-risico profiel voor 
een geneesmiddel voor kinderen op te stellen niet afdoende is. Vooral niet als men zich 
realiseert dat de evaluatie van  baten en risico’s zich beperkt tot gegevens die beschikbaar zijn 
op  het moment van de toelating van het desbetreffende geneesmiddel. Ondanks de 
beschikbare methoden om het baten-risico profiel op een kwantitatieve manier te analyseren, 
hebben ze een belangrijke tekortkoming, namelijk alle methoden zijn puur data gedreven. Als 
zodanig blijken ze ongeschikt te zijn om baten en risico’s te voorspellen voodat alle relevante 
gegevens verkregen worden. Door gebruik te maken van farmacokinetische en 
farmacodynamische modelering, een robuuste en mechanistische methode waardor ziekte- 
en geneesmiddel-specifiek eigenschappen worden meegewogen, kunnen bestaande klinische 
gegevens aangevuld en versterkt worden. Aangezien MCDA techknieken de 
besluitingsvorming uiteindelijk tot  getallen en cijfers omzetten, biedt deze  aanpak de 
mogelijkheid om een baten-risico profiel op een systematische en transparante manier te 
analyseren. Een bijkomend voordeel is dat MCDA  geïntegreerd kan worden met 
farmacokinetische en farmacodynamische modelering. Hierdoor kan een betrouwbaarder 
baten-risico profiel opgesteld worden , rekening houdende met de invloed van zowel het 
beloop van de ziekte als het gebrek aan experimentele data. 
 
In dit proefschrift werd de MCDA gekozen om de geïntegreerde  benadering te 
implementeren. Dit concept kan echter ook worden gebruikt in combinatie met andere 
kwantitatieve baten-risico methoden. In feit, er zijn verschillende voorbeelden in de 
wetenschappelijke literatuur waarbij modelering en simulatie gebruikt wordt in combinatie 
met een klinische utiliteitsfuncties of waarderingsfuncties. In tegenstelling tot die 
voorbeelden , is  in dit proefschrift voor het eerst gebruik gemaakt van een methode waarbij 
PKPD modelering volledig geïntegreerd is met MCDA. Aangezien het besluitvormingsproces 
aanzienlijk verbetert  kan worden biedt deze aanpak  belangrijke voordelen voor regulatoire 
autoriteiten, farmaceutische bedrijven en klinische deskundigen: 
1) Het studie protocol kan worden geoptimaliseerd. Hierbij wordt de kwaliteit van de 
data verbeterd en gewaarborgd voordat patienten  geïncludeerd worden in een 
klinische studie; 
2) Beschikbare kennis (bijvoorbeeld epidemiologische gegevens) kan op een formele 




3) Meerdere eindpunten kunnen simultaan worden geëvalueerd waarbij rekening wordt 
gehouden met onderlinge correlaties en tijdsafhankelijkheid; en  
4) Gegevens die verkregen zijn tijdens de klinische ontwikkelingsfase  kunnen worden 
aangevuld met gesimuleerde data, waardoor  de onzekerheden omtrent de baten en 
risico’s  meegewogen worden tijdens de analyse. 
 
Het vermogen tot extrapolatie stelt de analist of onderzoeker in staat nieuwe alternatieven te 
evalueren en te klasseren, en dit alles in real-time. Alhoewel onze aanpak niet per se 
gekoppeld hoeft te worden aan MCDA, zijn er een aantal belangrijke veranderingen nodig om 
de technieken met elkaar te kunnen integreren (Tabel 1).  
 
Tabel 1. Bijdrage van de voorgestelde modelmatige aanpak aan de verschillende stappen van MCDA.  
Multi-criteria decision analysis Modelmatige aank 
0: input  
1: bepalen van besluitvorming 0-1: Optimalisatie van input gegevens en aanvullen 
van klinische gegevens met virtuele scenario’s 
2: identificeren van uiteenlopende 
opties 
1-2: gevolgtrekking door extrapolatie: alternatieve 
opties 
3: identificeren van doelstelling en 
criteria 
2-3: rekening houden met correlaties tussen criteria 
4: scoring  
5: weegfactoren 4-5: besluitvormingssleutels en waarderingfuncties 
door experts 
6: bepalen van overall score  
7: analyseren van resultaten 6-7: beoordelen van bewijs van CTS en/of NITS om 
gepersonaliseerde geneesmiddeltherapie te 
bereiken 
8: gevoeligheidsanalyse 7-8: onzekerheden in het model kunnen worden 
gekwantificeerd en er kan rekening mee worden 
gehouden in de analyse 
 
Toekomstperspectief en conclusie 
De wetgeving rondom de goedkeuring van geneesmiddelen is wereldwijd aan verandering 
onderhevig. Dit komt niet alleen door vooruitgang in de farmaceutische wetenschappen en 
geneesmiddelontwikkeling, maar ook door veranderingen in het verwachtingspatroon van 
patiënten. Er is een toegenomen belangstelling voor het opstellen van een baten-risico profiel 
voor geneesmiddelen. Steeds meer onderzoeksprojecten maken gebruik van een 
gestructureerd en transparant proces waarbij rekening wordt gehouden met de eisen en 
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verwachtingen van verschillende belanghebbenden. De belangrijkste punten die hierbij 
consequent naar voren komen zijn: 
1) Systematisch gebruik van beschikbaar klinisch bewijs; 
2) Verbeterde grafische weergave van het totale baten-risico profiel; 
3) Een her-evaluatie van het baten-risico profiel gedurende de levensloop van een 
geneesmiddel door nieuwe (post-market) gegevens te integreren met data uit de 
klinische studies, oftewel adaptive licensing. 
 
Vanuit een theoretisch perspectief  vergen de  huidige methoden het verzamelen van nieuwe 
gegevens  om  baten en risico’s te kunnen beoordelen (Table 2) . Wij willen juist stimuleren 
dat het simultaan gebruik van beschikbare gegevens met geneesmiddel-ziekte modellen de 
basis kunnen zijn voor simulatie van klinische studies en/of ‘not in trial’simulaties. 
 
Tabel 2. Overzicht van de verschillen tussen de huidige aanpak en de voorgestelde modelmatige 
aanpak voor baten-risico analyse. CTS: Clinical Trial Simulations; NITS: Not-In-Trial Simulations. 
 
Huidige aanpak    Modelmatige aanpak 




Longitudinale  data 
Epidemiologische data: 
achtergrond frequentie  
(co-morbiditeiten en 
bijwerkingen) 









Op basis van klinische data  én 
virtuele patiënten (CTS en NTIS) 
Aanbevelingen vaak beperkt 
tot de beschikbare data, 
namelijk de geteste 
doseringsschema’s en/of  
patiënten populaties  
OUTPUT 
Aanbevelingen ook voor 
gextrapoleerde scenario’s en/of 
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